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Scope of the Thesis 
The combination of a progressive hereditary nephritis with sensorineural deafness was first 
described by Alport in 1927. In 1988, Flinter et al. defined diagnostic criteria for Alport 
syndrome: (1) family history of hematuria, predominantly in males progressing to end-stage renal 
disease; (2) characteristic thickening and splitting of the glomerular basement membrane, 
detectable by electronmicroscopy; (3) usually progressive high-tone sensorineural deafness; (4) 
anterior lenticonus and perimacular flecks. Three of these criteria are required for the diagnosis of 
Alport syndrome. The predominant form (85%) is X-linked, which explains the more severe 
manifestation of the disorder in males. The autosomal recessive form is responsible for about 15% 
of the cases, the autosomal dominant form is rare (< 1%). Biochemical studies pointed to a type 
Г collagen defect in the GBM of Alport patients and in 1990 the first mutations were identified in 
the type Г collagen <*5 (COL4A5) chain (Barker et al., 1990). The aim of this study is to 
characterize type Г collagen mutations and to correlate these with the clinical manifestations in 
Alport patients. 
The first chapter of the thesis: "The clinical spectrum of type Г collagen mutations" should be 
considered both as an introduction and as a review of mutation data and genotype-phenotype 
correlations. In chapter 2, 3 and 4 our data are presented on the X-linked form of Alport 
syndrome. Specific COL4A5 mutations and their effect on the mRNA are described in relation to 
the clinical features. In chapter 5 and б the first mutations in the COL4A3 and COL4A4 genes in 
autosomal recessive Alport families are presented. Linkage was found with COL4A3/COL4A4 
markers in a large family with autosomal dominant Alport syndrome suggesting the involvement 
of these genes as well (chapter 7). As benign familial hematuria (BFH) can not be differentiated 
clinically and by electronmicroscopy from the initial stages of Alport syndrome we investigated 
whether BFH could be a type IV collagen disease as well. In chapter 8 the first mutation in the 
COL4A4 gene in a BFH family is described, extending the clinical spectrum of type IV collagen 
defects. Finally, in chapter 9 progress and possibilities in molecular diagnostics, pathogenic 
mechanisms (cell and animal models) and therapeutic interventions in Alport syndrome will be 
discussed. 
7 

CHAPTER 1 
THE CLINICAL SPECTRUM OF TYPE IV COLLAGEN MUTATIONS 
Henny H. Lemmink1, Comelis H. Schröder1, Leo A.H. Monnens1, and Hubert J.M. 
Smeets2 
Department of Pediatrics', University Hospital Nijmegen, Nijmegen, Division of 
Genetics2, University of Maastricht, Maastricht, The Netherlands. 
Adapted from Human Mutation 9: 477-499 (1997) 
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Abstract 
Clinical manifestations of type Г collagen mutations can vary from the severe, clinical and 
genetically heterogenous renal disorder Alport syndrome to autosomal dominant familial benign 
hematuria. The predominant form of Alport syndrome is X-linked and more than 160 different 
mutations have yet been identified in the type Г collagen a5 chain (COL4A5) gene, located at 
Xq22-24, head to head to the COL4A6 gene. The autosomal recessive form of Alport syndrome is 
caused by mutations in the COL4A3 and COL4A4 genes, located at 2q3S-37. Recently, the first 
mutation in the COL4A4 gene was identified in familial benign hematuria. This paper presents an 
overview of type IV collagen mutations, including 8 novel COL4A5 mutations from our own 
group in patients with Alport syndrome. The spectrum of mutations is broad and provides insight 
in the clinical heterogeneity of Alport syndrome with respect to age at renal failure and 
accompanying features such as deafness, leiomyomatosis and anti-GBM nephritis. 
STRUCTURE AND FUNCTION OF TYPE Г COLLAGEN 
Type IV collagen is a multimeric protein composed of three so-called a chains. To date, 
six different α chains have been identified (αΐ-аб) with molecular weights of 170 to 185 kDa. 
Each a(IV) chain consists of a central collagenous domain of about 1400 residues containing Gly-
X-Y repeat sequences interspersed by short interruptions. X and Y mainly represent proline or 
lysine residues which are extensively hydroxy- and glycosylated. The N-termmal 20-30 amino 
acids, the 7S-domain, contain a signal peptide. The C-terminal non-collagenous (NC) domain of 
about 230 residues consists of two homologous halves each containing six cysteine residues 
(Pihlajaniemi et al., 1983). Type IV collagen chains associate intracellularly into triple helices. 
Assembly starts at the NC domain by disulphide bridge formation and progresses towards the N-
terminus (Fig. 1). Triple-helical type IV collagen molecules are secreted to form a supramolecular 
network through dimerization at the NC domains and tetramerization at the 7S domains (Fessier et 
al., 1982; Siebold et al., 1988; Dölz et al., 1988; Timpl, 1989). Additional lateral chain 
associations provide further strength to the type Г collagen network (Yurchenco and Ruben, 
1987). 
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The six o¡(TV) chains interact in different tissues in different combinations. The [al]2a2 
(IV) and [al]](IV) hetero- and homotrimers are ubiquitously present in all basement membranes 
(Langeveld et al., 1988; Timpl, 1989). The аЗ(І ), a4(IV), o5(IV) and o6(IV) are minor 
basement membrane components with restricted tissue distribution. The basement membranes of 
the glomerulus, inner ear, lung, eye and seminiferous tubule consist of 2 separate networks, one 
consisting of αϊ and a2 heterotrimers and one of tissue-specific combination of the other chains 
(Kleppel et al., 1992; Hudson et al., 1993b). For example, the al(IV) and а2(Г ) chains reside in 
the subendothelial layer of the glomerular basement membrane (GBM), while the аЗ(І ), а4(І ) 
and а5(Г ) chains are particularly prominent in the lamina densa (Butkowski et al., 1989; Kleppel 
et al., 1989a; Fig. 1). The high cysteine content of a4(IV) chain, probably involved in 
intermolecular assembly, may result in additional strength to the GBM. The аЗ(Г ) and а4(Г ) 
chains colocalize in a large set of basement membranes but, in contrast to the а5(Г ) chain, are 
absent from the epidermal basement membrane (Kashtan et al., 1986; Kleppel et al., 1989a; Sanes 
et al., 1990; Kleppel et al., 1989b; Yoshioka et al., 1994). The а5(Г ) and аб(Г ) chains do not 
always colocalize (Ninomiya et al., 1995) and the аб(І ) chain is absent from the GBM. 
Type IV collagen is the major structural component of mammalian basement membranes 
and serves as a scaffold for binding and alignment of other macromolecules, such as laminin, 
heparan sulfate proteoglycan and nidogen (Timpl et al., 1981; Timpl, 1989). It has a role as a 
physical barrier between different tissues and functions in cellular processes like filtration by the 
GBM. Moreover, extracellular matrix proteins such as type Г collagen mediate through 
membrane bound receptors adhesion, differentiation, cell signaling and tissue regeneration (Van 
den Berg et al. 1991; Kuehn et al., 1994). The Ν- and C-terminal region of the аЗ(І ) NCI 
domain contribute to the formation of the Goodpasture epitope that specifically bind the 
autoimmune antibodies in patients with Goodpasture syndrome (Saus et al., 1988; Kalluri et al., 
1991; Turner et al., 1992; Quiñones et al., 1992; Hudson et al., 1993b). 
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Figure 1: 
Schematic representation of the molecular structure of type Г collagen in renal glomerular 
basement membrane 
(A) The glomerular basement membrane (GBM) is located between epithelial and endothelial cell 
layers. (B) Supramolecular network of type IV collagen is formed by assembly of dimers (NC-NC 
domain) and tetramers (7S-7S domain) (C) Three o¡(IV) chains associate into a triple-helical 
protomer. 
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TYPE IV COLLAGEN GENES AND EXPRESSION 
The complete cDNAs encoding six distinct human type IV collagen chains, varying in length from 
6 to 10 kb, have been identified (Pihlajaniemi et al., 1985; Soininen et al., 1987; Morrison et al., 
1991; Gunwar et al., 1990; Hostikka et al., 1990; Pihlajaniemi et al.,1990; Kamagata et al. 1992; 
Sugimoto et al. 1993; Zhou et al. 1993a; Oohashi et al. 1994). The COL4A1 and COL4A5 gene 
comprise about 100-250 kb and contain, respectively, 52 and 51 exons (Soininen et al., 1989; 
Zhou et al. 1994a). The different number of exons has no functional significance as the 133-bp 
exon 19 in COL4A5 is a fusion product of the smaller exons 19 and 20 in COL4A1. For the 
COL4A2, COL4A3, and COL4A4 genes only part of the intron-exon structure has been elucidated 
(Hostikka and Tryggvason 1987; Quiñones et al., 1992; Kamagata et al., 1992; Sugimoto et al., 
1993). 
Type IV collagene are arranged in pairs on human chromosome 13q35-37 
(COL4A1/COL4A2; Boyd et al., 1986; Griffin et al., 1987), on 2q35-37 (COL4A3/COL4A4; 
Mariyama et al., 1992; Kamagata et al., 1992) and on Xq22-24 (COL4A5/COL4A6; Hostikka et 
al., 1990; Zhou et al., 1993a; Oohashi et al., 1994). Homology studies suggest an evolution in 
higher organisms from an ancestor gene, which is duplicated and inverted, followed by duplication 
of the gene pair to other chromosomes (Zhou et al. 1994b; Leinonen et al., 1994; Zhang et al., 
1996). The ai-class consists of COL4A1, COL4A3 and COL4A5, the a2-class of COL4A2, 
COL4A4 and COL4A6 (Mariyama et al. 1992; Zhou et al., 1994b; Zhang et al., 1996). The two 
classes differ in the number of exons, encoding the NC domain, which is 5 for the α ϊ class and 3 
for ál, although all chains differ at amino acid positions 1611-1630 and 1721-1747 of the NC 
domain (Leinonen et al., 1994). Eighteen cysteine residues are consistently conserved among all 
six chains; twelve cysteine residues in the NC domain, four in the 7S domain and two cysteines in 
interruption IX. The remaining 13 cysteine residues in the a4(IV) chain are located in the Gly-X-
Y repeat or in the interruptions of the collagenous domain and are not conserved. The other 
chains have a much lower cysteine content with only 2 to 5 nonconserved cysteine residues 
(Leinonen et al., 1994). The sequence homology of the NCI domains within the α ϊ class ranges 
from 69% to 83% and between members of the a2 class from 69% to 75% (Leinonen et al., 
1994). 
The type IV collagen gene pairs share a promoter region (Zhou et al., 1994b). The 
COL4A1 and COL4A2 genes are expressed ubiquitously, whereas the other chains have a 
restricted distribution (Kleppel et al., 1989a; Sanes et al. 1990). The expression pattern of the 
COL4A3 and COL4A4 indicates coregulation (Miner and Sanes, 1994), which is not the case for 
the COL4A5 and COL4A6 genes (Zhou et al. 1993a). Alternative splicing has been observed for 
COL4A5 (Guo et al., 1993) and COL4A3. Normal full length and shortened a3(IV) mRNA 
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transcripts containing no exon 2 and exon 4 sequences were identified. These shorter transcripts 
introduce premature stopcodons and are predicted to result in truncated proteins without NC 
domain, although the significance is yet unclear (Bemal et al., 1993; Feng et al., 1994; personal 
observations). Analysis of the 5' end of COL4A6 revealed two alternative promoters that control 
the generation of two different transcripts (Sugimoto et al., 1994). Experimental data on the 
developmental regulation of type IV collagen gene expression in the kidney are predominantly 
available from rat embryos. Only αϊ and а2(Г ) chains are detected initially; then а1-а5(Г ) 
chains are all present and finally аЗ-а5(Г ) become the predominant chains (Miner and Sanes, 
1994). Previous studies on fetal human kidney development provided preliminary evidence for a 
similar switch in humans (Kleppel and Michael, 1990), although all 5 chains remain present in the 
GBM (Hudson et al., 1993). This replacement/remodeling in GBM development is reminiscent of 
the embryonic to adult myosin and the fetal to adult hemoglobin switches (Whalen et al., 1981; 
Maniatis et al., 1980). 
The αϊ(IV) and а2(І ) chains are expressed ubiquitously, whereas the other chains have a 
restricted distribution (Kleppel et al., 1989a; Sanes et al., 1990). In human adult tissues the 
аЗ(Г ) and а4(Г ) mRNAs are coexpressed in kidney, skeletal muscle and lung (Mariyama et al., 
1994). The expression pattern indicates «¡regulation of COL4A3 and COL4A4 genes (Miner and 
Sanes, 1994) whose protein products can form an (аЗ)2а4 heterotrimeric complex (Johansson et 
al., 1992). A coordinate regulation of expression will be important in cells that secrete triple 
helical protomers containing different α chains in a fixed ratio. The а5(Г ) and аб(Г ) chains are 
both expressed abundantly in kidney, skin, heart, placenta, meninges and oesophagus but their 
ratios vary in brain and heart tissues (Zhou et al., 1993a). 
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ALPORT SYNDROME 
Clinical features 
The combination of a progressive hereditary nephritis with sensorineural deafness was first 
described by Alport in 1927. Alport syndrome is characterized by hematuria leading in males to 
renal failure at juvenile (before 31 y of age) or adult age (older than 31 y of age) (Atkin et al., 
1988). Usually, clinical features are less severe in females (Hasstedt et al., 1986; Flinter et al., 
1988). Alport syndrome is clinically heterogeneous and patients have been classified by their age 
at end-stage renal disease (ESRD) and the presence of accompanying features, such as 
sensorineural deafness and ocular lesions (lenticonus and perimacular flecks) (Sohar et al., 19S6; 
Perrin et al., 1980). Juvenile cases are with a single exception deaf and show ocular 
abnormalities. More rarely, patients develop diffuse oesophageal and vulvar leiomyomatosis 
(Cochat et al., 1988; García-Torres and Orozco, 1993) or macrothrombocytopenia (Epstein et al., 
1972; Eckstein et al., 1975; Peterson et al., 1985). Among patients with diffuse leiomyomatosis 
severe, congenital and bilateral cataracts are frequent (see Table 1). Alport patients who reach 
ESRD are dialysed or undergo renal transplantation. Some transplanted patients develop a post-
transplant anti-GBM nephritis, leading to irreversible gran failure (Cameron, 1991). 
According to records of the ERA-EDTA (European Renal Association-European Dialysis 
and Transplantation Association) Registry 72 to 166 new patients with Alport syndrome are 
reported each year between 1975 and 1993 in Europe (Rigden et al., 1996). The overall male-
female ratio was 3.4 : 1. The progression to complete renal failure necessitates renal replacement 
treatment (RRT). The median age for start of treatment for males is 20-24 years and for females 
30-34 years. Six and a half percent of all patients with AS, were less than 15 years of age at start 
of RRT and account for 1.61% of all children commencing RRT (Rigden et al., 1996). At 10 
years after commencing RRT 68% of males and 57% of females were alive. Renal transplantation 
was performed in 61 % of males and 46% of females with ESRD because of AS. The 5-year graft 
survival for male AS was 59% and for females 64% which is not significantly different from 
those with standard PRD, suggesting that the incidence of anti-GBM nephritis causing graft loss is 
perhaps lower than reported before (Gobel et al., 1992). 
15 
Electron microscopie and immunohistochemical analysis of Alport kidneys 
Renal biopies of Alport patients are characterized by irregular thinning/thickening and 
multilamellation of the GBM but young patients often show only thinning of the GBM (Spear et 
al., 1972; Hinglais et al., 1972; Rumpelt et al., 1974; Gubler et al., 1976). The involvement of 
type IV collagen in Alport syndrome was indicated by immunohistochemical analysis of GBM 
biopsies using anti-type Г collagen antibodies. The antibodies directed against type Г a3 and a5 
collagen chains did not bind to the GBM in renal biopsies in most Alport patients (Olson et al., 
1980; McCoy et al., 1982; Kashtan et al., 1986; Kleppel et al., 1989b; Savage et al., 1989). 
Further evidence came from studies of collagenase treated renal basement membranes from Alport 
patients, in which type IV collagen NC domains were absent (Kleppel et al., 1987; Thorner et al., 
1990). The type IV collagen COL4A3 and COL4A5 NC domains were also targets of anti-GBM 
antibodies, which occurred in some patients after renal transplantation (van den Heuvel et al., 
1989; Kashtan et al., 1990). The data also point to a possible type Г collagen defect as the cause 
of Alport syndrome. 
Alport genetics 
The estimated gene frequency of Alport syndrome is 1:5000 (Atkin et al., 1988). The disorder is 
genetically heterogeneous but the vast majority showed (85%) X-linked dominant inheritance 
(Feingold et al., 1985; Hasstedt et al., 1986). The X-linked Alport gene was mapped to the Xq22-
24 region (Atkin et al., 1988; Brunner et al., 1988; Flinter et al., 1989), in which the COL4A5 
and COL4A6 genes were subsequently localized (Hostikka et al. 1990; Myers et al. 1990). 
Mutations in the COL4A5 gene turned out to be the main cause of Alport syndrome. 
The autosomal recessive form (AR) comprises about 10-15% of the pedigrees and is 
linked to the COL4A3 and COL4A4 locus (Chan et al., 1993). Recently, mutations were 
identified in the COL4A3 and COL4A4 genes in AR Alport families (Mochizuki et al., 1994; 
Lemmink et al., 1994b). In these families, female patients were clinically indistinguishable from 
affected male siblings; carriers were asymptomatic and often consanguinous. Recently, the 
autosomal dominant form was mapped to the COL4A3 and COL4A4 locus as well (Jefferson et 
al., 1997), but mutations have not yet been identified. 
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Diagnostic criteria 
Flinter et al. (1988) proposed that at least three of the following four criteria 
were required for the diagnosis Alport syndrome: 
1. Family history of hematuria, in most cases progressing to renal failure (ESRD) 
2. Irregular thickening and splitting with multilamination of the GBM, shown by 
electron microscopy 
3. Characteristic eye lesions (i.e. anterior lenticonus and perimacular flecks) 
4. High-tone sensorineural deafness, which is usually progressive during childhood. 
This is a very strict definition. In most reported cases no data on eye abnormalities are available. 
FAMILIAL BENIGN HEMATURIA 
Familial benign hematuria or thin basement membrane disease is characterized by persistent 
hematuria, an electron microscopically detectable thin GBM and an autosomal dominant mode of 
inheritance. Renal function remains normal (Gauthier et al., 1989). In children differentiation 
between familial benign hematuria and Alport syndrome may be difficult, because both disorders 
manifested by persistent hematuria and thin GBM at that age. Several groups investigated whether 
familial benign hematuria could be a type IV collagen disorder as well. In three Japanese families, 
no linkage was found between the disorder and the COL4A3 and COL4A4 locus (Yamazaki et al., 
199S). In contrast, linkage was found in a large Dutch family and a pathogenic mutation was 
found in the COL4A4 gene (Lemmink et al., 1996). These results indicate that familial benign 
hematuria is a genetically heterogeneous disorder, part of which can be explained by type Г 
collagen defects. 
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MUTATION DETECTION IN TYPE IV COLLAGEN GENES 
Mutation detection techniques 
Basically two strategies have been applied to identify mutations in type IV collagen genes. First, 
Southern blot analysis was performed using cDNA probes to identify major gene rearrangements 
(Barker et al., 1990; Netzer et al., 1992; Renieri et al., 1992b; Zhou et al., 1993a; Smeets et al., 
1993; Antignac et al., 1994), in some cases using pulse field gel electrophoresis (Boye et al., 
1991; Vetrie et al., 1992; Antignac et al., 1992). Secondly, a variety of methods was used to 
screen for small mutations. The main approach has been SSCP analysis (Orita et al., 1989), 
followed by sequence analysis of fragments with a different electrophoretic mobility (Lemmink et 
al., 1993; Renieri et al., 1993; Nakazato et al., 1994; Boye et al., 1995). Some groups have used 
chemical mismatch cleavage (Boye et al., 1993), denaturing gradient gel electrophoresis (DGGE) 
(Zhou et al., 1992; Netzer et al., 1993), heteroduplex analysis (Peissel et al., 1994) or direct 
sequence analysis without any prescreening (Nomura et al., 1993) (reviews by Grompe, 1993 and 
Cotton, 1993).The COL4A5 gene was screened exon by exon, because the mRNA level was too 
low in PBL for routine investigation of large fragments of cDNA (Guo et al., 1993; Knebelmann 
et al., 1992; Lemmink et al., 1994a). By contrast, the COL4A3 and COL4A4 genes can be 
studied at the cDNA level (Mochizuki et al., 1994). 
COL4A5 MUTATIONS 
Large COL4A5 gene rearrangements 
Thirty-eight large- and medium-sized deletions have been identified (Table 1). The size of the 
deletions vary from single exons to the complete COL4A5 gene, spanning a region of around 250 
kb of genomic DNA (Table 1). The frequency of large deletions varies from 1-2% (Kawai et al., 
1996) to 16% (Antignac et al., 1994). The intragenic deletions were scattered across the gene, and 
no frequent deletion breakpoints were characterized. Deletions spanning the 5' ends of the 
COL4A5 and COL4A6 genes were associated with a rare combination of Alport syndrome with 
diffuse oesophageal and/or genital leiomyomas (Antignac et al., 1992; Zhou et al., 1993a; Heidet 
et al., 1995). The deletion breakpoint is always located in intron 2 of the COL4A6 gene (Zhou et 
al., 1993a). Alport patients with more extended deletions farther downstream COL4A6 do not 
have leiomyomatosis (Heidet et al., 1995). Thus far, no mutations have been identified in the 
COL4A6 gene only in patients with Alport syndrome (Zhou et al. 1993a; Boye et al., 1995; 
Heiskari et al., 1996). 
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Small COL4A5 mutations 
One hunderd and thirty-eight small COL4A5 mutations have been identified in Alport patients. 
They can be divided in either amino acid substitutions (n= 62), mutations creating premature stop 
codons (n= 69), infrante deletions (n= 6), and one infrante duplication event. The frameshift 
group comprises small deletions (n= 24), insertions (n= 11), splice site (n= 26), and nonsense 
(n= 8) mutations (Table 2). Amino acid substitutions were considered pathogenic when the 
underlying DNA mutations segregated with the disease in the respective families and when these 
mutations were not found in the general population. Additional evidence was derived from the 
evolutionary conservation of the altered amino acids and the nature of the alterations involved 
(Table 2). A total of 55 amino acid substitutions were detected in the collagenous domain, 49 
involving glycine substitutions (Table 2). All mutated glycine residues are part of the conserved 
Gly-X-Y stretches in the collagenous domain. The remaining 7 amino acid substitutions were 
located in the NC-domain. Mutations in the coding region, which were part of the consensus 
splice site sequences (Krawczak et al., 1992), were scored as splice site mutations and not as 
missense mutations. For example, substitution of the last nucleotide of exon 48 induces skipping 
of exon 48 at the RNA level (Lemmink et al., 1994a) and mutation of the last nucleotide of exon 
49 generates a complex pattern of aberrant COL4A5 splice products (Nomura et al., 1993). 
A variety of small mutations created premature stopcodons. Nonsense mutations, which 
changed an amino acid codon into a stopcodon were observed in 8 cases. Small deletions (n= 24) 
or insertions (n= 11) in majority caused frameshifts. Finally, 26 splice site mutations were 
detected, which destroyed highly conserved splice acceptor or splice donor consensus sequences 
(Krawczak et al., 1992). These mutations interfered with correct splicing and altered the reading 
frame (Nomura et al., 1993; Netzer et al., 1993; Lemmink et al., 1994a; Boye et al., 1995; 
Nakazato et al., 1995). 
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COL4A3 AND COL4A4 MUTATIONS 
The number of mutations in the COL4A3 and COL4A4 genes in autosomal recessive Alport 
syndrome is still low: six in the COL4A3 gene and three in the COL4A4 gene (Table 3), but few 
patients have been studied for only a small part of the gene. Patients were either homozygotes or 
compound heterozygotes for the mutations and their parents were asymptomatic carriers except for 
the family with autosomal dominant familial benign hematuria. All six COL4A3 mutations created 
a premature stopcodon. Two were nonsense mutations and three were deletions involving 5 and 7 
basepairs, respectively (Lemmink et al., 1994b; Mochizuki et al., 1994; Ding et al., 1995; Table 
3). A sixth mutation created a splice acceptor site in intron S, counting from the 3' end of the 
COL4A3 gene (Knebelmann et al., 1995). The two COL4A4 mutations in Alport patients were a 
nonsense and a missense mutation that occurred as homozygotes in patients (Mochizuki et al., 
1994). The missense mutation Gly 1201 Ser substituted a glycine in the collagenous domain. In a 
family with familial benign hematuria a similar pathogenic glycine substitution (Gly897GIu) was 
identified in the triple helical part of the protein (Lemmink et al., 1996). 
NON-PATHOGENIC AMINO ACID SUBSTITUTIONS IN TYPE Г COLLAGEN 
Discrimination between pathogenic and non-pathogenic amino acid substitutions can be difficult. 
This is especially the case for type IV collagen, in which no test is available to determine the 
effect of mutations on the production and function of the protein. Here we report the amino acid 
substitutions which do not fulfill the previously formulated criteria on pathogenicity. In the 
COL4A5 gene, Ala430Asp and the Lys664Asn substitutions were detected in Alport patients, but 
these mutations did not segregate with the disease and did not involve conserved amino acids 
(Leinonen et al., 1994). In addition, in the patient with the Lys664Asn substitution, a second 
pathogenic mutation (Prol517Thr) was identified (Lemmink et al., 1993). Similarly, two non­
pathogenic amino acid substitutions were identified in the COL4A3 gene (Leul474Pro and 
Glnl495Arg). Both mutations did not segregate with the disease. The Leul474Pro was found, 
although at low frequency, in the general population (Lemmink et al., 1994b). In contrast to the 
Glnl495, the Leul474 residue is highly conserved in all six human type IV collagen proteins 
(Leinonen et al., 1994) and in different species (Lemmink et al., 1994b) and the alteration was 
considered drastic. We want to stress that it is important to generate supportive evidence for the 
pathogenicity of amino acid substitutions. 
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EVALUATION OF COL4A5 MUTATIONS 
Mutation score 
A systematic analysis of large gene rearrangements, using the entire COL4A5 cDNA as a probe, 
has been performed for French (n= 88 families) (Antignac et al., 1994), Italian (n= 177 families) 
(Renieri et al., 1995), German (n= 20 families) (Netzer et al., 1992) and Japanese (n= 60 
families) (Saito et al., 1994) patients. The frequency of major rearrangements varied from 16% 
for the French patients to 1-2% for the Japanese. Most large rearrangements were deletions. A 
systematic search for small mutations in the COMAS gene has recently been completely analysed 
for small mutations in the Italian and Japanese population (Kawai et al., 1996; Renieri et al., 
1996). The mutation score varies from about 40-45% for the Italian and Japanese population to 
almost 35% for the British population after screening 40% of the COL4A5 coding region (Boye et 
al., 1995). It is still unclear where the missing mutations have to be found. Either they are located 
in the non coding regions or in another X-linked gene, or the patients do not suffer from Alport 
syndrome. 
Seven out of the 38 large rearrangements (18%) and 14 out of the 138 small mutations were de 
novo events (10%). Previously, it has been reported that in 15-18% of the cases no family history 
of Alport syndrome was present (Tryggvason et al., 1993), but this number included both de novo 
mutations and single autosomal recessive cases (Yoshikawa et al., 1987; Atkin et al., 1988). The 
large rearrangements may be due to misalignment of repeat sequences in the large COL4A5 and 
COL4A6 introns (Dahan et al., 1995). A percentage of 10-15% new mutations is comparable with 
other X-linked disorders. 
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Distribution 
The large deletions are dispersed all over the gene and no hot spots for deletion breakpoints have 
been identified. The number of small mutations seems to be less at the 5' end (Fig. 2), but most 
investigators have started their analysis from the 3' end. As yet, there is no evidence for 
mutational hot spots. Only a few mutations have been found more than once in different families. 
Substitutions of glycine residues at the 129, 325, 638, and 1143 positions were identified in nine 
families (Table 2). Each family revealed a different nucleotide substitution thereby excluding a 
common ancestor. Five different mutations were found in more than one unrelated family from 
The Netherlands, the United States, the United Kingdom, Finland, France, Japan and Italy (Table 
2). For example, the Arg 1563 codon comprises the last 2 nucleotides of exon 48 and the first of 
exon 49. The one but last nucleotide of exon 48 (4889C-»T) is altered in two families from the 
Netherlands and the United States (Zhou et al., 1993b) (Table 2), and the last nucleotide in exon 
48 is changed in three unrelated families (4890G-»A) from Denmark, the Netherlands and the 
United States, respectively (Lemmink et al., 1993; Zhou et al., 1993b). In the Dutch family, we 
demonstrated that the 4890G-»A originated in the mother of the patient (unpublished data). 
Haplotype analysis in Italian families using intragenic polymorphic markers indicated that the 
Gly869Arg and Gly866Glu mutations originated independantly, while the 1685del34 mutation, 
present in two families, originated from a common ancestor (Renieri et al., 1996). The 
Gly869Arg was also found in a British family. Genealogical and haplotype studies of families with 
the same mutation are necessary to determine whether families are related. 
EFFECT OF COL4A3, COL4A4 AND COL4A5 MUTATIONS 
Amino acid substitutions 
In the collagenous domain of the COL4A5 and COL4A4 genes the vast majority of the missense 
mutations in Alport syndrome replace glycine residues, which interrupt the characteristic triple 
Gly-X-Y repeat and impairs correct alignment of the type Г collagen triple helix. The position of 
interruptions present in collagenous domains of type IV collagen is conserved through evolution 
indicating functional relevance (Leinonen et al., 1994). The introduction of an interruption is 
predicted to impair correct alignment and folding of the type Г collagen triple helix. Glycine 
substitutions are common in other collagen disorders as well and are frequently detected in the 
COL1A1 and COL1A2 genes in patients with osteogenesis imperfecta or in the COL3A1 gene in 
patients with Ehlers Danlos syndrome (Kuivaniemi et al., 1997). 
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Figure 2: 
Localization and distribution of small mutations in the collagen а5(Г ) chain 
Boxed numbers, 1 to 138, correspond to the COL4A5 gene mutations described in table 2. 
Numbers in italics, 1 to 51, indicate individual COL4A5 exons. 
COL4A5 gene 
I 
^ ^ ^ COL4A5 chain 
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In familial benign hematuria, heterozygosity for a glycine substitution was identified as well. 
Because of the similarities with the other homozygous COL4A4 glycine substitution in an Alport 
patient, we hypothesized that familial benign hematuria could reflect manifesting carriership of 
autosomal recessive Alport syndrome (Lemmink et al., 1996), although this was not described for 
the parents of the Alport patient (Mochizuki et al., 1994). 
Of the remaining 11 cases, in which no glycine was involved, a cysteine residue was 
altered or created in 3 cases (Table 2). Cysteine residues are thought to play a role in intra- and 
interchain assembly of type Г collagen chains by disulphide bridge formation and substitutions 
can impair correct folding (Zhou et al., 1991b). The remainder of the amino acid substitutions are 
located in the NC domain and involve conserved amino acid residues. It is unclear whether the 
considered non-pathogenic amino acid substitutions have no effect at all. Probably they can 
modify other pathogenic COL4 mutations. 
Premature stopcodons 
The introduction of premature stopcodons is predicted to lead to truncated proteins. However, 
such stopcodons may impair the maturation of transcripts (Urlaub et al., 1989; Cheng et al., 
1990; Hamosh et al., 1991; Baserga and Benz, 1992) or alter the splicing of the рге-mRNA, 
resulting in skipping of the exon that contains the premature stopcodon (Dietz et al. 1993; Fischer 
et al. 1993). In several studies on COL4A5 mRNA, the mutation was identified in the mRNA as 
such (Knebelmann et al.,1992; Nomura et al., 1993; Lemmink et al., 1994a). However, only PBL 
RNA was studied, and a definite conclusion awaits the analysis of kidney samples from patients 
(Guo et al., 1993). In Samoyed dogs with Alport syndrome, kidney RNA has been tested (Zheng 
et al., 1994). The COL4A5 mutation in these dogs is Glyl027Stop. A drastic reduction of 
COL4A5 kidney mRNA was shown on Northern blot (Thomer et al., 1996). These observations 
are different from our observations in human PBL-RNA. Therefore, more data are needed on the 
basic mechanisms through which nonsense mutations exert their pathogenic effect. Still, 
independent of the mechanism involved, the net result at the protein level is likely to be the 
absence of a functional COL4A5 chain either because mutant COL4 chains are subject to 
preferential protein degradation or are not transported in and secreted out of cells or are not 
incorporated into the extracellular COL4 network (General Discussion; Fig. 1). 
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PHENOTYPE-GENOTYPE CORRELATIONS 
Leiomyomatosis (COL4A5/COL4A6 mutations) 
Patients suffering from Alport syndrome and diffuse oesophageal and/or genital leiomyomatosis 
are characterized by having large deletions, extending from within the COL4A5 gene to intron 2 
of the COL4A6 gene. The presumed absence of both the COL4A5 and COL4A6 chains prompted 
speculations about a role for type Г collagen in smooth muscle differentiation and morphogenesis 
(Zhou et al., 1993a). However, despite the deletion of the promoter sequence of the COL4A6 
gene a specific probably hybrid COL4A6 transcript could be identified in oesophageal tumour 
tissue of these patients (Heidet et al., 1995). 
Juvenile and adult Alport syndrome (COL4A5 mutations) 
Mutations that are predicted to result in the complete absence of COMAS protein or truncated 
COL4A5 protein with no NC domain consistently cause the juvenile form of Alport syndrome. 
Because of the absence of the NC domains, the COL4A5 chain can not be incorporated into triple 
helical type Г collagen molecules. These mutations include all large rearrangements, but also 
those small mutations, that lead to premature stop codons. Only one of the latter mutations has the 
adult phenotype (Lemmink et al., 1993). Immunohistochemical studies have to reveal, if mutant 
COL4A5 chains of these patients are present in the GBM. Small in frame deletions or insertions 
cause juvenile Alport syndrome. Amino acid substitutions can lead to either juvenile or adult 
Alport syndrome. It is tempting to speculate that the juvenile form is predominantly associated 
with mutations resulting in absence of protein in the GBM and that the adult form may be caused 
by missense mutations that allow incorporation of the chain. This should be tested by 
immunohistochemistry. Finally, juvenile and adult Alport syndrome has been reported for 
members of the same family (Knebelmann et al., 1992; Renieri et al., 1994b) indicating that not 
only the specific mutations determines the phenotypic expression. 
Deafness (COL4A3/A4/A5 mutations) 
The majority of Alport patients suffer from progressive high-frequency sensorineural deafness. In 
the group of patients with COL4A5 mutations 30 male patients were not deaf of which four had 
adult and nine juvenile Alport syndrome. The other 17 patients were still too young to be included 
(Tables 1, 2). A Glyll43Ser mutation was identified in an Italian kindred with an adult Alport 
phenotype and deafness (Renieri et al., 1994b), but a different substitution (Gly 1143Asp) in a 
Danish kindred was associated with the juvenile phenotype without deafness (Zhou et al., 1992a). 
Identical mutations cause different age at onset of deafness (Barker et al., 1996). 
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Thus, it seems that different substitutions of one specific amino acid can result in different clinical 
phenotypes. Of the 6 patients with a COL4A3 mutation, four were deaf and for the other two no 
auditory data were available. The two Alport patients with a COL4A4 mutation were not deaf. It 
has been speculated that the presence or absence of deafness could be related to tissue specific 
splicing (Brunner et al., 1991). Our data indicate that this is not the case. Mutations in the same 
exon can result in a phenotype with and without deafness. It seems more likely that the threshold 
for phenorypic effects differs between the kidney and the inner ear BM. 
Anti-GBM nephritis 
About 1-5% of transplanted Alport patients develop a specific anti-GBM nephritis, subsequently 
leading to renal graft loss (Milliner et al., 1982). Data are available on 46 transplanted patients 
among who were 41 with a COL4A5 mutation, four with a COL4A3 mutation and one with a 
COL4A4 mutation (Tables 1-3). All patients except one had early onset (juvenile) Alport 
syndrome. In nine transplanted patients, 20% of the total number of transplantations, a specific 
anti-GBM nephritis was detected. All nine except one carried large deletions or premature 
stopcodons and were predicted to result in truncated COL4A3 or COMAS proteins without NC 
domain. The one exception is a splice site mutation resulting in ал mRNA without exon 38. The 
deletion does not disrupt the reading frame, but it should be tested whether this truncated chain is 
present in the GBM at all (Netzer et al., 1993). Four patients with characterized COL4A3 were 
transplanted and three of them developed an anti-GBM nephritis (Table 3). These patients carry 
mutations which are predicted to produce СОЫАЗ protein from which most part of the NC 
domain is absent. These data strongly suggest that Alport patients with a type IV collagen 
mutation resulting in the absence of the NC domain have an increased risk of developing anti-
GBM nephritis after renal transplantation (Smeets et al., 1992; Ding et al., 1995; this report). 
The absence of mutant a(IV) chains can distort association with the other normal а(Г ) 
chains. The absence of normal and mutated type Г collagen chains in the GBM of patients 
corroborates with the finding that anti-GBM antibodies were directed against type Г collagen аЗ 
and a5 epitopes, although not always against the mutated chain. A COL4A5 mutation can induce 
an anti-GBM nephritis directed against either COL4A3 or СОЫА5 (Hudson et al., 1992; Kalluri 
et al., 1994). Anti-GBM antibodies in patients with COL4A3 mutations were directed against 
COL4A3 in one case, and against both COL4A3 and COL4A5 chains in another case (Kalluri et 
al., 1995; van den Heuvel, unpublished data). It is obvious that other factors than the genetic type 
IV collagen defect are probably implicated in the immune response, as about 70% of Alport 
patients contain no а5(Г ) protein in the GBM, only 1-5% of the transplanted Alport patients 
develop anti-GBM nephritis (Milliner et al., 1982: Gubler et al., 1993). A similar conclusion can 
be drawn from the absence of anti-GBM posttransplant nephritis in patients with deletions of 
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either the COL4A3 or COL4A5 NC domain or the entire COL4A5 chain (Gubler et al., 1993), 
the absence of anti-GBM nephritis in a second graft (Milliner et al., 1982; Rassoul et al., 1990), 
and the intrafamilial discordance with regard to the occurrence of GBM alloimmunization, 
observed in one family with a COL4A5 deletion (Kashtan et al., 1991). 
THE TYPE Г COLLAGEN NETWORK IN THE NORMAL AND ALPORT GBM 
The elucidation of type Г collagen mutations in Alport patients has improved our knowledge of 
normal interactions of type Г collagen molecules in the GBM. Immunohistochemical analysis of 
renal biopsies from Alport patients with large COL4A5 deletions (Ding et al., 1995) or small 
deletions introducing premature stopcodons in either the COL4A3 or the COL4A5 gene showed 
that the COL4A3, COL4A4 and COL4A5 proteins in the GBM were differently distributed or 
absent, but that the αϊ and a2(IV) chains were still present (Kleppel et al., 1989b; Gubler et al., 
1993; Nakanishi et al., 1994; Lemmink et al., unpublished data). These data confirm previous 
observations that the α3/α4/α5 chains form a complex that is separate from the al/a2 chains in 
the GBM (Kleppel et al., 1992; Hudson et al., 1993a). 
In the GBM of Alport patients, the α3/α4/α5 network is either absent or altered. The 
absence of this network induces the synthesis of the αϊ and a2(IV) chains and two other collagene 
in the GBM, of types V and VI, respectively, resulting in the characteristic ultrastructural changes 
of the Alport GBM (Kashtan and Kim, 1992). The accumulation of the αϊ and а2(Г ) chains, 
type V and VI collagen, and perhaps other proteins may be viewed as a developmental arrest of 
the αϊ and a2(IV) "fetal" isoforms (Miner and Sanes, 1994; Kalluri et al., 1997). 
Immunohistochemical analysis of renal biopsies revealed the absence of mutated as well as normal 
a(IV) chains in the GBM in about 70% of the male X-linked Alport patients (Gubler et al., 1993). 
This is consistent with the percentage of mutations leading to a COMAS chain that cannot be 
incorporated in the GBM. Alteration of the аЗ/а4/а5 network has been reported for a patient with 
an amino acid substitution in COL4A4 (Gly-*Ser). All five COL4 proteins were present in the 
GBM (Gubler et al., 1995). Also in a group of patients with a late onset of renal failure 
(Nakanishi et al., 1994), which are most likely caused by COL4A5 amino acid substitutions 
(Table 2), this was the case. The distribution of all five COL4 chains is different, which results in 
a predominantly thin GBM structure (Gubler et al., 1995; Nakanishi et al., 1994). 
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FUTURE PROSPECTS 
Progress in defining Che type Г collagen gene mutations in Alport syndrome has been extremely 
rapid during the last couple of years. The number of mutations in the COL4A5 gene is yet 
sufficiently high for initial genotype-phenotype correlations. Still, only 50% of the mutations has 
been detected in evident X-linked Alport syndrome. Research will be directed at screening the 
non-coding areas ot the COL4A5 gene and at the development of new technology for mutation 
detection to find the remainder of the mutations. The recently reported method of resequencing 
complex genes by high density DNA arrays or "CHIPS" (Chee et al., 19%) is very promising in 
this respect. On the other hand, comparable with hemophilia A (Lakich et al., 1993), a major 
mutation may long be uncharacterized, and can exist also in X-linked Alport syndrome. Apart 
from new molecular technology, a comprehensive protocol has to be developed based on clinical 
records, family history and immunohistochemistry with chain-specific antibodies to guide mutation 
analysis in the three huge collagen genes. Especially, immunohistochemical analysis of the 
epidermal basement membrane (EBM) is promising as a first test, as about half of the patients 
with a mutation in the COMAS gene lack this chain from the EBM (Zhou and Reeders, 1996). 
Many of the functional consequences of type Г collagen mutations are, however, based 
on predictions rather than experimental evidence. Experiments like in situ hybridization, 
immunohistochemistry, and transfection studies, will be employed to study the manifestations of 
the mutations at the RNA and protein level. The reported coordinated reduction of transcription of 
the COL4A3 and COL4A4 genes, because of a mutation in the COL4A5 gene, in a dog model 
(Thomer et al., 1996), has to be confirmed for mutations in humans. Furthermore, intrafamilial 
variation in expression of Alport syndrome with respect to ESRD and development of anti-GBM 
nephritis suggests that it is not only the genetic defects that counts, but also a yet unknown 
number of factors, which contribute to the nature and severity of clinical manifestations. The 
implications of type IV collagen defects have become of more general importance by the 
identification of a COL4A4 mutation in persistent hematuria and of an unexplained role in benign 
smooth muscle cell proliferation in leiomyomatosis, associated with Alport syndrome. Basic 
information on type IV collagen gene regulation, precise definition of all aspects of the genetic 
defects, and risk factors and knowledge of the different physiological roles of type Г collagen is 
of key importance for prognostic predictions and for the successful development of therapeutic 
approaches, such as gene therapy, which are currently being investigated (Tryggvason et al., 
1997). 
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Different mutations in the СОЫА5 collagen gene in Iwo patients with 
different features of Alport svndrumr Alport syndrome is a hereditary 
rendi disease in which progressive renal failure is olten accompanied by 
sensorineural deal ness and ocular abnormalities Recently mutations 
were detected in the type 1\ collagen a* chain gene in Alport syndrome 
patients We searched lor mutations in this gene in IK unrelated 
patient;» and in two patients abnormalities were detected In the gene of 
patieni BB we identified a complex deletion which included the exons 
encoding the non collagenous domain and part of the collagenous 
region This patient showed иагк onset nephritis (end stage renal 
disease at 17 years) with deal ness Within a vear after receiving a 
kidney from an unrelated donor he developed an antiglomerular 
basement membrane nephritis In patient \VJ a point mutation was 
detected changing a tryptophane mio a senne m the non collagenous 
domain His clinical features are milder (renal failure at 31 years no 
hearing loss) and a recent renal allograft did not provoke anti 
glomerular basement membrane disease These initial data suggest that 
differences in the extent ol disruption of the non collagenous domain 
may correlate with the severity and or heterogeneity of Alport syn­
drome and with the development ol nephritis in renal allografts 
Alport syndrome (AS) is a progressive hereditär) glomerulo 
nephntts with a heterogeneous clinical picture Patients can be 
classified by their age at end-stage renal disease ( ESRD) and the 
presence of accompanying features, such as hearing loss ocular 
malformations macrolhrombocytopenia and leiomyomatosis of 
the esophagus [11 Typical ultrastructural anomalies of the 
glomerular basement membrane (GBM) include characteristic 
lesions of the lamina densa The clinical heterogeneity of AS 
may reflect the involvement of different genes, because 
X linked dominant autosomal dominant and autosomal reces-
sive modes of inheritance have been reported for AS [2] 
However the vast majority of AS pedigrees published thus far 
show X-lmked dominant inheritance [1 3-5] Some trans 
planted male patients develop a post-transplant anti-GBM ne 
phntis, leading to irreversible graft failure [6] In II out ol 13 
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cases reported [6] nephritis appeared within nine months aftei 
transplantation Identification of patients predisposed to thr 
ami-GBM disease has not yet proven possible 
Recently the cloning of the basement membrane type IV a* 
collagen chain (C0L4A5) gene has been reported [7] Assign 
ment of this gene to the region on the long arm of thí 
X-chromosome. where the AS gene must be located togethei 
with the almost exclusive location of the gene product in thí 
GBM made the involvement of the C0L4AS gene in AS very 
likely This was confirmed by the identification of mutations ir 
the C0L4AS gene m 3 out of 18 AS kindreds [8 9] and 3 out ol 
38 in another study [10] 
We searched for mutations in the C0L4A^ gene in a group ol 
18 AS patients First we have screened Southern blots from the 
genomic DNAs of our patients for major gene rearrangements 
From published data [8-10) it seemed likely that major gent 
rearrangements were only á minority of the mutations involved 
Therefore we also initiated a search for point mutations A 
combination of in vitro amplification of the exons coding for the 
NC-domain with a search for single strandcd-DNA conforma 
tion polymorphisms (SSCPÌ [II 12) was applied The confor 
mation of denatured single stranded DNA is sequence depen 
dent and determines the electrophoretic mobility of the DNA 
molecule Most mutations alter the conformation of a DNA 
fragment and will result in mobility shifts on non-denatunnt 
Polyacrylamide gels In our group of 18 AS patients, wc 
detected two patients with a mutation in the 3 -end of the 
COL4AS gene Both the mutations and the clinical picture diffei 
between these patients which indicates that analysis at the 
gene level may become an indicator of prognosis for thi* 
disease 
Methods 
Patients 
Since the age of 10 patient BB was known to suffer frorr 
proteinuria and hematuria He developed sensorineural deaf 
ness Renal biopsies show typical abnormalities of the glomer 
ular basement membrane consisting of irregular thickening anc 
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thinning together with a multi lamellated aspect with m-
tramemhranous granules on eleclronmicroscopy The disorder 
was progressive and at the age of 17 the patient reached 
end-stage renal disease (ESRD) Transplantation with the kid 
ney of an unrelated donor was followed by rapidly progressive 
antiglomerular basement membrane nephritis leading to loss of 
the transplant within a few days of seven months after grafting 
(13) His affected maternal grandfather died from renal failure at 
the age of 26 ν ears 
Patient WJ had suffered from a progressive loss of renal 
function since the age of 27 Renal disease has been slowly 
progressive wuh rapid deterioration of kidney function from the 
age of 33 Λ renal biopsy showed similar abnormalities as were 
observed in the first patient At age of 3S the patient received a 
cadaveric kidney transplant This transplant has functioned 
adequately for nine months Fxamination bv standard audio 
metry did nol show hearing loss The patient has a similarly 
affected brother The pedigrees of both patients are consistent 
with X linked inheritance with more severe disease in affect ed 
males than in affected témales 
Materials and methods 
Chromosomal DNA was isolated from peripheral blood [14] 
DNA (IO Mg) was digested with FcoKI Pstl and Taql (Gibeo 
BRL) resolved by agarose gel electrophoresis and immobilized 
on Gene Screen plus , M (Du Pont NEN Boston Massachu-
setts USA) by Southern blotting according to standard proce-
dures [151 The COL4AS" cDNA probes pJZ4 pHT14 pPL3l. 
pMD-6 and pPC-4b (Fig 1 [7] Zhou el al unpublished 
observations) which cover the entire cDNA were ^P labeled 
by random primer synthesis [16] Prchybndization and hybrid 
ization were performed at 6^°C in 0 5 м N a , H P 0 4 / N a H : P 0 4 
(pH = 7 2)f7<7r (wt/vol) SDS Filters were washed three times 
for five minutes and once for 30 minutes at 6^°C in 40 ілм 
Na
:
HPO 4
/NaH 2PO 4/0 Wc SDS For autoradiography fillers 
were exposed to Kodak X ray films for one to four days at 
- 7 0 e C 
COL4AS" exons l-s" were amplified in vitro using the PCR 
methodology (17] Exon flanking primers (Pharmacia Uppsala 
Sweden) were synthesized based on (he sequence data of 7hou 
et al IIS] The pnmer sequences are (Г indicates the forward 
primer. R the reverse primer) 
exon I AS IF S -GAT CTG ATT GTC TTA TTT CTT ATT-3 
ASIR S-TAA AAC АСА AAA GGA ATT CTT 
CAA 3 
COL4A5 chain 
cDNA clones 
kb lig 1 iDSA ііот^ of Ila COL4A4 )itnf 
exon 2 AS2F * TTGCGGCAC ATT TTT CCT TGT CTT 3 
AS2R < GGA ССГ GAA TTA AAG СТА TA* 
GCV3 
exon 3 AS3F ^ -ATT ATG TTC CTT CTC CTT TTC CTT 3 
AS3R « ATG АСА ΑΛΤ GCA AGG <\AG AGI 
GTA 3 
exon 4 AS4F S -CTT TAC TGT TTT CTC 1CC AAA ГСТ 3 
AS4R S -AAA AGT CAC AGC TAA АТС AAT 
G C C 3 
exon 5 ASSF ^ -TCT TGT ATA CTG ATT ATT TCG TGG 3 
ASSR S CAG TAG GAA ATT AGA TAT TGA 
TTA 3 
Mutation scanning was performed according to the procedure 
of Onta et al [II 12] Single strand DNA was с lee trop h ore sed 
under non-denatunng conditions on a Φ/t Polyacrylamide se 
quencing gel (with and without lOOr glycerol) in the cold room 
(4eC) at s" walls for 20 hours or at 40 watts for three hours 
Autoradiographic exposure was overnight Sequence analysis 
of double stranded PCR products was perlormed using the 
sequencing kit of Pharmacia Template DNA was generated 
according to the method described by Casanova et al [19] PCR 
products of COL4AS exon 4 were digested with Bsrl (New 
Fngland Biolabs Ine Beverly Massachusetts USA) and ana 
lyzed on 4e} agarose gels stained with ethidium bromide 
Results 
Southern blot analysis of DNAs of AS patients was per­
formed to screen for major gene rearrangements In only one 
case were structural alterations detected in the COL4AS gene 
No hybridization signals were visible with the probes pMD 6 
and pPC4 b in the DNA of patient BB (Fig 2A) Most signih 
cant was the absence of the entire NC-domam in the COL4A*> 
chain of this patient His gene was not deleted completely 
because probe pPL 31 and pHT 14 showed hybridization with his 
DNA though manv of the bands which were visible in the 
DNA of controls were lacking (Fig 2B C) The data are 
suggestive for the presence of iwo deletions in his gene I he 3 
part of the gene was completely absent but ρ PL 11 detected 
EcoRl fragments of 2 6 kb (Fig 2B) and I 4 kb (not visible) 
indicating that most likely the exons 16 or 17 to 20 which are 
covered bv the s part of this cDNA probe were present 
However probe pHT14 which lay at the ^ side adjacent to 
pPL3l also lacked a number of the bands which were visible 
in the DNA of control individuals (Fig 2C) Because there was 
no map available of the S end of the gene it was unclear which 
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Fig. 2. Α. Soulhern blot analysis of LcoRI digested DNA of p.ment BB and his family with probes pMD-6 .ind pPC4-b These probes hybndi/.e 
with COL4A5 e\ons 1-11 and detect EcoRI fragments of. respectively. 7.5 kb. 6.6 kb. 2.4 kb. 1.4 kb and 2 overlapping fragments of 1.2 kb. The 
UNA of patient BB (22IK) does not show an> hybridization. B. Southern blot analysis of EcoRI digesied D N A of patient BB and 3 male controls 
(CI with probe pPL31, The D N A of the patient displays a normal 2.6 kb fragment and ajunel ion fragment of 6 6 kb C. Analysis of the same blot 
as in 211 with probe pH I 14 Five of the bands, which are visible in the D N A of controls are missing in the D N A of patient BB However, four other 
bands and two junction fragments (6.6 kb and 5 4 kb) are present 
of the exons were missing. Probe pPL3l detected one junction 
fragment of 6.6 kb and probe pHTI4 two junction fragments of 
6.6 kb and 5.4 kb (Fig. 2B.C). These junction fragments were 
also present in the DNA of the mother and bister of the patient. 
who both displayed hematuria, and revealed carnership of the 
same complex deletion The junction fragments were absent in 
the DNA of his health) grandmother (not shown!. Probe pJZ4. 
covering the 5' part of the gene, gave a completely, norma! 
picture (data not shown) 
We screened the five exons coding for the NC-domam for 
small mutations, using single-strand conformation polymor 
phism (SSCP) analysis [11. 12]. This method revealed the 
presence of a mutation in exon 4 (numbered from the V end) in 
patient WJ (Fig. 3). Compared to control samples, the mobility 
of the amplified fragment was clearly altered. Direct sequencing 
of the PCR products revealed a single base mutation in the 
DNA of the patient, which was not present in the DNA of 
controls (Fig. 4). His affected brother carried the same mutation 
and his mother was heterozygous. The single base alteration led 
to a substitution of a guanine for a cytosine. changing a 
tryptophane codon into a serine codon. The single base muta­
tion also destroyed a Bsrl restriction site, which facilitated 
DNA studies in the family of the patient As shown in Figure 5. 
the absence of the Bsrl site co-segregated with AS. Besides the 
father of patient. 50 healthy controls I?.** males and 25 females) 
were tested for the Bsrl polymorphism. All normal controls 
showed presence of the Bsrl site. In the other 16 AS patients no 
mutation has been detected so far. 
Discussion 
In two patients belonging to clinically different types of AS. 
we have detected mutations in the V part of the C01.4A5 gene 
For patient BB. two deletions in his COL4A5 gene led to the 
absence of the normal NC-domain and part of the collagenous 
region. This complex deletion is different from the ones re 
ported before [8. 10]. and the gene product might either be a 
shorter collagen chain or contain a nonsense stretch of amino 
acids. Therefore, a relationship to dysfunctioning of the GBM 
and the development of renal disease is quite obvious. The 
second patient (WJ) shows only a single base alteration in the 
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SSCP ANALYSIS ΕΧΟΝ 4 
Male 
patients 
Male 
controls 
Female 
patients 
Female 
control 
10 
Fig. 3. SSCP analysis oj exon 4 hi AS patu-nts and controls. Exon 4 of patient WJ liane Hi) shows an altered mobilili 
amplification produci is visible for the deletion patient BB liane Ы 
372/AP 
male 
control 
3052 3053 3060 
G A T C G A Τ С G A T C 
-—"" Шк 
Туг 
Туг 
G A T C 
С S e r 
Τ Leu 
G T r p 
Туг 
Туг 
Fig. 4. Sequence analysis of exon J DS A of patient WJ. Ins affettiti brother his mother atul и malt- < ontrol. The G to С trans version in the 
patients changes a Trp codon (TGG) into an Ser coUon ITCG). The mother is heterozvgous and displays both a G and а С ut th.il site 
fourth exon of the NC-domain (counted from the V end). The 
expected effect of the amino acid substitution would be a mild 
alteration of the hvdrophobicnv of the protein segment, with as 
vet unknown consequences for structure and function of the 
protein. However, there are two lines of evidence that this base 
substitution is very llkel) the causal mutation. First, the sub­
stituted tryptophane residue is highly conserved at that position 
in both halves of the NC-domain in all t\pe IV collagen* from 
Drosophila to humans [2(>-2.1| Evolutionary conservation is a 
strong indication of functional relevance of ammo acids Sec* 
ondlv. we tested both the fami I > of patient WJ and a number of 
controls. In the family we found co-segregation ot the mutation 
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372/AP 
3060 3053 3054 3052 3061 
Fig. 5. Bsrl difiesiion o1 exon 4 of putieni WJ und lm family I he PCR 
produci is 2УН bp long. Digestion v.ith Bsrl Generales tuo fragments ol 
\2H and 110 Ьр m controls <f.e.. 3054). The mutation has destroyed the 
Bsrl site in the l ) \ λ ot patients 30M and 3060. Their mother (3052) and 
sister П0У>1) are heterozygous 
with the phenotypic expression of the disease. In contrast, in ?0 
health) controls (75 chromosomes) no mutation was found. 
Therefore, we conclude that this mutation is not a neutral 
polymorphism, although it still remains possible that other 
mutations can exist within the remaining unspanned part of the 
gene. 
The two patients described here have different clinical lea-
lures. Early onset of ESRD and hearing loss was found in 
patient BB. who carries a complex rearrangement in his 
COL4AÍ gene, leading to the absence of a large pari of the 
normal COL4AÍ chain. The course of the disease is less severe 
in the second patient and no hearing loss is delectable. No 
major rearrangements have been found in his COL4AÍ gene. 
The single base mutation affects the NC-domain. but the 
consequenties appear to be limited to the glomerulus The 
reason for this is not clear at present The kidnev might be more 
sensitive to alterations of the COL4A5 chain, although tissue-
specific isoforms of the COL4A5 chain may exist. Further 
studies of COL4A5 expression in different tissues will help to 
solve these questions. 
The complex deletion in the COL4A? gene of' patient BB 
includes the entire NC-domain and. since the patient lacks the 
normal epitopes of the COL4A5 NC-domain. is probably one of" 
the factors involved in the development of anti-GBM nephritis 
after kidney transplantation. The reactivity of the anti-GBM 
antibodies of this patient was similar to Goodpasture antibodies 
and a monoclonal antibody directed against the Goodpasture 
antigen iMCA-P,) [13]. A large deletion is onlv one of the 
causes leading to the absence of the entire protein or part of it. 
a variety of other, small mutations can have a similar effect. For 
example, small deletions or insertions, which cause a shift ol 
the reading frame, will result in a nonsense protein, and point 
mutations, which introduce premature stop codons or prevent 
normal transcription, will lead to truncation or absence of the 
protein. Our data suggest that AS patients who have one ot 
those mutations in their COL4A5 gene may be at risk for the 
development of anti-GBM nephritis upon kidnev transplanta-
tion. It is obvious that more data on mutations in the COL4A5 
gene of patients with anti-GBM nephritis need to he collected to 
estimate this risk proper!},. 
Two mechanisms were hvpothesized to explain the develop-
ment ot anti-GBM nephritis in a subgroup of AS patients |24|. 
The first hypothesis assumes that all patients lack the immuno-
logical tolerance for the Alport antigen, but that the occurrence 
of anti-GBM nephritis is dependent on the immunological 
setting of" the patient. The second hvpothesis postulates a 
subgroup of patients with specific mutations in their gene that 
prevent the expression of certain epitopes of the protein. This 
latter possibility is supported hv our data. It is ev idem that the 
nature of the mutations in the COL4A5 gene is onlv one of the 
factors involved: other endogenous and exogenous factors 
contribute as well to the provocation and seventv of the 
immune response, leading to anti-GBM nephritis [13. 24]. A 
clear demonstration of the involvement of exogenous factors 
forms a familial case of four male patients, who were all 
transplanted, but of whom onlv two lost their allografts because 
of anti-GBM nephritis [25]. 
The two mutations described here increase the total number 
reported to eight, of which seven have been characterized in 
detail. These mutations are all different, which helps to explain 
the clinical heterogeneity of X-linked AS The two deletion 
patients (patient BB reported here and patient 197701 from 
kindred LP [S]) both suffer from severe hearing loss, whereas 
hearing loss is absent in our patient WJ. This corroborates the 
suggestion of Barkeret al [8| that severitv of deafness is directly 
correlated with the severity of the defect in COL4A.V A wide 
variety of mutations implies that each AS kindred might earrv a 
different mutation in COL4AÍ and that for each kindred a 
specific mutation must be identified. For osteogenesis imper-
fecta (Ol) similar findings were reported [2ft]. More than 70 
mutations have been identified in type I collagen genes as the 
molecular cause of different forms of Ol and insight into the 
relation between mutation and severity of the disease is grow-
ing. Still, the picture is far from complete and it is estimated [26| 
that the generation of an initial mutation map ot' type I collagen 
genes requires the analvsis of the phenotvpic effects of at least 
200 mutations. The size of the COL4A5 gene is similar to those 
genes and the number of mutations needed tor the establish-
ment of a proper correlation between mutations in COL4A5 and 
AS phenotypes mav be similar as well 
In conclusion, our data suggest that gross rearragemenis ut 
the 3' end of the COL4A5 gene will lead to chnicallv severe AS 
with early onset nephritis and profound deafness. Mild muta-
tions on the other hand, like the missense mutation at the 3' end 
of the gene in patient WJ. will lead to a less severe phenol ν pe. 
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Moreover our finding of a large deletion of the 3 end of the 
COL4A5 gene in a patient with a de naso anti-GBM nephritis 
after transplantation implies that a similar correlation may exist 
between the seventy of disruption of the NC-domain and the 
development of anti GBM nephritis 
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The type IV collagen a5 chain (COL4A5) genes of pa-
tients with Alport syndrome were tested for major gene 
rearrangements by Southern blot analysis, using 
COL4A5 cDNA clones as probes. In addition, individ-
ual exons were screened for small mutations by single-
strand conformation polymorphism (SSCP) analysis. 
Four new COL4A5 mutations were detected. A duplica-
tion of the nine most 3 located nucleotides of exon 49 
and the first nucleotide of intron 49 was identified in 
the COL4A5 gene of one patient. Two patients dis-
played single base substitutions leading to, respec-
tively, a proline to threonine and an arginine to glu te-
mine substitution in the C-lerminal end. Both substitu-
tions involve amino acids conserved through evolution. 
In COL4A5 intron 4 1 a mutation changing the splice 
acceptor site from AG to AA was identified. All muta-
tions cosegregate with the clinical phenotype of Alport 
syndrome in affected family members. In a control pop-
ulation of 50 individuals tested by PCR-SSCP these 
mutations were never identified. Together with two 
mutations reported previously, a total of six mutations 
were found in 26 patients with Alport syndrome (23%) 
after systematic screening of about 30% of the COL4 A5 
coding region. The clinical features of these six 
patients are described in detail. •<- 1993 Academic Pm*. ine 
Alport syndrome is a hereditary nephritis with a heter-
ogeneous clinical picture Renal function deteriorates 
progressively and males reach end-stage renal disease 
(ESRD) usually before the age of 30 In most females the 
course of the disease is less severe and ESRD is infre-
quent. The majority of patients suffer from progressive 
sensorineural deafness as well Other features like eye 
lesions (lenticonus or penmacular necks), macrothrom-
bopathic thrombocytopenia, and leiomyomatosis of the 
esophagus are rare. Finally, after kidney transplantation 
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some patients develop a specific anti-GBM glomerulone­
phritis in the donor kidney, leading to irreversible graft 
failure (4) Diagnosis of our group of Alport patients was 
based on clinical course, family history, and, if available, 
TABLE 1 
Oligonucleotide Primers Used to Amplify 
COL4A5 Exons 
FiiunSi AS-nF 1 GAT ( T O ATT OTT Т Т Л Τ Γ Τ l T T ATT 1 
lUShp) Ah-tlH S TAA AAC A( A AAAGGA A T T C T T C A A 1 
Fxon W Ah'iOP 4 T I G ("ПО ГАС A I T Т Т Т Г Г Т ТОТ СТТ 1 
(¿41 bp} AS-K1R "і GGA CC Τ GAA Т Т Л АЛ(. С ГА ТАА ОСА 1 
Fxnn 49 AS49F S ATT АТ(. T l С СТТ СТС СТТ TTC СТТ Τ 
UTSbpi AS49R F> ATO АСА AAT C.CA AGGAAG ACT GTA 1 
Exon 48 A4JHF 1 ( T T 1АГ Т( .Т Т Т Т Π С TXT AAA Т Т Т Ϊ 
Ι.' ΙΑ b|il A M M R ·» AAA ACT VAC AGC ТАА АТС AAT G< С ì 
hxnn A" AM7F 5 TCT TGT ATA CTG ATT ATT TCO TOG Τ 
І /ПЬрі АЧ47Н r> CAO TAG GAA ATT AGA T A I K . A T T A 1 
F »on 46 A ^ f i F 't TAT TTC. AAT GCC TCA TTC T T T TCC 1 
UVi l ip l AS4<>R •> ACC AAC AGC AT С T T T TAC TTC. TC 1 
Kion 4S Ab45l· S CCC TTC AAA Т Т Т ОТО TOT T T T OTC Ì 
(186 bp) ASJîR 1 OAT AAT AAA GAT OAT CTO CAT TCO Ί 
F.»in 41 44 AS4 1 44F => OTA АСА Т Т Л ATO ATT Т Т Л Τ Γ Ι ATT С I 
l l U b p l A M I 44H 1 TAT AAC TAT ( Τ Ί I AG GAA ГАА GTC Í 
Exon4¿ AS42F 4 AA Г (.1С OTC ATT TOC TGT ( . ( . A T I A I 
1191 bp) AM2H S-CATCAG A I A TCT A( Τ TCC ATT TCC 1 
Fion 41 АЫIF τ АТС TTC ТАА TTA TAC Т Т Г А( Τ TTC ì 
l¿40hpl AS4IR -) С Л Т Т С Т С С Т А С С ACT ГАС GGA ( 1 
Fxon 40 AS40b 4 TGT T T T OTT TTG Т Т П О Т ACT CTG 1 
(KW bpl AS40R r> TTG АТГ TAG CAT GTT TTA TTA AGG 1 
Exon 39 AS19F V GOT GTA ACC TOC TOT A( Τ CAA T T 1 
I IV i hp) ASI9R 1 AAT AOG AAA ΑΛΤ GAA AAA СТА CAÍ» » 
Exon ΊΆ AS16F 5 TCA T T T TTA AAT TGA ОСТ СТТ TAC ( 
ІИ9Ьр) AS IHR => AAC AGÍ AAA CTG TTA TTT TTC A K . 1 
Noie Pr imer sequences used Гог Ihe amplif icat ion of 14 Г О Ы А г і 
exons from the 1 end F indicates the forward primer Ft the reverse 
pr imer Based on sequences published in (18) 13 pairs of oligonucleo­
tide primers were synthebized to ampl i fy exons 38 to Ή w i t h f lanking 
i n t r o n sequences ol the COL4A1) цепе The lengths of the PC Η prod 
u n are indicated in parentheses 
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A 
О : 
JT 
b NORMAL SEQUENCE 
...TCCTTCATGATG gtattttacact ttttatag CATACAAGTGCA... 
S F M M H T S A 
exon 49 intron 49 exon 50 
SEQUENCE PATIENT JT 
...TCCTTCATGATGGTTCATGATG gtattttacact ttttatag CATACAAGTGCA... 
exon 49 exon 50 
FIG. 1, (Α) PCR SSCP analysis <>l COL4A5 exon 49 fragment in the famik of patient JT. Numbers indicate the exon 49 PCR-amphhed 
DNA fragments with different migration shifts. Patient .IT is indicated (1 ) Double-stranded exon 49 fragment; (2) double-stranded exon 49 
fragment containing the duplication. 13) single-stranded exon 49 fragment; (41 single stranded exon 49 fragment containing the duplication: 
and (5 and 6) heteroduplexes af normal and mutated exon 49 strands Health\ males (or healthy females): bands 1 and 3; affected males: bands 
2 and 4; female heteroz\goies bands 1-6. PCR 114) was performed using 100 ng leukocyte DNA in '2'> yl standard mixture in the presence of '1 
μ(Ί |n-3"PjdOTP. Thirty cycles were performed consisting of 50 s at 9 2 T (denaturationi. 50 s at 55*C (annealing), and 1 5 mm at 72°C 
(elongation I. AM 14 exons could he amplified except exon 50. Oligos AS51R and AS49F were used for the first PCR round and AS50F and AS50R 
lor exon 50 in a nested PCR of 30 cycles amplification under the same conditions SSCI' electrophoresis was performed on a всі nondenatunng 
Polyacrylamide gel containing ΙΟΎ glycerol (12) in IX TBF, buffer for 4 h at 40 W and for 16 h at 6 W in a cold room (4°Cl <B> Sequence 
analysis of exon 19 DNA of patient -IT and a male control Amino acid residues are indicated by the one-letter code. Capital letters indicate exon 
sequences and lowercase intron sequences The 10-bp duplication is underlined 
the characteristic electron microscopic patterns in renal 
biopsies. In most pedigrees Alport syndrome segregates 
as a dominant trait linked to markers from the Xq22-
q24 region. The gene for the огб (IV) collagen chain 
(COL4A5) was assigned to the same locus on the X 
chromosome and the subsequent localization of the gene 
product in the GBM made the involvement of the 
COL4A5 gene in Alport syndrome very likely (6, 11). 
This was confirmed by the identification of mutations in 
the COL4A5 gene in Alport patients (1, 2, 8, 13, 15-17, 
19-21). 
Southern blots of restriction enzyme-digested DNA 
samples (Taql, Pstl, and EcoRl) of our group of 26 unre­
lated patients with Alport syndrome were tested with 
COL4A5 cDNA clones covering the entire cDNA (15). 
The only major structural alteration detected was a large 
complex 3' deletion (15). PCR-SSCP analysis was ap­
plied to screen for small mutations in the coding region 
of the COL4A5 gene, starting from the 'S end (Table 1). 
For SSCP analysis two control samples, denatured as 
well as nondenatured, were included to identify the nor­
mal pattern and the double-stranded fragments. Under 
the two conditions, each exon showed a clear separation 
between the single-stranded and double-stranded frag­
ments. Sometimes additional bands, possibly represent­
ing different conformations of single-stranded DNA 
(12), were observed. In 4 patients electrophoretic mobil­
ity shifts of amplified exon DNA were observed and in 
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each case a mutation could be identified by sequence 
analysis 
A migration shift of both the single and double-
stranded bands was detected in exon 49 of male patient 
JT (Fig 1A) Sequence analysis revealed an insertion of 
10 nucleotides at the exon 49-intron 49 border (Fig IB) 
The inserted sequence was a duplication of the nine 
most 3 located nucleotides of exon 49 and the first nu 
cleotide of intron 49 SSCP analvsis of exon 49 in the 
familv of the patient showed co inheritance ot the inser 
tion with the disease phenotype (Fig 1A) Heterozygote 
carriers of the insertion were easy to identitv because 
heteroduplexes formed between normal and mutant 
DNA, displayed even larger migration shifts (Fig 1A, 
bands 5 and 6) Two diirerent single base mutations were 
identified in exon 48 ш female patient HB and in male 
patient AB HB was heterozygous for the mutation and 
both the normal and the shitted single stranded hands 
were detectable bequence analysis revealed a missense 
mutation resulting in the change of the CCT codon for 
proline 1517 to ACT for threonine (Fig 2) Her affected 
daughter carried the same mutation The second muta 
tion in exon 48 concerning male patient AB »as a G to 
A mutation (data not shown), changing the CGA codon 
for arginine 156Э to CAA for glutamine This mutation 
was also found in his affeded nephew and mother (not 
shown) Both exon 48 mutations involved highly con 
served amino acids from the NC domain (Table 2) The 
fourth mutation was detected by SSCP andlvsis of exon 
42 in male patient DC Direct sequence analysis revealed 
a G to A mutation abolishing the splice acceptor site of 
intron 41 An affected aunt of this patient carried the 
same mutation She was heterozvgous for the mutation, 
as shown b\ SSCP and subsequent sequence analysis 
(data not shown) SSCP analysis of the other exons did 
not reveal additional mobility shifts in the 14 3 terminal 
exons in our group of 26 patients 
The causative role ol these mutations in Alport syn 
drome is based on several lines of evidence First in each 
pedigree the mutation cosegregates with the AS pheno 
type in the family Second the mutations are not neu 
trai The 10 bp duplication in exon 49 of the COMAS 
gene of patient JT causes a frameshift Because only the 
GT dinucleotide remains from the original (onsensus 
splice donor sequence, it is unlikely that normal m RNA 
can still be produced The destruction of the splice ac 
ceptor site in intron 41 in patient DC interferes with 
normal splicing The exact characterization of the effect 
of these two mutations awaits analysis of the COL4A5 
mRNA from both patients The missense mutations af 
feet amino acids which are strongly conserved in both 
halves of the NC domain of all type IV collagen genes 
from Caenorhabditis elegans to man (Table 2) Evolu 
tionary conservation indicates functional relevance and, 
therefore, these mutations are thought to interfere with 
the normal functioning of the COL4A5 chain Finally, in 
tests of 50 controls (25 females and 25 males) by PCR-
SSCP for the exons 42, 48 and 49, none of these muta 
tions were identified Therefore, it is unlikely that these 
mutations are neutral polymorphisms To what extent 
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patient HB female control 
F I G . 2 . Sequence ana lys i s of exon 48 D N A o í female pa t i en t H B 
a n d a female con t ro l . T h e si te of the С to A t r a n s v e r s i o n is indicated 
by a n arrow P a t i e n t H B is heterozygous for t h e m u t a t i o n . Unlabe led 
P C R p r o d u c t s of individual e x o n s were isolated from l'< e t h i d i u m 
b r o m i d e s t a i n e d agarose gels Direct sequence ana lys i s of t h e double 
s t r a n d e d P C R p r o d u c t s was per formed us ing t h e TT s e q u e n c i n g kit 
( P h a r m a c i a . Uppsa la , S w e d e n ) 
these substitutions affect the formation or the structure 
and lateral associations of the triple helix remains to be 
determined. The proline to threonine substitution 
changes the amino acid containing a secondary amino 
group within a cyclic carbon ring structure into an 
amino acid with a smaller side chain with a hydroxyl 
group which is more hydrophilic and may be involved in 
the formation of hydrogen bonds. The tryptophan to 
serine substitution changes the hydrophobicity and the 
arginine to glutamine substitution the polarity of'this 
part of' the molecule. However, as long as little is known 
about the exact structure of the type IV collagen chains, 
it is not possible to estimate the structural and func­
tional effects of amino acid substitutions on the 
COL4A5 chain. 
The clinical features of our total of six patients, with 
characterized mutations (15; this report) are presented 
in Table 3. In comparing the clinical features of patients 
with the mutations, we used anamnestic data of the sons 
of female patient HB and of the nephew of patient DC, 
because DC is still very young. Four of the six patients in 
whom we identified mutations had clinically severe Al­
port syndrome with ESRD before the age of 25 (Table :i ). 
The mutations involved were the complex deletion of 
the 3' end of the gene, the destruction of the splice accep­
tor site in intron 41, and the proline to threonine and 
arginine to glutamine substitutions in the NC domain. 
Surprisingly, the 10-nucleotide duplication in patient 
-IT gives rise to a less severe form of Alport syndrome. 
Maybe normal mRNA is still produced, diminishing the 
effect of the frameshift mutation. Also, the Trp-1538 -*• 
Ser amino acid substitution caused adult onset of ESRD 
(>30 years) in patient WJ (Table 3). As yet. the number 
of mutations detected by us and others is too small to 
allow good phenotype-genotype comparisons. Predic­
tions based on mutation data are possible only for pa­
tients with a COL4A5 5' and upstream deletion, who 
may be at risk for leiomyomatosis (2), and those with 3' 
deletions, who may be at risk for the development of 
anti-GBM nephritis after transplantation (15). 
Five of our total of six mutations (15; this report) were 
detected in the NC domain of COL4A5, and three were 
located in exon 48. We systematically analyzed about 
30rf of the coding region of the gene. Mutations have 
also been identified in the part of the gene coding for the 
collagenous domain, which lies outside the collagenous 
region that we have screened for mutations (2, 8, 13, 17, 
19, 20). The scale of mutations disturbing the type IV 
collagen network and leading to Alport syndrome must 
be quite diverse and in most cases unique for each family 
analyzed. The arginine-1563 to glutamine substitution 
described here is the only mutation so far that has also 
been identified in two other kindreds (21). The ongoing 
effort of characterizing COL4A5 mutations in Alport 
syndrome will provide further insight into the heteroge­
neity of the clinical phenotype and the structure and 
function of the COL4A5 chain in the basement mem­
brane. 
TABLE 3 
Clinical Phenotypes of Six Alport Patients with Characterized COL4A5 Mutations 
P a t i e n t s COL4AÓ mutat ion* 
Age at 
E S R D 
Alport p h e n o t y p e 
H e a r i n g OB.M 
spl i t t ing 
Anti-C.BM nephr i t i s 
a l ter kidnev 
t ransplantat ion 
Yes 
N o 
1. B B ¿ Large complex 3 ' e n d delet ion" 17 Yes N o Yes 
2. W J δ P o i n t m u t a t i o n exon 48 (Тгр15,ЧЯ-* S e r ) " 33 N o No Yes 
3. -IT 6 10-bp i n s e r t i o n e x o n 49 > 3 0 * in -- 2) Yes N o Yes 
4. H B î P o i n t m u t a t i o n exon 48 ( P r o l 5 1 7 — T h r ) 16* in = 2) Yes N o n.d d 
5. DC <5 Splice m u t a t i o n i n t ron 41 16* in - 2) Yes N o Yes 
6. A B ¿ Po in t m u t a t i o n exo ι 48 l A r g l 5 6 3 - • G l n í 2 5 ь in - 2) Yes N o Yes 
-115). 
* Age at E S R D is given as m e a n i n t r a k i n d r e d value for affected m a l e s π ; 
r
 No kidney t r a n s p l a n t a t i o n . 
d
 Not d e t e r m i n e d . 
n u m b e r of males . 
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A variety of mutations have been Identified in the 
X-linked type IV collagen a5 chain (COL4A5) gene In 
patients with Alport syndrome. A substantial number 
of these mutations were predicted to have an effect on 
RNA splicing. For 4 such mutations in our group of 
patients the effect of the DNA mutation on the COL4A5 
mRNA structure and stability was analysed. An alter-
ation of the Invariant splice acceptor site of intron 41 
resulted In a shift of the actual splicing to either a 
cryptic splice site within exon 42 or the normal splice 
site in the next intron. A single base substitution of the 
final nucleotide of exon 48 resulted In the removal of 
the entire exon. Two frameshift mutations, в 10 
basepair duplication in exon 49 and a single base 
deletion in exon 41, were incorporated in the mRNA as 
such and resulted in a stretch of mlssense codons 
terminated by a premature stop codon. Exon skipping 
was occasionally observed in these samples, but not 
reproducibly in every experiment. In healthy controls 
exon skipping was never detected. Analysis of female 
carriers revealed that In only one case was the stability 
of the mutated mRNA reduced in comparison with the 
normal transcript. The extent to which the non-
collagenous domain was predicted to be deleted 
correlated with the severeness of the disease. 
INTRODUCTION 
Alport syndrome is a hereditär,- renal disease which progresses 
to renal failure and which is often accompanied by sensorineural 
deafness ( 1 ) Patients can suffer from eye lesions (lenticonus or 
perimacular flecks), macrothrombocytopenia or leiomyomatosis 
as well (2,3) Some patients develop a specific anu-GBM nephritis 
after kidney transplantation, leading to irreversible graft failure 
(4) Most male patients reach end sage renal disease (ESRD) 
in early adulthood, but in female patients ESRD is infrequent 
Characteristic for Alport syndrome is irregular thickening and 
mululaminalion of the glomerular basement membrane (GBM), 
as seen under electron microscope (5) For X-linked Alport 
syndrome, which is the predominant form of this disorder, 
mutations have been found in the type Г collagen a5 (COL4A3) 
chain gene (6-15) 
We present here the detailed RNA analysis of two mutations 
in the COMAS chain affecting consensus splice site sequences 
and two frame shift mutations The frame shift mutations were 
investigated at the RNA level as well, because these mutations 
create preliminary stopcodons, which alter splice site selection 
(16,17) 
The effect of these four COL4A5 gene mutations on the mRNA 
was studied by RT PCR analysis of total RNA extracted from 
lymphocytes To test whether the stability of the mutated mRNA 
was altered, a female earner was investigated in relation to the 
X-inactivation pattern 
Our results allowed a prediction of the altered COL4A5 protein 
in all four cases and these alterations were related to the nature 
of the clinical features 
RESULTS 
COL4A5 gene mutations 
Three of the four mutations studied at the RNA level were 
described before (15) The fourth mutation was detected in male 
panent JJ and his affected family members by PCR-SSCP analysis 
of exon 41 (Fig 1A) Direct sequence analysis revealed a G 
nucleotide deletion in codon 1204 or 1205 (Fig IB) The 
predicted effect of this mutation is a frameshift with a preliminary 
stop codon in exon 42 
COL4A5 mRNA analysis 
RT-PCR analyses were performed on total RNA. extracted from 
PBL and EBV transformed lymphoblastoid cell lines of four male 
Alport patients and of related female earners Because of the lov. 
abundancy of the COL4A5 mRNA ш lymphocytes, we performed 
at least three independent RT reactions for each patient and only 
reproducible results are presented and discussed here Total RNA 
isolated from PBL and EBV transformed lymphocytes of normal 
healthy individuals and kidney, from a patient with polycystic 
kidney disease, were used as controls Negauve controls consisted 
of reaction mixtures in which reverse transcriptase was omitted 
No fragments were amplified in the negative control (data not 
shown) cDNA fragments encompassing the mutation were 
generated by nested PCR (Fig 2) All nested PCR reactions of 
the three controls (kidney, PBL and EBV transformed PBL) 
resulted in the amplification of a single cDNA fragment of the 
normal length and sequence (data not shown) 
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_____
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ds 
В 
DNA sequence control; tag GC CAA AAG GGT GA 
1204 120b 
intron 40 βχοη 41 
DNA sequence patient JJ; tag GC CAA AA* GGT GA or 
tag GC CAA AAG 'GT GA or 
tag GC CAA AAG G'T GA 
i n t r o n 4 0 exon 41 
Figure I. A: PCR-SSCP analysis of genomic exon 41 sequences in the family 
of patient JJ (lane 4) Double stranded (ds) and single stranded (ss) DNA fragments 
are indicated Affected males (lanes 1 and 4) and females (lanes 3 and 5) show 
shifted single stranded fragments when compared to the single stranded fragments 
of rwo healthy males (lanes 2 and 6) B: DNA sequence ot exon 41 of male patient 
JJ * denotes the G nucleotide deletion (three possibilities) Intron sequences are 
indicated in lower case and exon sequences in upper case Codons were numbered 
as described before (14) The underlined sequence is highly homologous with 
the 5 donor consensus splice site (29). 
RNA analysis of the splice site mutations 
From cDNA of patient DC with an alteration of the invariant 
splice acceptor site ag to aa in intron 41 two fragments were 
amplified with an inner set of primers, covering exons 41 to 47 
(Fig. 2, fragment B). Besides the normal sized 798 bp fragment 
a shorter 664 bp fragment was found (Fig. 3. lane 2). Direct 
sequence analysis revealed that the fragment of apparenti) normal 
length missed the first G of exon 42 (data not shown). This 
mutation shifted the reading frame creating a missense stretch 
of amino acids and a premature stop in exon 42 (Fig. 4). The 
smaller cDNA fragment (Fig. 3. lane 2) contained no exon 42 
sequences as exon 41 was spliced to exon 43 (Fig. 4). Again 
the reading frame was altered and the predicted effect on the 
protein was similar to the G nucleotide deletion (Fig. 4). In a 
blood sample from the mother of patient DC a single cDNA 
fragment of normal length (Fig. 3. lane 1) and sequence was 
detected (data not shown). The presence of only the normal 
transcript could not be explained by a non-random X-inactivation 
collagenous doma'n I NC domain 
JJ OC AB AT 
• • • • 
5' 3B 39 40 41 42 43 44 4S 4G 47 4B 4! SO SI 3 
В 
|>Г A 
С 
Figure 2. The coding regions ot exons 38 to 51 of the COL4A5 cDNA are 
indicated as filled noxes. separated by vertical lines and the 1 non coding region 
as a horizontal line Horizontal arrows represent oligonucleotide primers that were 
used to amplify three overlapping cDNA fragments Fragments Α. В and С arc 
indicated by the open bones Fragment A encompasses exons 47 to 51 (794 bp) 
and was generated with pnmer pairs 276 277 (outer) and 7K 79 (inner), fragment 
В encompassing exons 41 to 47 (798 bp) and fragment С exons 19 to 4.1 (477 
bp) were amplified with pnmer pairs 328 329 ι outer) and 330 331 (innen and 
412 413 (outer) and 414 415 (inner) oligonucleotide pairs, respective!) The map 
positions of the mutations in patients AB. AT. DC and JJ arc indicated by arrow 
heads Vertical arrov. shows the border of the collagenous and non-collagenous 
(NC) domains Exons. oligonucleotide primers and fragments Α. В and С are 
not to scale Pnmer sequences: 276: 5 CTC AAG GCT TAC CAG GTC CAA 
CT-3 . 277 5 -TAA AGT TGG GGA CAA TGA GAC AC 3 ; 78: 5 ' ТА A 
AAC АСА AAA GGA ATT CTT CAA-3'. 79 5 -GCC AGG TAC CCG TGG 
TTT GAA 3 . 328: 5 -CTG GCC AAA AGG GTG ATG GAG G-3 . 329 5 -C-
TG CCA GCC GTC CCC AAG TC-3 . 330: 5-TCC AGG TCC AAA GGG 
CGA AC 3 : 331 5 TAG ACC TGA AGT GTT CCC TGT GG-3 . 412 5-AA-
C CTG GTC CTG TAG GTG GTG G-3': 413: 5' TCA TGC CTG GGA АТС 
CTG GAA C-3 . 414 5 -CTC CAG GCG AAA AAG GCA AAC C-3 : 415 
5 CTT TCA TTC CAT TGA GAC CCG GC-.V 
pattern, because both her parental chromosomes existed partial!) 
in an inactive (methylated) state (data not shown. 18. 19) 
The cDNA of patient AB with a transition to A of the last G 
of exon 48 was amplified with primer sets covering exons 47 
to 51 (Fig. 2, fragment A). A single cDNA fragment was detected 
which was reduced in size (data not shown). Direct sequence 
analysis of this fragment showed that exon 48 was skipped as 
exon 47 was spliced to exon 49 (Fig. 4). The deletion changed 
the reading frame of the downstream sequences, leading to a 
stretch of missense codons following exon 47 and a premature 
stop in exon 49 (Fig. 4) His earner mother displayed two cDNA 
fragments, one of normal and one of reduced size from which 
exon 48 had been deleted, as was found b> direct sequence 
analysis (data not shown). 
RNA analysis of the frameshift mutations 
PCR fragment A (Fig. 2) was also generated for patient AT. who 
carries the same mutation as his brother JT (15). Onl) a single 
fragment was amplified (Fig. 3. lane 4). Direct sequence analysis 
revealed that the additional 10 bp were incorporated into exon 
49 resulting in a preliminar} stopcodon in exon 50 (Fig. 4). His 
mother had both the fragment with the 10 bp duplication as well 
as the normal fragment (Fig. 3. lane 3). 
A single cDNA fragment (Fig. 2. fragment C) of normal length 
was amplified for patient JJ with a G nucleotide deletion in exon 
41 (data not shown). Sequence analysis revealed the presence 
of the deletion (data not shown) similar to what was found in 
the genomic exon 41 sequence (Fig IB). A preliminar) stop 
codon was introduced 102 bp downstream in exon 42 (Fig. 4). 
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Figure 3. Analysis of COL4A5 RT-PCR producLs of 2 Alport patients and their 
mothers on d-i ri denaturing Polyacrylamide gel Lane I and 2 contain fragment 
В amplified trom cDNA trom the mother of DC and patient DC. respectively 
Lane 3 and 4 show fragment A amplification from cDNA from the mother of 
AT and proband AT himself 
Direct sequence anal>sis of PBL-RNA of his affected sister who 
was heterozygous for the mutation, revealed a mixture of two 
cDNA species with and without the G nucleotide deletion (data 
not shown). 
For each patient with a shift or splice site mutation smaller 
fragments were amplified in addition to the cDNA fragments 
described here in about one out of three RT-PCR assa\s. but 
never in an\ of the control samples. Sequence analysis showed 
in each case a specific skipping of the exon containing the 
premature stop codon. Howe\er. in nearh all cases the additional 
skipping of exons introduced a nonsense stretch of amino acid 
residues with the introduction of a novel preliminar) stop codon 
further downstream except one {data not shown). The skipping 
of exon 42 in the RNA of patient JJ did restore the reading frame. 
DISCUSSION 
Splice site mutations 
The two splice site mutations induced the skipping of specific 
exons from the COL4A5 mRNA. The mutation in patient DC. 
the 'agG' sequence at the border of intron 41/exon 42 into 'aaG'. 
created a new splice acceptor site that included the first nucleotide 
ofexon42('aG'). This new splice site functioned less efficiently. 
because two cDNA fragments were generated, one containing 
exon 42 sequences and the other from which exon 42 was 
skipped Both transcripts had similar signal intensities (Fig. 3, 
lane 2) and contained a preliminary stopcodon encodmg truncated 
COL4A5 proteins (Fig. 4). Similar mutations have been described 
before, but in only two cases RNA analyses were included (20). 
The mutation in patient AB was expected to change 
glutamine-1563 for arginine (15). but turned out to cause the 
removal of exon 48 (Fig. 4). Therefore, the real effect of this 
mutation could only be determined from the mRNA. Apparently, 
the final nucleotide of an exon is important for correct use of 
the splice donor site (21) and such a mutation can prevent binding 
of the Ul small ribonucleoprotem (snRNP) complex to the 5' 
end of the intron (22. 23). resulting in alternatively spliced RNA 
(24). The same arginine-1563 has been found to be mutated in 
three other patients, two of whom carry the same mutation as 
our patient (25). It would be of interest to know whether in these 
4 0 41 « 2 
4! TAA 
3 8 «О 41 4 3 
2B Ьр 
тел 
За 3» 40 41 42 43 44 46 4β 47 48 
1 О t>ß 
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Figure 4. Schematic representation of aberrant COL4A5 cDN As of the four male 
Alpon patients Exons are indicated by closed boxes and numbered Open boxes 
represent stretches of missense sequences (lengths are given in bpi. terminated 
by preliminar} stopcodons Exon skipping is indicated by bended curve connecting 
the two flanking exons Exons 4 7 - 5 1 comprise NC domain (Fig 2) 
patients alternatively spliced COL4A5 species were detected as 
well. Complete exon skipping has been reponed for G to A or 
to С mutations at similar positions in the COLIA 1 gene (26). 
in the COLI A2 gene (27) and in the COL4A5 gene (28). In other 
genes, however, skipping was only partial (20). 
Frameshift mutations 
The two frameshift mutations were incorporated in the mRNA 
as such, predicting a protein with a truncated, nonsense stretch 
of amino acids at the carboxy-terminal end. Premature stop 
codons were created, respectively. in exon 50 ( 10 bp duplication; 
patient AT) and exon 42 (G nucleotide deletion: patient JJ). 
Because of lack of homology with the splice donor site consensus 
sequence (29). the ten basepair duplication was not removed by 
splicing. The G nucleotide deletion in the lysine-1204 or 
glycine-1205 codons created a sequence with high homology to 
the 5' splice donor consensus sequence (Fig. IB). However, only 
a single cDNA fragment was amplified by RT-PCR in this 
patient. Hence, the putative splice donor site had not been used 
In the fibrillin and ornithine δ-aminotransferase genes (16) and 
the E2 gene of the mitochondrial branched a-keto acid 
dehydrogenase (BCKD) complex (17) nonsense mutations have 
been shown to induce skipping of the exon containing the stop 
codon and in that way restoring the reading frame. 
We have no conclusive evidence that preliminary stop codons 
created by frameshifts induce exon skipping in the COL4A5 gene. 
Occasionally, alternative splicing removed the exon containing 
the stop codon, but not reproducibly in every RT-PCR 
experiment. However, this additional exon skipping did not 
restore the reading frame except in one case. The skipping event 
was specific and was never encountered in normal controls. Most 
likely the poor reproducibility is the reflection of the very low 
abundance of these transcripts in the pool of PBL-mRNAs 
Further work on the in vitro expression of normal and mutant 
cDNA constructs may further elucidate this phenomenon. 
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Figure 5 A Schematic representation оГ interchain disulfide bonds after dimcnzation of two type IV collagen chains via their NC domains in normal individuals 
(modified from reference 38) Solid black lines indicate the NC domain and comprise exons 47 to 51 bxon-exon boundaries are indicated bv arrowhead the N 
and C-terminal ends by NH-, and COOH respectively Stippled line represents the collagenous domain В Schematic representation of possible interchain disulfide 
bonds of two truncated rvpc IV α ϊ chains as predicted for patient AT Dotted line represents missense sequences containing one introduced cysteine residue The 
NC domain of a 5 (IV) and α I (IV) chains are structurally closely related (39) Numbers and symbols are identical as for figure SA 
Obviously, RNA from kidney tissue would be preferable, but 
this tissue was not available for these patients However, 
illegitimate mRNA transcripts in peripheral blood cells have 
proven to be a reliable source for detecting and studying mutations 
in disorders such as Duchenne or Becker muscular dystrophy 
and familial hypertrophic cardiomyopathy (30-33) 
Stability of the mutated mRNA 
Reduced levels of mRNA containing premature nonsense codons 
have been described m several reports caused either directly by 
nonsense mutations or indirectly by frameshift mutations 
(16,34—36) To investigate if Alport syndrome in our patients 
was caused by a reduced amount of COL4A5 rather than an 
altered COL4A5, we studied the gene expression of COL4A3 
in female earners Three out of four carriers expressed both the 
normal and the mutated allele Because of the low amount of 
the COMAS mRNA m PBL, it was not possible to quantify the 
expression level in relation to the X mactivation partem PCR 
amplification as performed, may qualitatively reflect the presence 
of normal and aberrantly spliced products, but absolute levels 
of COL4A5 mRNA can not be determined Only the mother of 
pauent DC expressed solely the normal gene (Fig 3, lane 1) 
Her X-inactivauon pattern was random and, therefore, we must 
conclude that the stability of both mutated mRNAs (Fig 4) is 
reduced Two other more speculative mechanisms have been 
proposed to explain the effect of preliminar, stop codons The 
'translational translocation' model (34) and the 'nuclear scanning' 
model (35) both predict that the effect of preliminary stop codons 
is RNA degradation and that the effect of these mutations should 
be discussed m terms of reduced levels of mRNA Both models, 
however, do not preclude the formation of a truncated protein 
and in male patients with Alport syndrome, even m a low amount, 
this will be the only COL4A5 protein available, which may cause 
the clinical heterogeneity in Alport syndrome (see below) 
Clinical features 
Type Г collagen a chain is composed of three domains the N-
termmal region Í7S region), the central collagenous domain and 
the C-terminal non-collagenous (NC) region (37) The COL4A5 
NC domain contains two homologous halves each containing six 
conserved cysteine residues which are used for dimenzation 
(38,39, Fig 5A) 
Three of the four male patients described suffered from juvenile 
Alport syndrome Two lack the entire NC-domain and part of 
the collagenous domain and one (Fig 4, patient AB) about 80% 
of the NC-domam, making it completely non-functional This 
corroborates results from patients with deletions that include at 
least the NC-domain who are severely affected as well (14) Only 
pauent AT is over thirty years of age and has not yet reached 
complete renal failure Because each COL4A5 chain in this 
patient misses one half of the NC domain still six cysteine residues 
arc left, from which four could be used for dimenzation (Fig 
5B) This suggests that half of the NC domain may be sufficient 
for incorporation of type Г collagen in basement membrane 
network 
PATIENTS, MATERIALS AND METHODS 
Patients' samples 
Guucal спіегы for Alport syndrome were as described before (40) Genomic 
DNA was isoUied from peripheral blond (41) Peripheral blood lymphocyies (PBL) 
were separated from hepanmzed blood by centnfugauon (400 x g) through a layer 
of Histopaque 1077 (Sigma St Louis MO USA) followed by rinsing twice with 
ice-cold PBS Lymphoblastom B-cell lines were created bv transformation with 
Epstein Ватт virus (EBV) (42) RNA was isolated from PBL and cultured EBV 
transformed lymphoid cell lines by the RNA zo)™ method (43) Total RNA was 
stored as an ethanol precipitate at - 2 0 ° C 
cDNA synthesis 
Two to Five pg of total RNA extracted from PBL EBV lymphoblastoid cells 
or kidney (pauent with polycystic kidney disease) in a volume of 10 μΐ aquadest 
was incubated for 10 minutes at 65°C under a layer of mineral oil (Sigma St 
82 
Louis. MO. USA) The sample was snap-chilled on ice and 200 pmol oiigo-dT 
primers. 200 pmol random hexamers (Promega. Madison Wl. USA), β μΙ 
5 x reverse transcnption buffer (Gioco BRL technologies. Gaithersburg. MD, 
USA), 200 U Superscript™II RNaseH reverse iranscnptase íGibco BRL 
technologies. Gaithersburg. MD. USA). 5 μΐ 10 mM dNTPs (Boehnnger, 
Mannheim. Germany) and 40 U RNAse inhibitor (Promega. Madison WI, LSAl 
were added in в total volume of 40 μΐ After 1 hour at 42 "C the reaction was 
stopped by incubation at 96°C for 5 minutes and die cDNA samples (RT mixture} 
»ere stored at - 2 0 " C 
A 40 μ\ mixture containing 4 μΙ 10 x PCR buffer (670 mM Tns-HCl. pH 8 8. 
166 mM fNH»)SOj. 67 mM MgCl ;. 1 7 mg'ml BSA (Boehnnger. Mannheim 
Germany) and 100 mM 0-mercaproethanol 200 ng outer forward pnmer. 200 
ng outer reverse pnmer (Fig 2) was added to I U Ampli-Taq DNA polymerase 
(Perkui-Elmer Cetus Norwalk. CT. USA) and ΙΟμΙ of RT mixture on ке After 
denaruration at 94CC for 5 minutes thirrv cycles of PCR (denaturauon at 94DC 
for 1 minute, annealing at 58°C for 1 minute and extension at 72°C for 3 minutes) 
were perlormed m a DNA thermal cycler (Perkin-Elmer Cetus. Norwalk, CT. 
USA) Samples (I to 2.5 all of the first PCR product were added to a 30 μΙ 
mixture of 3 μΐ 10 x PCR buffer. 5 μΙ 10 mM dNTPs (Boehnnger. Mannheim. 
Germany) 100 ng inner forward pnmer. 100 ng inner reverse pnmer and 1 V 
Ampli-Taq DNA polymerase to perform a second PCR amplification of thirty 
cycles including 2 μΟ 3 ;P-dCTP (denaruration at 94 *C for 1 minute, annealing 
at 60°C for 1 minute and extension at 72 a C for 2 minutes) The PCR product 
was analyzed on a 4 £ Polyacrylamide gel containing 8 M Urea Unlabeled PCR 
products were electrophoresed on 2% agarose gel stained with ethidium bromide 
PCR-SSCP aiuuysb 
PCR-SSCP analysis of individual COL4A5 exons was performed as desenbed 
before (15). 
Direct sequencing of PCR-fragments 
PCR fragments were isolated from agarose gels after electrophoresis by the •freeze-
squeezc method as desenbed before (15) Cycle sequencing was performed 
according to the Taq dyedeoxy™ terminator protocol from the manufacturer 
(Applied Biosystems Foster City. CA USA) using 200 ng to 1 μg PCR fragment 
as template and the forward or reverse inner PCR-pnmer as sequencing pnmer 
The fluorcsccmly labeled PCR products were extracted twice with 
рпепоГсЫогоІогтп and subsequently precipitated with ethanol at - 2 0 ° C The 
pellets were washed in 70Я ethanol and solubilized in 5 μΐ 96% formamide. 
Ι μΙ 50 mM EDTA pH 8 0 Samples were electrophoresed on a 6% 
Polyacrylamide β M urea gel and analyzed by an automated ABI 373A DNA 
sequencer (Applied Biosystems, Foster City, CA. USA) 
X-uuctivalHHi analysis 
Genomic DNA was digested with either Psil only or with ЛгІ and the теіпуініюп 
sensitive enzymes Hpaii or Hhai ( 3 - 5 U ^ g DNA. Gibco BRL technologies 
Bethesda, MD. USA) (19) After agarose gel electrophoresis. DNA was 
immobilized by Southern binning This blot was screened with probe M27/3 
(DXS255) (44), radiolabeled by random pruning using a12P-dCTP (45) This 
probe is informative in most cases and the inactivation pattern of both X-
chromosomes can be compared (18) 
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Alport syndrome (AS) is an hereditary disease of basement membranes characterized by 
progressive renal failure and deafness Changes in the glomerular basement membrane 
(GBM) in AS suggest that the type IV collagen matrix, the major structural component of 
GBM, is disrupted We recently isolated the genes for two type IV collagens, аЗ(І ) and 
a4(IV), that are encoded head-to-head on human chromosome 2 These chains are 
abundant in normal GBM but are sometimes absent in AS We screened for mutations in 
families in which consanguinity suggested autosomal recessive inheritance 
Homozygous mutations were found in аЗ(І ) in two families and in ct4(IV) in two others, 
demonstrating that these chains are important in the structural integrity of the GBM and 
that there is an autosomal form of AS in addition to the previously-defined X-lmked form 
Tvpe [V collagen forms a macromolecular 'chicken wire 
meshwork that, along with laminine, proteoglvLans and 
entactin/nidogen, pro\ ides the nonstructural component 
ot the glomerular basement membrane (GBM)1 We 
now know of six type IV collagen isoforms, аІ(Г )-
а6(І\ Γ ".which have very similar structures each has a 
С terminal non collagenous (NCI) domain of -230 
residues and an -1,400 residue collagenous Glv X-Y repeat 
that forms a triple helix with two other chains and an N 
terminal'75 domain Four of these tnmers interact at 
their N terminal ends and two interact via disulphide 
bridges at their С terminal ends to generate the type IV 
collagen meshwork' и Although this superstructure has 
been formally established onlv for networks consisting of 
the abundant αϊ (IV) and a2(IV) chains the striking 
homologies between the six chains suggest that their 
modes of interaction are similar Initial studies of the 
distribution of the six chains show that the al(IV) and 
a2(IV) isoforms are ubiquitous whereas the аЗ(І )-
аб(І ) chains have a limited distribution1"1 1* '6 
Currently we have no understanding of the differential 
functions of the six isoforms, in viewof the great difficulty 
in devising assays for these functions studies of type IV 
collagen mutations in humans and animals may provide 
important clues to their roles in different basement 
membranes (BMs) 
Alport syndrome (AS), the most common form of 
hereditary glomerulonephropath\, manifests as 
proteinuria, hematuria and progressive loss of glomerular 
filtration' A progressive deafness that is most pronounced 
at high frequencies is usually present The striking 
lamellation and splitting that characterize the GBM in AS 
suggest that the genetic defect leads to disruption of the 
structure of the membrane Because the tvpe IV collagens 
are assumed to be important structural components of 
BM the genes encoding the six isoforms are candidate 
sites for AS mutations 
All formsof mendehan inheritance have been postulated 
for AS1 but linkage studies show that X linked forms 
predominate These studies were supported bv the 
disco\erv in several AS kindreds, of mutations in COI 4A5, 
an X linked gene encoding the oc5(IV) chain which is 
found in GBM and some other BMs4lül14* COL4A5 
mutations include deletions of all or part of the gene, 
single base mutations that disrupt disulphide bonding 
or disturb the collagenous repeat and splicing mutations 
and deletions that alter chain length and presumably 
disrupt polymerization18 '4 
Although COI 4A5 mutations are probably responsible 
for most cases of AS, several families have been reported 
in which the pattern of inheritance makes X linkage 
unlikely' *°" For example, in a study of 41 families, four 
pedigrees, all consanguineous were believed to be 
autosomal recessive"0 Severe earlv disease in girls, which 
is rare in the X linked form, was a striking feature of the 
phenotypc Nevertheless, becauseof the small famih size, 
the mode of inheritance in these families cannot be 
confirmed except b\ the detection of mutations in an 
autosomal gene 
Along with laminins proteoglycans and other 
componentsofGBM, the fourautosomal type I\ collagen 
genes {COL4AÌ-COL4A4) are candidates for mutations 
in cases where COL4A5 can be excluded by linkage testing 
with genetic markers, throughacompletemutation screen, 
or where there is a pattern of disease inheritance that is 
inconsistent with X linkage TheaHIV )anda2(IV)chains 
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Fig. 1 Pedigrees. Filled symbols indicate patients with 
Alport syndrome. Double lines indicate consanguineous 
mating«, in family BE. 1-2 and 1-5 are second cousins. 
are the least likely sites for AS mutation since functional 
defects in these abundant ubiquitous chains would be 
expected to be lethal due to .severe developmental and 
structural effects in many essential organs. By contrast, 
the ct3( í V ) and a4( IV ) chains have a restricted distribution 
which includes GBM'*""'. Moreover, several studies have 
shown that anti-аЗП ) antibodies, which occur naturally 
as auto-antibodies in Goodpasture syndrome, fail to react 
with the GBM in many AS patients^-4. Similar results are 
found with anti-cc4(IV) sera implicating both of these 
chains in the pathogenesis of the disease*. 
We have recently shown that COL4A3 and COL4A4 are 
arranged in a head-to-head manner on chromosome 2 
(refs 26,27), and have clonedayeast artificial chromosome 
which contains the entire transcription units of both 
genes (MM., unpublished data). We now describe a 
study to search for mutations in these genes in seven 
families with a form of AS likely to be autosomal recessive. 
The features that distinguish these families are the presence 
of known or suspected consanguinity, severity of disease 
in affected females in the first decade of life and 
asymptomatic parents. In four of the seven families, we 
have detected homozygous mutations in COL4A3 or 
COL4A4, demonstrating the existence of an autosomal 
recessive form of AS. 
Clinical findings 
Family VB. This family has been described previously3*. 
The female proband (Fig. I, H-l). who had haematuria 
from 4 years of age, had typical ultrastractural lesions of 
AS on electron microscopy of a renal biopsy, and 
sensorineural deafness. Renal function deteriorated 
gradually until haemodialysis was started at age nine. She 
received a renal allograft at age ten and developed anti-
GBM nephritis six months later. Her brother (II-2) has 
haematuria, deafness, and deteriorating renal function. 
The parents have no symptoms. There is no known 
consanguinity but the parents and their known ancestors 
originate from the same small village in the Netherlands. 
Family DU. An 11-year-old Belgian female (Fig. Ì.II-1) 
was referred for end-stage renal disease (ESRD). School 
examination had revealed proteinuria and 
microti a ematuria at age seven. At age 11, the patient was 
transplanted with a kidney from her mother. Currently, 
the patient is 16 years old and no rejection or anti-GBM 
nephritis has occurred. Electron microscopy of the native 
kidney revealed lamellation and splitting of the GBM, 
classical features of AS. Antibodies against the 0c3( IV) and 
0t4(lV) chains did not react with GBM. At age 13 an 
audiogram showed bilateral sensorineural hearing loss. 
The parents are first cousins. Both have normal renal 
function and urinalysis. The father has mild bilateral 
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have persistent microscopic haematuria with proteinuria 
at age six. Glomerular filtration began todeteriorate at age 
11 and ESRD occurred at age 14. No deafness or ocular 
abnormalities have been observed. At age seven extensive 
thinning and focal thickening of the GBM were observed 
on renal biopsy. There was normal labelling of the GBM 
with antibodies to both a3(IV) and tx4{IVi. The second 
daughter ( IV- 2 ) was found to have persisten t microscopic 
haematuria at age five. The nephrotic syndrome without 
a decrease in renal function was noted at age \ 1. No 
deafness or ocular abnormalities were found. The parents 
are Berbenans from Algeria. They are first and fourth 
cousins (double consanguinity) and have tested negative 
for haematuria and proteinuria. Neither they nor their 
third child ÍIV-3) has any renal symptom or deafness. 
Patient 
. CTT TTT STA CM GGfi AAT CM CGA GCC САС . 
leu Phe Val СЭп Gly Asn Gin Arg Aia His 
. СТТТГТСЛАСДАСЗЗАААТСААТСАСГССДС . 
leu Phe Val üln Gly Asn Gin * 
sensorineural hearing ïoss, attributed to his work 
environment. The three siblings have normal renal 
function, and no haematuria. Audiography is normal in 
twoofthem but the third hasa mild unilateral hearing ¡loss 
ÍII-3). 
Family BE. The older daughter ( Fig. 1, ! V-1 ) was found to 
Family GA. An Italian girl (Fig. 1, II-3), observed in 
Belgium, was found to have albuminuria and haematuria 
at age eight. Renal function deteriorated progressively 
and haemodialysis was started at age 18. The patient was 
transplanted with an HLA-matched cadaver kidney. No 
kidney tissue was available for study. Audiography was 
normal. The parents' families share the same surname 
and originate from the same village in Italy but there is no 
known consanguinity. The mother has normal renal 
COLLAGENOUS DOMAIN 
TT 
а4(1 ) 
COL4A4 
Fig. 4 AS mutations in COL4A4. a. DNA and deduced 
ammo acid sequences of COL4A4 in family BE and in a 
normal· subject. A schematic representation of the C-
terminal end of a4(IV) is shown. The six vertical bars within 
the white box represent collagenous interruptions. The C-
terminal NC1 domain is shaded. Pnmers A4181F and 
A4185R were used for cDNA amplification. A homozygous 
single-base substitution of G to A replaces glycine with 
serine This mutation lies between interruptions V and Vi 
(indicated by two vertical arrows) in the collagenous 
domain of ct4(IV). The amino acid sequence of interruption 
VI is underlined, b, DNA and deduced amino acid 
sequences of CQL4A4 in family GA and in a normal 
subject. A schematic representation of COL4A4 genomic 
DNA. together with the pnmers used for PCR amplification 
and sequencing, are shown. Exons are shown by white 
boxes and introns by horizontal lines. Pnmers A4IF10 and 
A4185R were used for genomic DNA amplification. A 
homozygous single-base substitution of A for С causes 
conversion of a serme codon to a stop codon. The lower 
case letters in the DNA sequence indicate the ¡ntron 
sequences, and upper case letters indicate the coding 
sequences. 
.«^ TKCATGATC^GœcCACCTOGTCCAarca» .. Normet 
Gly Lei His Авр Ц Gly Pro Pro Qly Pro Val Cuy 
GOT TIG СДГ СКГ GTS GCD CCA CCT ЛОТ CCA GTC GGA .. Paient 
tar (BE) 
b COL4A4 
COLLAGENOUS DOMAIN 
A4IF1B 342 bp _ А 4 1 И В 
Normal . . ctEagGG ACT ICA OCA CCA CCT GOT CCT ŒA.. 
Ser Ser Gly Pro Pro Gly Pro Ala 
Patient - • CttagCG ACT IIA OCA CCA CCT GST OCT CCA.< 
(GA) Ser * 
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function and no unnarv abnormalities at age 53 The 
father is hypertensive. Although his renal function is 
normal and proteinuria is absent, microhaematuna has 
been found intermittently. Among the patient's three 
sisters, one (ÌI-1 ) started haemodialvsis at age 12 and died 
6 months later, another (11-4) died from renal failure at 
age eight. The second sister (II-2), currently aged 11, has 
no haematuna and has normal renal function No member 
of the fa mil) is deaf. 
Mutations in COL4A3, the a3(IV) collagen gene 
We identified different homozygous mutations in the 
NCI domain of COL4A3 in two families with AS In 
familv VB, direct sequencing of PCR amplified cDNA 
from the lvmphocvtes of an affected female demonstrated 
a homozygous 5 bp C'TTTT deletion (Fig 2a). This result 
was confirmed in the genomic DNA of the patient and in 
her affected brother. There are ten 5 bp deletions that 
would result in the observed sequence difference. All of 
them produce a frame-shirt and have the exact same effect 
on the amino acid sequence — a missense sequence of 33 
amino acids and premature chain termination (Fig 2b,c) 
There are also five possible 5 bp tandem repeats including 
the one shown. A "replication slippage" at am* of (en 
points is a hkelv cause oí the observed change (Fig 2) The 
proband developed anti-GBM nephritis after renal 
transplantation In a competi tiveFLISAI data not shown), 
binding of the patient's serum was inhibited bv increasing 
concentrations of Goodpasture sera which contains 
autoantibodies directed at the NCI domain of аЗ(І ) 
chain ' ' 
InfamiK Dl', we sequenced exon 5 of COL4A3, counting 
from the 3' end' , and detected a homozygous single-base 
substitutionof I forC(Fig Эя) This mutation replatesan 
arginine codon with a stop codon in the NCI domain, 
shortemngthea3(IV)chainbvl90amino-actds(Fig.3b); 
it isexpected to disrupt 11 of the intermolecular disulphide 
bonds that stabilize the homodimenzation of NCI 
domains. Immunohistochemical staining of a renal biopsy 
specimen (not shown) revealed that this patient's GBM 
does not react withanti-a3(IV)oranti-a4(IV) antibodies 
These findings suggest that the nonsense mutation in this 
familv nor onlv disturbs the assembly of type IV collagen 
molecules containing truncated аЗ(Г ) chains but also 
disrupts stable incorporation of the a4( IV) chain into the 
GBM'-
Mutations in COL4A4, the a4(IV) collagen gene 
We identified different homozygous mutations in the 
collagenous domain of COL4A4 in two families with AS 
In familv BE, we found a G to A substitution on direct 
sequencing of Ivmphocvte cDNA representing a segment 
ofthe3'ihirdoftheot4( IV) collagenous domain (Fig 4a) 
This result was confirmed in the genomi«. DNA of the 
patient and in her affected sister The mutation results in 
the substitution of a serine residue for a glvcine residue 
that is part of the Glv-X-Y collagenous repeal. There is 
good reason to believe that this mutation is pathogenic 
(see below) 
In familv G A a homozygous substitution of A for С was 
foundinthecollagenousdomainofa4(IV)(Fig 4b) This 
mutation replaces a serine codon with a stop codon 
causing premature chain termination and shortening of 
thea4(IV) chain bv 453 amino acids 
Discussion 
We have found four different homozygous mutations m 
the аЗ(І ) and a4(IV) chains in AS pedigrees. These data 
demonstrate the existence of an autosomal recessive form 
of Alport syndrome and show that the disease is genetically 
Table 1 Primer sequences 
RT-PCR 
COL4A3 
Genomic DNA 
COL4A3 
(ΕΧΟΝ 5) 
(ΕΧΟΝ 4) 
(ΕΧΟΝ 3) 
(ΕΧΟΝ 2) 
(ΕΧΟΝ 1) 
COL4A4 
(ΕΧΟΝ 4) 
(ΕΧΟΝ 3) 
(ΕΧΟΝ 2) 
Foward primer sequence (5 -3') 
A3F10 ce-G^^-i^-revr-GCC 
A3F2 —G—CrC^r¿CC^..C7CT 
A3F4 £СААЗ~ГГл~-· G^j^G 
A3F5 CCC-^-rCA-C^-CTG-
A4181F GCTCACAAAGGAACTAAAGC 
A4181F GG7CAGAAAGGA\C?AAAGG 
A4F11 GGÍ TGACTGTZCCCGAATC 
A4F12 СArtAGGC'TTGGCCCTGGATA 
A3F10 CCTGG7 7CAGATCGATTCCC 
A3IF4 GC7-GTGTG7AG7AACGA7GC 
A3F2 7CGC7CTCAACACCAGCTCT 
A3IF2 -CAAGCCCAATGGACAGAGT 
A3IF1 GACC 4AAAATTCCC7TT7ATGC 
A4IF10 AGGC^C-^-AACAGGGACAAGA 
A4IF9 ¿rCTTCCAAn-GCAA^GAG 
A4IF3 A C " G C C A U A A C A G A G G T G C T 
A4F2-2 CCCAGG ~"rCTTGCeTCCCG7A 
A4IF1 M C C " G G " G~GTCCC7GAT 
Reverse pnmer sequence (5 -3') 
A3R1 rAG-^AToGCAGCCA^T 
A3R2 Г'ГЛГ-.GGAA-TC-TZC 
A3R3 C i G - C - C — - C T T C i T C C 
A3R5 AA^GCTCAGGATACC^G^ 
A4185R C/GGn*7G""CC?:AG._=AG 
A4R15 CCAGGAAJGC'TGGoATC 
A4R1 A T ^ C C C W T C V ^ ^ C J - G 
A4R13 С0С\7-СТСТъС-.^-\С 
A3IR1 
A3IR4 
A3IR3 
A3IR2 
A3R5 
A4165R 
A4IR9 
A4R18 
A4IR2 
A4R13 
""GCA^GTGG-JVC^GCA 
CCAT^ACViUvaiAAG" 
"'ХГ'ААСАТГС.'Т^АЗС 
TGAATAGT^CTCCñA-
ΑΑ-Χϊί,'ΤίΧ AUG V * C X 
TCTAT-CGCCSiC'CT 
CGTCT'AGC-A-TGC -
The exons are numbered from 3' end of the genes 
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heterogeneous with involvement, in different families, of 
the аЗ(І ), o4(IV) and ct5(IV) chains 
Based on the limited number of cases with аЗ(І ) and 
a4(IV) mutations described here, the autosomal and X-
hnked forms of AS appear to be phenotypically 
indistinguishable renal failure and sensorineural deafness 
ma\ result from mutations in the аЗ(І ) or a4(IV) or 
a5(IV) chains The significant difference between the 
autosomal and X linked forms is that the former affects 
males and females equall) whereas the latter is rareh-
associated with progressive renal failure in females 
Three of the AS mutations we have documented result 
in prematurely terminated collagen chains There are 
several lines of evidence to suggest that the fourth, a 
homozygous glycine-to-serine mutation observed in 
familv BE, is also pathogenic First, both affected females 
were homoz\gote!) whereas the asymptomatic parents 
and unaffected brother are heterozygous for the mutation 
(data not shown) Second, the mutant allele was not 
observed in 32 unrelated individuals from the same North 
African population (data not shown) Third, similar 
glycine to-senne substitutions have been described in the 
fibrillar collagens al(I) and a.2(I), in osteogenesis 
imperfecta",J Unlike the fibrillar collagens, type IV 
collagens contain between 21 and 23 short interruptions 
of 1 to 24 ammo acids in the collagenous domain*"'0 
Although the function of these interruptions remains 
unknown, the\ aregenerallvassumed to pro\ ide flexibility 
for the molecule The substitution in famiU BE occurs 
between interruptions V and VI ofthea4( IV) collagenous 
region (hg 4л) bincethismutationeffectivelvcreatesan 
additional interruption, its effect might be considered 
trivial Howe\er, comparison of the sequences of six lype 
IV collagen chains, where known, indicates that the 
positions of the interruptions are highly conserved3* 
1
 *
x
 ** Moreover, the ct4(IV) chain appears to form 
triple helical protomers with other isoforms including the 
аЗ(І ) chain'* the registration of the triplets ma\ be 
disrupted b\ the additional interruption created bv the 
serine substitution This, together with the fact that a 
senne-for-glycine substitution has been observed in the 
a5(IV) chain in a patient with X-hnked AS"\ suggests that 
the mutation observed in family BE is indeed pathogenic 
Itisinterestingtonolethattheglycine to serine mutations 
in both the a4(IV) and аэ(І ) collagens are recessive 
whereas similar mutations in fibrillar collagens arc 
dominant 
The аЗ(І ) and ct4("V) chains are found in a number 
of tissues beside the glomerulus and cochlea, yet the other 
sues of expression (the lung, choroid plexus and 
neuromuscular junction, for example) are not overtly 
Received 9 March accepted 24 May 1994 
affected by the аЗ(І ) and ot4(IV) mutations 
demonstrated here Currently we know little of the chain 
compositions of BMs in different tissues nor of the nature 
of intermolecular interactions between tvpe IV collagen 
isoforms It is possible that functional abnormalities are 
limited to tissues in which a critical subset of the man\ 
possible interactions between different isoforms take place 
Studies of type IV collagen network architecture, function 
and variation are needed to explain the observed pattern 
of disease in Alport syndrome 
Methodology 
RT PCR For families VB and BE total cellular RN \ was prepared 
from Ivmphoblasts * The RNA (2 μg) was tonserled in cD\A t" 
oligo dT or random primed cDN A wnihcsis using superscript rev erse 
transcriptase (BRLl The cPNA (I μ] oui of 20 μΐ cDNA synthesis 
reaction l was amplified b\ PCR using primers as described in Table 
l The primers for COL4A 3 were based on published sequence " * 
and the primers of COL4A4 were based on published sequence * ** 
and unpublished sequence (M M manuscript in preparation) 
standard 30 μΐ PLR reactions were performed 3 mm at 94 X. 
followed b\ 15 cvcles of 60 s ai 94 "С 60 s at *8 %. 90 s at 72 К with 
a final elongation step of 10 min at 72 °C 
PCR amplification. Genomic DNA was extracted from peripheral 
blood ieukoevtes and amplified bv PCR using the primers described 
m Table 1 The intron pnmer sequences were obtained trom the 
sequence of genomic PCR products amplified using primers based 
on the sequences of the flanking exon (ОЫАІ Iniron 1 (between 
exon 1 and 2) A3F4 and A3R3 Intron 2 A3F11 ( 5 -
CATGTCCTCACGGCTGGAT-3 ) and A3R2 Intron 3 A3F2 and 
A3R11 (S-TGTGAAU,GCTATGGCGATC-3) Intron 4 A3FI 
(5-TCAAACCACAGCAATTCC-3)andA3Rl COL4A4 Intron 2 
A4F2 2 and A4R13 for A41F10 A4l8lFandA4 185R for A411-9 
A4IFI0 and A4I8DR for A4IR9 A4ÏF9 and A4183R ( 5 -
GAAGGTC AACACTCCCAG-3 ) PCR conditions were as above 
The exon/intron structure of COI 4A.Ì is based on published data ' 
and that of COL4A4 is based on published data11'" and our 
unpublished data 
Direct sequencing of PCR-products The PCR products were 
sequenced using ads DNAcvLlesequencmgl.it BRL) withthe same 
primers used for PCR amplification In addition A4l83RandA4R2l 
(э-ССАТСТТПССАК ACATC-3 ) were used to scquente the 
A4181F A4R1S PCR product and A4F2 2 A4E2R1 (5 ACAGG-
CTCCTC С AGGTCTGC-3 ) and A4191К 5 -AC С AAGGAGüAG-
GGCAGG-3 )wereusedtosequencetheA4Fl2 A4R13PCRproduct 
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A group of 22 unrelated patients with sporadic or non-
X-llnked Alport syndrome were screened for mutations 
In the поп-collagenous domain of the type IV collagen 
Q3 (COL4A3) chain gene The five 3 -exons of this gene, 
located on chromosome 2qter, were tested by single 
strand conformation polymorphism analysis and direct 
sequencing One patient was heterozygous and 
another homozygous (Mochizuki er al, Nature 
Genetics, in press) for a deletion of five nucleotides 
A third patient appeared to be a compound 
heterozygote for two different nonsense mutations In 
two patients and the father of a deceased patient we 
found a heterozygous substitution of an evolutionary 
conserved leucine by proline However, segregation 
data of the mutation and a COL4A3/COL4A4 CA-repeat 
marker in their families argued against a causative role 
of the missense mutation Even drastic changes of 
strongly conserved amino acids, as in the Leu36Pro 
case, may not be significant Autosomal recessive 
inheritance due to pathogenic COL4A3 mutations 
accounts for at least 13% of Alport syndrome cases In 
this sample It Is concluded that COL4A3 is a major 
gene In the genetically and clinically heterogeneous 
Alport syndrome 
INTRODUCTION 
Alport syndrome is a progressive hereditär) renal disorder with 
characteristic ultrastructural lesions of the glomerular basement 
membrane (GBM) (I) Patients have been classified by the 
severity and nature of the clinical features combined with genetic 
segregation data in Alport families (2) In the vast majority of 
these families Alport syndrome segregated as an X linked 
dominant trait ( 3 - 5 ) More than 60 different mutations have now 
been detected in Alport patients in the X-chromosomal COL4A5 
gene (Second International Workshop on Alport syndrome 
February 1993 New Haven) (6) A second X-chiromosomal type 
IV collagen chain gene (COL4A6) has been identified head to 
head to COL4A5 (7) Deletions including the 5 ends of both 
the COL4A6 and COL4A5 genes have been described in four 
cases of Alport syndrome in combination with oesophageal 
leiomyomatosis (7) 
Apart from X linked pedigrees a smaller number of families 
has been described for which autosomal recessive inheritance was 
suggested (8 9) Three independent lines of evidence pointed to 
a crucial role of the COI 4A3 gene product in a subset ot Alport 
patients (ι) immunohistochemical studies have revealed the 
absence of reaction of Goodpasture antisera with the GBM ot 
some Alport patients (autoantibodies against the non collagenous 
(NC) domain of COL4A3) (10 l l ) (n) anti renal allograft 
antibodies from patients with an ami GBM nephritis after kidnev 
transplantation were shown to be directed against the COL4A3 
NC domain (12) and (in) in autosomal recessive Alport svndmme 
genetic linkage was demonstrated with the COL4A3 COL4A4 
locus at the terminal region of the long arm of chromosome 2 
(13) Recently we have described the first mutations in the 
COL4A3 gene in female patients from consanguineous marriages 
(14) In the last few years we have collected 50 unrelated Alport 
patients with and without family history This sample consists 
of 18 sporadic (15 males and three females) 28 X linked one 
autosomal dominant and three autosomal recessive cases 
Although male patients predominated in the sporadic group 
making the involvement ot an X linked gene for the majority 
likeh we decided to screen the entire group of sporadic and non 
X linked cases for mutations in the NC domain ot COL4A1 This 
enabled us to evaluate the prevalence ol mutations in the COL4A3 
gene in Alport syndrome 
RESULTS 
Human genomic DNAs from 21 unrelated Alport patients and 
the parents of one deceased patient (no 6537) were screened b\ 
single strand conformation polymorphism (SSCP) analysis tor 
mutations in the five exons encoding the NC domain of the 
COL4A3 gene For exons 1 2 and 3 counting from the 3 end 
of the gene no mobility shifts were observed (data not shown) 
For exon 4 one of the patients (no 5178) showed a single 
stranded fragment of increased mobility in addition to the normal 
fragment (data not shown) Screening of exon 5 revealed aberrant 
fragments in four patients including the patient with the exon 
4 abnormality In one of these cases (no 6447) the mobility ot 
the exon 5 double stranded band was increased and 
heteroduplexes between normal and mutant strands were 
identified (Fig 1 lane 11) This suggested a small deletion in 
exon 5 Surprisingly the DNA of patient 5178 showed a mobility 
shift of the double stranded band which might reflect a 
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heteroduplex, and onl> barely visible shifts of the single stranded 
bands (Fig I. lane 1 ) An identical single-stranded fragment shift 
was further identified among two unrelated patients (no 4014. 
no 5639 (Fig. 1. lane 7)] and the father of deceased patient 6537 
1 3 5 7 β 11 13 18 17 
г * β β ίο η M i e 
· · — * » « . « . . «««f«« ds 
Figure 1. SSCP anal> sis of ехоп 5 о\ the COL4A3 gene in АІроп раііепь ( lanes 
i I'M Lane ! (patient no 5178ι shows an altered double-stranded ids) Iragmcni 
(arrowheadi In lanes 7 (patient no 5ή34) and 11 (patient no 644"Ί shifted single-
stranded issi tragmenLs are indicated b\ arrows The sample in lane 11 also shows 
altered mobilities .>! ds fragments (asterisk) as well as heteroduplcxes ol normal 
and mutaied ss Iragments laiTowheadsi Lanes Iftand Ρ contain denatured and 
non4lenatured control DVA >amples. respecmeh . as a standard for the mobilia 
οι ihe ds-traumeni 
Арап from the aberrant band, all individuals showed also the 
normal band. 
Direct sequence analysis was performed to determine the nature 
of the variants Patient 6447 with the shorter double-stranded 
exon 5 fragment was heterozygous for a deletion of five 
nucleotides (CTTTT) in exon 5 (data not shown). This sequence 
was duplicated in normal individuals (CTTTTCTTTT). but was 
present only once in the patient- The predicted result of this 
frameshift mutation is a truncated protein with a non-functional 
NC domain (Fig. 2). An affected brother and sister from another 
family, who were homozygous for this mutation. ha\e been 
reported elsewhere (14). Patient 5178 with an altered SSCP 
pattern in both exon 5 and 4 showed an Arg43Stop mutation 
(CGA-TGA) in exon 5 and a Ser86Stop (TCA-TGA) in exon 
4 (counting from the first ammo-terminal amino acid of the NC 
domain). To confirm that both COL4A3 genes were affected, 
we sequenced individual COL4A3 cDNA clones from this 
patient. COL4A3 cDNA was generated from peripheral blood 
Kmphocytes by reverse transcription — polymerase chain reaction 
(RT-PCR) and cloned in vector pCR-Scnpt™SK. Sequence 
analysis of seven clones revealed in three clones the Arg43Slop 
mutation and m four clones the Ser86Stop (data not shown). Thjs 
result proved that the patient indeed w<ts a compound heterozygote 
for the different nonsense mutations- It was predicted that the 
NC domains of the COL4A3 proteins of this patient contained 
onlv 42 and 85 ammo acids, respectively (Fig. 2). 
In two other patients (nos 4014 and 5639) and the father of 
deceased patient 6537. who displayed an identical band-shift on 
Non collagenous domain 
COL4A3 gene 
COL4A3 mRNA 
C0L4A3 protein 
Predicted 
COL4A3 protein 
Patient 6447 
(5 bp deletion) 
Patient 5178 
(Arg43Stop> 
(Ser86Stop) 
Нциг 2. The predated effect of the three identified COL4A3 gene mutations on the COL4A3 protein structure The normal COL4A3 gene (arabic exon sequence 
numbering) and mRNA structure is given in the upper two panels The altered С terminal regions of the COL4A3 proteins for the different patients arc depicted 
in the lower three panels The hatched boxes indicate the exonic sequences coding for the COL4A3 non-collagenous domains, the double-hatched boxes indicate 
the COL4A3 amino acid sequence and the stippled box indicates non-СОЫАЗ amino acid sequence The numbers indicate amino acid residues overlapping exon 
borders icounting stans at the first ammo acid ol the non-collagenous domain from 5' to 3' end) The 5 bp deletion causes a frameshift introducing a nonsense 
stretch ol 33 ammo acids, which is terminated b> a premature stop codon (14) Arrows indicate the site of the mutation 3' UTR 3-untranslated region 
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SSCP, sequence analysis revealed a Τ to С substitution, changing 
the Leu36 codon CTT into the proline codon CCT. In each case 
the normal sequence was visible as well. Family members of 
two cases were available to test the segregation of the Leu36Pro 
substitution. The mutation was identified in the mother and sister 
of patient 5639 (family A. Fig. ЗА). Surprisingly, the sister had 
also inherited from the father the same allele of a COL4A3 С A-
repeat (14: primer sequences available upon requestl as the 
patient, but she lacked clinical features. In the second family 
(family B. Fig ЗА), we initially tested both parents, because the 
affected son (6537) had died at the age of 24 years. The Leu36Pro 
mutation had been identified in the healthy father (data not 
shown). But sequence analysis of DNA. extracted from paraffin-
embedded hepatic tissue from the deceased son 6537. revealed 
that he had not inherited the Leu36Pro missense mutation from 
his father. His unaffected sister did not carry this mutation either. 
Both sibs inherited the same COL4A3 marker alleles from their 
parents (Fig. ЗА). Subsequent clinical examination revealed 
proteinuria and haematuria in the mother, but not in the sister. 
This was confirmed by the segregation of marker S9 (DXS17: 
Fig. 3B). closely linked to COL4A5. making the X-linked form 
of Alport syndrome in this family more likely. Our data suggest 
Wu/tau IwiTPr* Uu/Pro Liu/uu 
COL4A3 A2 A4 Al A3 COL4A3 A2 A3 Al A3 
Il 1 i 2 ] 3 ΐ | Ι I 
t è a ό * 
L»u/fro LaWi.au Lau/Pro Lau/Liu Laui'lau 
COL4A3 А 2 А Э A 2 A 1 A2 A3 С014ДЭ A3 Al A3 Al 
D-pö 
BI BI B2 
» f i г 
0 β 
2 8 6 BI B2 81 81 S2 OXS17 Cl CI C2 
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Figure 3. (A) Segregation analysis of ine Leu36Pro muiation and the segregation 
ol a С О Ы А З COL4A4 CA repeal marker m iwo Alpon families (351 Al . A2. 
A3 and A4 indicale COL4A.3 alleles. The absence or presence of the Leu36Pro 
mutation in e*on 5 of the COL4A3 alleles is indicated b> Leu or Pro. respectively. 
U-3 (tamily A) and Π-2 (family B) represent patients 5639 and 6537. subsequently. 
<Bt Segregation analysis of COL4A5 alleles were performed using COL4A5 2B6 
(Bl B4i and DXSI7 t C l - C t ) markers (35.36) in members of lamihes A and B. 
that the Leu36Pro substitution is not the causative mutation in 
these families. 
DISCUSSION 
Pathogenic COL4A3 mutations 
Three different pathogenic mutations have been detected m three 
unrelated patients with Alport syndrome from our sample of 22 
cases. We have previously reported an affected brother and sister 
who were homozygous for a 5 bp deletion in the СОЫАЗ gene 
(14). In a second case the same 5 bp deletion was identified. In 
the third patient both COL4A3 genes contained premature stop 
codons (Arg43Stop and Ser86Stop). The identification of an 
Alport patient who was homozygous for the Arg43Stop mutation 
provided further support for the pathological significance of this 
mutation (14), Both nonsense mutations and the 5 bp deletion 
are predicted to cause COL4A3 chains m which more than 70rr 
of the NC domain is absent (Fig. 2). It can now be safeh 
concluded that the role of the COL4A3 gene m autosomal 
recessive Alpon syndrome is evident 
In other disorders, caused by mutations in genes for structural 
proteins, both dominant and recessive mutations have been 
identified in the same gene ( 15-18). Mutations that present the 
formation or the incorporation of a protein are otten recessive, 
whereas mutations that do not impair the appropriate targeting 
of extracellular proteins are usually dominant. The three 
mutations that we have identified m the COL4A3 gene introduce 
premature stop codons and will lead to a truncated protein. The> 
will probably not be included in a collagen triple helical molecule, 
for which an intact NC domain is necessary (19). A recessive 
mode of inheritance is in line with these observations 
Non-pathogenic COL4A3 missense mutation? 
In two patients and the father of a deceased patient a proline for 
leucine missense mutation was identified. The evidence that this 
amino acid substitution could cause Alport syndrome appeared 
to be strong. First, the specific leucine was conserved in all type 
IV collagen chains from CaenorhabdiM elegans to humans (6. 
20 — 27). which indicated functional significance Furthermore. 
leucine is a strong helix-forming amino acid, whereas proline 
has helix-breaking properties (28). Computer analysis by protein 
modelling according to Chou-Fasman (29) predicted a change 
in hydrophobicity m the specific area due to the substitution (data 
not shown). Finally, we found the same Leu to Pro mutation 
in two unrelated patients with Alpon syndrome and the father 
of a third patient. Therefore, we initially concluded that this 
mutation was involved in autosomal recessive Alpon syndrome. 
Segregation data in the family of two of these cases, however. 
were not in favour of a causative role. In family A (Fig. ЗА) 
an unaffected sister of the male patient contained the same 
mutation in her maternal COL4A3 gene and inherited the same 
paternal COL4A3 CA-repeat allele as her brother. In case of 
autosomal recessive inheritance, she should have been affected 
as well. X-linked Alport syndrome was not very likely as well. 
because the mother and oldest sister carried the same COL4A5 
allele as the affected boy (Fig. 3B). but lacked clinical signs. 
A new COL4A5 mutation in the male patient is an alternative 
explanation, but has still to be investigated. 
Even more striking was family В (Fig. ЗА), in which the 
healthy father carried the Leu36Pro substitution, but his affected 
son did not. This case was initially considered sporadic, but 
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ТвЫе 1 Oligonucleotide pnmers used to amplify COL4A3 cDNA sequences 
lexons 1-51 
Pnmer séquences 
vi' 5 CAG CTC GAT CAG ATG GAT TGC С 3 
ss
1
 s TAG AGA CCC AGA TCA CAG AAC TGA С 3 
5<1 ' GGA AAA CGT GGA GAC AGT GGA TC ' 
5-П S ATA CCT AAA TAA CAG CAT GTT CTG TC 3 
further clinical investigations revealed haematuna and proteinuria 
in the mother but not in the sister making an X linked mode 
ot inheritance likely This was confirmed b> the segregation data 
ot marker DXS17 (Fig 3B) From these data it was evident that 
the Leu36Pro mutation was not causali) involved in this family 
Thus without a functional assay it is difficult to predict the effect 
ol amino acid substitutions Even drastic changes of strongly 
conserved amino acids as in the Leu36Pro case may not be 
pathogenic The presence or absence of clinical features in an 
individual who is homozvgous for this mutation will provide 
the definite answer to this question of pathogenies Whether 
this substitution tan have a secondary effect on another mutated 
tvpe IV collagen chain with which it forms a triple helix remains 
to be elucidaied as well 
Genetic heterogeneity of Alport syndrome 
The detection of pathogenic COL4A3 mutations in three patients 
with Alport svndrome in our sample is in line with previous 
studies which suggested thai about lOVt of Alport syndrome 
pedigrees could be explained bv autosomal recessive inheritance 
(8| Our group ot 50 patients consisted of 28 clearly X linked 
cases in which we delected nine COL4A1 mutations after 
analvsing about 409< of the gene (10 3D In the remaining 22 
cases we have no» identified ihree patients with a mutation in 
one or both of their COL4A3 genes Therefore about 6% of 
the total number ol Alport syndrome cases (and about 13% of 
those that are not clearlv λ linked! m our sample are caused by 
COL4A3 mutations The actual number may be higher because 
we onlv screened the five terminal exons of the COL4A3 gene 
(about 10Я ol the coding sequence) All cases with COL4A3 
mutations had typical renal histologv as well as characteristic high 
Irequencv hearing loss Thus the only obvious indication for an 
autosomal recessive aetiology was early-onsei renal insufficiency 
in a Iemale patient In our initial studies we concentrated solely 
on COL4AS as the major gene involved in Alport syndrome 
but now we can conclude that analysis of the COL4A3 and 
COL4A4 (14) genes is warranted in autosomal recessive and 
sporadic Alport syndrome cases especially if it concerns severely 
atlected females 
MATERIALS AND METHODS 
Alport patients 
Twcnrv rwo lanulres with Alport ivndromc mamlv of Dutch ongm were studied 
Diagnosis was ba&ed on clinical course (main features progressive renal failure 
and hearing loss famih history and the characteristic electron microscopic pattern 
m renal biopsies (32) DNA was extracted from blood (33) or from paraffin 
embedded ussue (34) 
SS( p analvsK 
PCR was pertormod on 100 ng leukoevte DNA m 25 μ) standard mixture ГРегкіл 
Ыгпсг Ceius) using 50 ng pnmers in the presence of 2 μ Ο [a ì P]dCTP Thirt) 
cvcles were performed consisting of 50 s at 92°C (denaturatoli) 50 s at 50°C 
(exon 4 | or 55ЧГ (елопз I 2 3 and 5) (anneaJmg) and I 5 nun at 72DC 
(elongation) All live NC domain encoding exons could be amplified (14) SSCP 
analysis was performed on a 0 5 x MDfc gel (AT Biochem Malvern PA) in 
0 6XTBF buffer for 6 h at 40 W and for 16 h at 6 W ai 4 a C 
Sequence analysis 
PCR fragments punfted from agarose gels using the freeze squeeze method 
were evele sequenced (30) and analysed on an automated sequencer (Applied 
Biosvstems 373 A Foster City CA) Réaction conditions using d\edeox\T 4 ' 
terminators we*e according to protocols provided by the manufacturer (Applied 
Biosvsiems Foster Cit) CA) 
Polymorphic markers 
CA repeat analysis was performed using a COL4A3 COL4A4 CA repeat marker 
according to a protocol developed bv Mochizuki et al (14 pnmer sequences 
and protocol available upon request) Markers S9 (DXS17) and COL4A5 (2B6) 
were tested as described belorc (36 37) 
R T - P C R anaivsis 
Isolation of total RNA from peripheral blood Ivmphocytet and generation ol 
COL4A3 cDN A was performed according to prcviouslv desenbed meihodologv 
(30) Pnmer pairs 542 5^2 (outer) and 551 543 (inner) (Table I) were used to 
amplih CÜL4A3 cDNA encompassing the NC domain PCR fragments were 
isolated after electrophoresis by the freeze squeeze method (31) Isolated cDNA 
fragments were cloned into pCR S tnp t r !SK( •*) vector at iordint to tht 
manufacturer (Stratagene La Jolla CA) Individuals clones were isolated using 
standard procedures (38) and sequenced as desenbed before 
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Autosomal dominant Alport syndrome linked to the type IV collagen x3 
and cc4 genes (COL4A3 and COL4A4) 
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А Ρ Maxwell 
Department of Nephrolog> Belfast City Hospital Departments of Medical Genetics and Pathology Queen s University 
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Abstract 
Background Alport syndrome is a hereditary nephritis 
that may lead to end-stage renal disease (ESRD) in 
young adult life and is often associated with sensorineu­
ral deafness and or ocular abnormalities The majority 
of families are X-lmked due to mutations in the 
COL4A5geneat Xq22 Autosomal forms of the disease 
are also recognized with recessive disease having been 
shown to be due to mutations in the COL4A3 and 
COL4A4 genes on chromosome 2 Familial benign 
haematuna has also been mapped to this region in 
some families 
Subjects and methods We describe a large family with 
autosomal dominant Alport svndrome in which males 
and females are equally severely affected and one 
member with a mild sensorineural deafness reached 
ESRD aged 35 years Renal biopsy in four affected 
patients demonstrated characteristic thickened and 
split glomerular basement membranes on electron 
microscopy 
Results Genetic linkage analysis using markers on 
chromosome 2q demonstrated co-segregation of the 
disease with the markers D2S3S1 and D2S401 with a 
maximum lod score of 3 4 at zero recombination 
Linkage to the COL4A4 gene was confirmed using an 
intragenic COL4A4 polymorphism Mutation analysis 
has revealed a missense Leu36Pro mutation in exon S 
of the adjacent COL4 A3 gene in the unaffected mother 
which may lead to a more severe phenotype in affected 
family members carrying this mutation 
Conclusion Mutations in the COL4A3 and COL4A4 
genes can cause a spectrum of glomerular basement 
membrane disease ranging from autosomal recessive 
Alport syndrome to autosomal dominant Alport syn­
drome and familial benign haematuna 
Key words familial benign haematuna hereditary 
nephntis type IV collagen 
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Introduction 
Alport syndrome is a progressive hereditary nephro­
pathy associated with characteristic ultraslructural 
abnormalities of the glomerular basement membrane 
(GBM) The majority of families demonstrate X-lmked 
transmission of the disease [1] Classically males 
develop haematuna and deafness at a young age and 
progress to ESRD in their early 20s Other associated 
features include eye signs [2] (anterior lenticonus 
penmacular flecks) leiomyomatosis [3) and possibly 
macrothrombocytopathia Females tend to be less 
severely affected Renal biopsy of patients with Alport 
syndrome oiten shows minimal abnormality on light-
microscopv and standard immunofluorescence Elee 
tron microscopy however shows typical changes with 
thickening and splitting of the glomerular basement 
membrane [4] 
In 1988 the Alport locus was mapped to Xq22 [5] 
and when the COL4A5 gene was cloned and mapped 
to the same region ( 6 ] it became a very strong candidate 
as the Alport gene This was confirmed in 1990 bv the 
finding of mutations in the COL4A5 gene in three 
kindreds with Alport syndrome [7] Since then more 
than 200 mutations in the gene have been described 
[8 9] Autosomal forms of Alport syndrome are also 
known to occur and in 1993 mutations in COL4A3 
and COL4A4 were desenbed in families with 
autosomal recessive Alport syrdrome who had a very 
similar phenotype to the X-hnked disease [10 11] 
Autosomal dominant disease is also described but is 
much less common [12] 
In this study we performed genetic linkage analysis 
on a large family with autosomal dominant Alport 
syndrome using intragenic markers and microsalellite 
markers on 2q flanking the COL4A3 COL4A4 loci 
Subjects and methods 
The index patient (IH2) presented with asymptomatic micro 
haematuna and hypertension detected during j medical 
examination for insurance purposes He had a past history 
107 
of sarcoidosis diagnosed by node biopsy Maximum pro· 
teinuna was β 6 g 24 h His renal function deten orated and 
be reached end-stage renal failure aged 35 years Audiometry 
revealed a mild high-tone sensorineural deafness His father 
had a long history of microhaematuna proteinuna (4+ on 
unnalvsis) and hypertension with subsequent documented 
renal failure (serum creatinine 200 μτηο! 1 ) prior to his death 
aged 68 vears from myocardial infarction 
Screening of other siblings revealed four sisters and one 
brother with microhaematuna and proteinuria Renal func­
tion was only mi Id К impaired (Table 1) Audiograms were 
normal in these patients The probands mother (113) had 
no evidence of microhaematuna on three occasions and had 
normal renal function No lamilv member showed evidence 
of eye signs platelet abnormalities or leiomvomatosis There 
were no nail or patellar abnormalities All familv members 
were Caucasian and bom in Northern Ireland There was no 
evidence ol consanguinitv Renal biopsy was earned out on 
four patients Light microscopv showed normal cellulantv 
without foam cells Immunohistothemistrv using monoclonal 
antibodies directed against individual tvpe IV alpha chains 
was not performed Electron-microscopv revealed basement 
membranes which were irregular in densuv and outline with 
areas of fibrillation characteristic of Alport svndrome 
Criteria for diagnosis 
A member of the famiK was considered affected if micro­
scopic haemal una was found on a minimum of three occa­
sions bv dipstick unnalvsis Two voung children in the fourth 
generation {aged 1 and 3 vears) were tested Each showed a 
trace o! protein onlv on one of three occasions and in view 
of their ages were considered as possiblv affected and were 
excluded from the linkage anahsis 
DNA anal\ sis 
DNA was extracted from venous blood of familv members 
and analysed for inheritance of informative microsatellite 
polymorphisms 
denatured for 3 mm at 94 С followed by 35 cules o! 
amplification at 94 С for I nun 55 С for 1 nun and ~Ί С 
for 1 mm and finally extended at 72 С for a further 5 mm 
PCR products were separated by electrophoresis on a 6 
denatunng Polyacrylamide gel and visualized b\ 
autoradiography 
Intragenic markers for COL4A3. COL4A4 and COL4A^ 
were analysed The 2B6 marker was used for COL4A* [13] 
An intragenic COL4A3 microsatellite polymorphism had 
previouslv been isolated by Toshio Mochizuki and primer 
sequences and PCR conditions were sent bv him ( personal 
communication) A conformational polymorphism in e\on 
7 of COL4A4 was used as an intragenic marker lor this 
gene PCR was performed on 100 ng DNA in 25 μ) reaction 
containing 50 ng pnmers one of which was end labelled with 
Λ2
Ρ Tmnv cycles of 94 С I min 50 С 1 mm and 72f h 
min were performed (Pnmer sequences (711 712) available 
on request from В Smeets Nijmegen) 
Smgle-strand conformational polymorphism (SSCP 
f 14 J 
Five microlitres of PCR product was mixed with 5 μΐ formam-
ide loading buffer and denatured for 5 min at 94 С Thi 
samples were run on a 0 5 χ MDEgel(ATBiochem Mähern 
PA) with 10'«glycerol in ОбхТВЕ for 16h at 6W ai room 
temperature 
Linkage anah sis 
Lod scores were calculated using the MLINK program I rom 
the computer package LINKAGE (v 5 1 ) [И] Л cent 
frequency of 0 0001 was assumed for the disease 
Mutation anah sis 
Exons 1-5 of COL4A3 were amplified by PCR (primers and 
conditions as published) [10] and analysed bv SSCP \n\ 
products showing band shifts were sequenced using an 
Applied Biosystcms 373A automated DNA sequencer 
Polymorphic markers 
All flanking microsatellite ohgo-pnmers were obtained from 
Research Genetics Ine (Huntsville AL USA) The poly­
merase chain reaction (PCR) was used to ampli I у the poly­
morphic region in a reaction volume of 10 μ! containing 
25 ng DNA 200 umol dNTP 0 25 μΜ each primer (one of 
which was end-labelled with [,"P]ATP) 1 5 mM MgCl2 
I ж PCR buffer, and 0 2U Taq polymerase Samples were 
Results 
Linkage analysis 
The X-linked form of the disease was unlikely from 
pedigree analysis and the COL4AS gene was excluded 
by linkage analysis using the markers 2B6 and 2B20 
(data not shown) 
ТаЫе 1 СІшкаІ details of affected family members 
Familv 
member 
112 
Ш2 
UM 
1116 
MIS 
III 12 
uns 
Ape (yrs) 
Died 
39 
37 
36 
3< 
32 
28 
Sex 
M 
M 
F 
F 
F 
F 
M 
Creatinine 
clearance 
(ml min) 
ESR> 
IOS 
69 
93 
70 
71 
24 h 
ргок 
4 + 
86 
03 
34 
29 
27 
25 
urinar} 
:in (g) 
Deafness 
Mild 
No 
No 
No 
No 
No 
Eye 
No 
-No 
No 
No 
No 
signs H\ penension 
Ves 
les. 
Ves 
Vet 
No 
Ves 
No 
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Fig. I. Rena] biops> electron-micrograph (χ 7000) from proband demonstrating a markedh irregular and thickened glomerular basement 
membrane with areas of fibrillation. 
Eight polymorphic markers across the region 
2q35-37. where the COL4A3 and COL4A4 genes have 
been located, were then analysed Positive lod scores 
were obtained with all markers (Table 2). The max­
imum two point lod score of 3.44 occurred between 
the disease gene and the locus D2S4Ü1 at zero recomb-
ination. Significant linkage was also found with the 
less informative COL4A4 single strand conformational 
polymorphism (SSCP) variant which was found to 
segregate with the disease throughout the family with-
out recombination with a maximum lod score of 2.9. 
The COL4A3 microsatellite was not informative for 
the disease in this family: however, analysis of recomb-
ination events allowed localization of the COL4A3 
gene to a 12 cM region between the markers D2S130 
and D2S396. 
Mutation analysis 
SSCP analysis of exons 1-5 (counted from 3 end) of 
COL4A3 was performed and a band shift in exon 5 
was detected which segregated w ith one of the maternal 
haplotypes and not with the disease. Sequencing of 
this exon revealed a single T->C substitution changing 
the amino acid Leu36 into Pro (Figure 2). This muta-
G G G T T T T C T T T T C T T T T T G 
Table 2. Results of two-point linkage anaKsis between disease gene 
and chromosome 2 markers 
0.01 0.05 0.1 0.2 
D2S128 
D2S126 
D:SBO 
D2S351 
COL4A.1 
COL4A4 
D2S40I 
D2S396 
D2SI72 
D2S407 
- 2 . 2 6 
- 2 . 2 6 
0.30 
3.01 
0.19 
2.96 
3.44 
— X 
— X 
-
r 
1.38 
1.38 
0.29 
2.96 
(1 IS 
291 
3.38 
1 38 
1.38 
ι 04 
1.85 
1 X< 
U 24 
2.77 
0.16 
2 ~ : 
3 12 
1 S6 
1 S6 
1 55 
1.87 
1.87 
0.20 
2 51 
0 13 
2 4~ 
2.82 
1 8" 
[ 8" 
1 6 
1.55 
1.55 
(I 12 
1 « 
0.07 
1.93 
2.15 
1 55 
1 55 
1.37 
1 114 
1 (14 
II lit. 
1 31 
0.04 
1 30 
1 41 
1 1)4 
1 1)4 
0.95 
0.43 
0 43 
0.01 
0.57 
0.01 
0.57 
0.6 
1)45 
1)4? 
1)41 
С οι trol itqut net 
G G G T T T T C T T T T C TfCT Τ Τ Τ G 
M ям i l »equine« 
: 
Fig. 2. i marks the heterozygous Т :6Ч-«С point mutation detected 
by automated sequencing This converts CTT leucine residue at 
position 36 to CCT proline 
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tion has previously been desenbed as a non-pathogenic 
missense mutation [11], however, in this family the 
unaffected members (112 and 1114) who do not carry 
the Leu36Pro mutation may have a less severe pheno-
type than those carrying the mutation (Table 1) 
Discussion 
Alport syndrome is a genetically and phenotypically 
heterogeneous disease X-lmked Alport syndrome is 
by far the commonest, but autosomal recessive and 
autosomal dominant forms have also been described 
and are said to be the mode of inheritance in 15% of 
families [12] Flinter et al [16] proposed that Alport 
syndrome can be diagnosed if at least three of the 
following four entena are fulfilled ( 1 ) positive family 
history of haematuru chronic renal failure, (2) elec­
tron-microscopic evidence on renal biopsy of Alport 
syndrome. (3) high-tone sensorineural deafness, and 
(4) characteristic eye signs The family described fulfils 
these diagnostic entena but shows a milder phenotype 
than is usually found in classic X-linked Alport syn­
drome The older age at end-stage renal failure, min­
imal deafness, and absence of eye signs is similar to 
the phenotype of previously desenbed families with 
autosomal dominant hereditary nephritis [17] 
Type IV collagen is the major structural protein of 
the GBM and forms the basic framework into which 
other constituents are bound Mutations in the 
COL4A5 gene and the COL4A3'COL4A4 genes have 
been shown to cause X-hnked and autosomal recessive 
Alport syndrome respectively In this family an 
X-linked pattern of inhentance was unlikely from 
pedigree analysis, and involvement of the COL4A5 
locus was excluded by linkage analysis We then 
mapped the disease to the long arm of chromosome 2 
and linkage was confirmed to the COL4A3 COL4A4 
gene locus The COL4A3 and COL4A4 genes arc 
arranged close together and both are therefore very 
strong candidate genes for this disease We can hypo­
thesize that mutations in these genes produce abnormal 
a3(IV) and a4([V) chains which fail to incorporate 
properly into the tnple helix of type IV collagen 
leading to a destabilization of the molecular superstruc­
ture Heterozygous mutations may lead to a less severe 
phenotype than homozygous mutations as there are 
still normal a3(IV) an i4(IV) chains being produced 
Mutation analysis in this family has led to the 
detection of a missense mutation in eton 5 of COL4A3 
on one of the maternal chromosomes which she has 
passed on to the majonty of her children This muta­
tion changes an evolutionary conserved leucine residue 
to proline, but has previously been described in two 
families as non-pathogenic [II] In our family the 
mutaiion is not pathogenic by itself, in that heterozy­
gotes have no clinical features, but may lead to a more 
severe phenotype in affected patients who carry this 
Π •6 
'0J0 
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Ш 
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Fig. 3. Family pedigree showing ha pio types Гог markers D2S130— D2S351 —COL4A3 microsaiellue—COL4A3 exon 5 Leu36Pro mutation 
(LT*)— COL4A4 SSCP—D2S401—D2S396 С males Ζ female Filled symbol is an affected individual Roman numerals represent 
generations and numbers identify family members The shaded haplotype segregates throughout the family with the disease Recombination 
events in patient Ш8 allow localization of COL4A3 and COL4A4 between markers D2S130 and D2S39Ú 
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mutation The proband's father (112) who did not 
reach ESRD and patient III4 seem to have a less 
severe clinical phenotype and are the only two affected 
familv members not to carry the Leu36Pro mutation 
It is also possible that a second mutation ma\ be 
present in the maternal COL4A3 or COL4A4 account­
ing for the more severe phenotype 
Familial benign haematuna ( FBH ) is a related glom­
erular basement membrane disorder characterized by 
isolated microhaematuria normal renal function and 
typical ultrastructural changes on electron-microscopy 
Recently linkage analysis has mapped this disorder to 
the COL4A1 and COL4A4 loci [18] We postulate that 
mutations in the type IV collagen genes result in a 
spectrum of disease ranging from thin basement mem­
brane disease to autosomal recessive and autosomal 
dominant Alport syndrome This variation in clinical 
expression due to different mutations in collagen genes 
is well recognized Different mutations in the COLI Al 
and COL1A2 genes have been shown to cause osteo­
genesis imperfecta type VII Ehlers-Danlos syndrome 
and osteoporosis with the seventy of the osteogenesis 
imperfecta ranging from a lethal neonatal form to a 
mild form with only minor fractures in childhood [19] 
Recessive and dominant disease from mutations m the 
same gene has also been reported previously for the 
COLI 1A2 gene in osteochondrodvsplasias [20] 
We conclude that mutations in COL4A1 or COL4A4 
can result in autosomal dominant Alport syndrome in 
addition to autosomal recessive Alport syndrome and 
familial benign haematuna and is entirelv compatible 
with the known clinical vanabihty of collagen 
mutations 
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Abstract 
Benign familial hematuria (BFH) is characterized by auto­
somal dominant inheritance thinning of the glomerular 
basement membrane (OBM) and normal renal function It 
is frequent in patients with persistent microscopic hema 
tuna but cannot be clinically differentiated from the initial 
stages of Alport syndrome a severe GBM disorder which 
progresses to renal failure We present here linkage of be 
mgn familial hematuria with the С OL4A3 and COL4A4 
genes at 2q35 M (Z m a x 3 58 at О 0 0) Subsequently a 
glycine to glutamic acid substitution was identified m the 
collagenous region of the COL4A4 gene We conclude that 
type IV collagen defects cause both benign hematuria and 
Alport syndrome Furthermore our data suggest that BFH 
patients can be carriers of autosomal recessive Alport syn 
drome (J Urn Invest 1996 98 1114-1118 ) Key words he 
matuna · Alport syndrome · basement membrane · collagen 
- mutation analysis 
Introduction 
Hem J luna is the presenting symptom in a large number of re 
nal disorders ІГ the htm кипа occurs in childhiKxJ is isol itcd 
and is of glomerular origin the diagnosis is dilhcult lo reach 
Btnign hematuria Alport svndrome and IgA ncphropalhv all 
present with persistent hematuria Pari ic и I i rk differentiation 
between Alport svndrome which is ι severe rLnul disorder 
progressing to renal failure in most eases ind benign hema 
luna is mandatory for eorrcel prediction of prognosis ind gc 
nctic counseling In benign hemalum electron microscopic 
analysis of renal biopsies shows thinning of the glomerular 
basement membrane (GBM)1 (!-"*) while in Alport svndrome 
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1 Abbreviations used m this paper BFH benign familial hematuria 
GBM glomerular basement membrane 
renal biopsies are characterized by irregular thickening and 
mulliljmination of the GBM (4) However thinning of the 
GBM ma\ be Ihe onlv microscopic abnonmhtv in vounger 
Alport patients (*> 7) which hampers the differentiation be 
tween the two disordeis in childhood Renal biopsies of 6*i 
children with isolated hematum persisting for at least one vcar 
revealed histological abnormalities consistent with Alport svn 
drome in eight cases and consistent with benign hematuria in 
H cases (Я) A positive familv hislorv was detected in 23 of the 
43 c ises 
I hi. mi|or structural component of the GBM is formed by 
a tvpc IV collagen network As vet ых different tvpe IV col 
I »een eh uns hive btcn identified and the respective genes 
were cloned Mutations were delected in three type IV col 
lagen genes in Alport syndrome The majontv was present in 
the λ linked tvpe IV collagen a5 (COI 4ЛЧ) gene but re 
ccnllv mul liions in the Ivpe IV collagen u3 and «4 (COI 4A У 
A4) genes have been reported in patients with the autosomal 
recessive form of this disease (K 9) These latter two collagen 
genes ire locih/cd head to head on the lip of the long arm of 
chromosome 2 (10) Considering the similarities in GBM ab 
normalities autosom il Alport svndrome and BFH could be 
the severe and mild forms of diflercnt molecular genetic de 
fects in the same genes Here we report linkige of the 
COÌ4AVA4 locus to BFH in a large Dutch fimilv ( I I ) and 
the identilic ilion of a pathogenic mutation in the LOL4A4 
gene 
Methods 
Patunt\ The index pútienl (III 10 sec Fi¿. I) presented with hema 
tuna at thi. age of Ч сагч 1 hert were no concomitant abnormalities 
ι e glomcrul ir filtration rale was normil and h\percalciuria was ab 
sent 1 here wab also no hypertension The morphology of the eryth 
rocvles in the urinar) sediment indio ted л glomerular origin of ihe 
cells Audiographv ind fundoscop) revealed no abnormalities Fam 
ily historv was negalo e for renal failure and deafness One year Idler 
a renal biops) was performed Electron microscopi of the biopsy 
specimen showed regions with malformations of Ihe glomerular base 
ment membrane tvpical for Alport syndrome and regions which 
were thin Further investigation of the familyshowed microscopic he 
matuna in both parents and his younger brother ( M i l l ) but no other 
symptom!» suggestive for Alport syndrome Renal function was nor 
mal in the parents (II 7 and II 8 normal serum creatinine concentra 
lion) Microscopic hematuna was present in three sisters of the father 
(II 7) and in half of their off spring as well as in the grandfather (I I 
Fig 1 ) Particularly important is that this 75 yr old man had a normal 
serum creatinine concentration In the family of the mother (11 8) he 
matuna was also widely present Her 76-yr old father had hematuria 
and a normal creatinine level her mother was healthy It was con 
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eluded that the family history on both sides strongly supported the di-
agnosis BPH. The index patient might have inherited the disorder 
form both parents, which could explain the aberrant morphology of 
the biopsy specimen. He is presently 16 years old and symptoms are 
hematuria and recently developed proteinuria (0.5 grams/liter). He-
maturia was defined as a condition with 10 or more erythrocytes per 
mm1 urine, established bv the quantitative sediment method of Gade-
holt (12). Individuals with borderline values were repeatedly ana-
lyzed. All family members could unambiguously be scored as either 
affected or unaffected. 
Linkage analysis. Blood samples were collected from family 
members and genomic DNA was isolated by a salting out procedure 
(13). The COL4AÍ/COL4A4 CA repeat was PCR amplified using 
125 ng of primers ÇAUF (5'-ATC TCT CAO GOT GCXÌ TGC-3') 
and CAÍ1R (5'-CTC ATT GAT АСА CAC AAA TGC A-3') and 
50-100 ng DNA template in a standard Cetus buffer with 2 mM 
MgCk After 3 min at 944'. four initial cycles were performed of ì min 
at 94*C. 1 min at 584" and I min at 724' followed by 30 cycles of I 
min at 94°C. 1 min at 55 С and ì mm at 72*0. One of the primers was 
fluorescentiy labeled and the PCR product was analyzed on an ABI 
373A Automated Sequencer using the Genescan software package 
(Applied Biosystems. Foster City. CA) A C01.4A4 HaelII RFLP 
uas identified by SSCP and subsequent sequence analysis and is 
caused by a neutral mutation at the H98glycine residue of the 
COL4A4 gene. PCR was performed on 100 ng genomic DNA using 
100 ηε of imronic oligonucleotides A4IFÏ0 (5'ÀGGCACTATAAC-
AGGGAOAAGA-3') (9)
 and 714 {S'-CCTCATIGCATTÌGGAAG-
GT-3'). 2ÍK) μΜ dNTPs. 5% DMSO in Ampii-Taq buffer containing 
67 mMTrts-HCl (ρίΙ K.8). 16.6mM (NH-)S04.6.7 mM MgCkO.Ì7 
mg/ml BSA (Boehringer Mannheim. Germany) to a total volume of 
25 μΙ. The sequence of oligo 714 is the reverse of oligonucleotide 
A4IF9 (9). After5 min of denalurationat 9ÉfC 1 U Ampli-Taq DNA 
polymerase (Perkin-Hlmcr. Norwalk. CT) was added and 30 celes of 
PCR were started (denaturation at 94 С for 1 min. annealing at 62'C 
for 1 mm and extension at Ί- С for 1 mm and 30 s) If the Haeltl site-
is present, digestion of the P( R fragment (260 bp) gives two bands of 
182 and 78 bp (dala not shown). 
Two point and multipoint lod scores were calculated using the 
MLINK and LINKMAP options of the LINKAGE package com­
puter program (version 5.03) (Ϊ4). BFH was defined as ад autosomal 
dominant disorder with complete penetrance, The disease frequency 
was estimated to be 0.0001. 
Mutation analysis. RNA was isolated from peripheral blood 
lymphocytes (PBL) or EBV transformed PBL from affected and nor­
mal individuals by RNAzol extraction (15). COL4A3 and COL4A4 
cDNA fragments were generated by RT-PCR analysis as described 
before (8. 16). Oligonucleotides were designed to amplify COL4AJ 
and COL4A4 cDNA by multiple overlapping cDNA fragments. 
DNA fragments were sequenced on an ABI 373A automated se­
quencer. Reaction conditions using dyedeoxy "'-terminators were ac* 
cordmg to a protocol provided by the manufacturer (Applied Biosys­
tems. Foster City. CA). The Gly897Glu mulation was identified in 
the PCR fragment, flanked bv outer primers 945 (.V-GCGAAO-
GGTGACATGGT1GTATCA-3) starting ai position 1871 and 946 
(5'-CCTCrCAGAAGGTCAACACTCCCAG-3') starting at position 
4074 (17) in a first round of 35 cycles; denaturation for I mm at 92 0. 
! mm 30 s of annealing at 60 С and extension for 3 min at 72X. Two 
microliters out of the first PCR reaction was used as template for a 
second round of 35 cycles using inner primers F100 (5'-AAGGCC-
TCCCGGGACTOCCA-3'> at position 2750 and RI0I (5-CGGGAG-
GTCCTATGGCTC 3') at position 3017 < 17); denaturation for t miri 
at 92 C. t min 30 s oí annealing at 55 С and extension for 2 mm at 
72 С The Gly897Glu mutation created an Alul restriction site and 
was screened at the genomic DNA level bv PCR amplification using 
oligonucleotides F100 (5-AAGGCCTCCCCGGACrOGOA-3'i and 
1106 (5-ACCTGGAGGACCAGGTAGC-3·) and digestion with 
Alul restriction enzyme (GIBCO BRL Gait hersburg. MD). If the 
mutation is present the 104-bp PCR fragment is cleaved in two frag­
ments of 86 ,md IS bp. ¡he smallest fragment is not visible. 
Results 
Linkage analysis. Linkage analysis was performed with two 
novel polymorphic markers from the COL4A.VCOL4A4 lo-
cus. The most informative marker was a CA repeat, isolated 
from a YAC clone with an insert of 540 kb. containing both 
COL4A3 and COL4A4 genes (18). The other marker was a 
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Figure I. Segregation analysis of type IV collagen «3 and a4 markers in the BFH family. Haplotypes were constructed for the type IV collagen 
α3/α4 CA repeat and the type IV collagen a4 HaeffI RFLP. Type IV collagen α3/α4 CA repeal fragments are indicated as the length of the PCR 
fragment in basepairs (76,78. and 80 bp). The НаеІП RFLP alleles are represented by 1 (Haelll site absent) and 2 (Haelll site present). The 
hapîotvpe [78.2], shown as black bars, «^segregates with BFH. Filled symbols indicate individuals with hematuria. Arrow indicates index patient 
(Ш-10). 
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Type IV collagen chains 
< Z D α з(і ) 
- 4 » 0!4(IV) 
Ö5(IV) 
<Z> 
TTT GGA GAT GAT GGG СТА CCT GGT CCT ι 
W 
<z> 
Л Л Л Л Л Л Л Л Л Л Л Л Л Л Л « ) — < 
Д Л А Л Я Л ^ Д О Д О ™ » 
ι TTT GGA GAT GAT GAG СТА CCT GGT CCT 
Figure λ GlyS97Glu substitu­
tion in the type IV collagen «4 
chain in Bf-Ή Sequence analysis 
ol type IV collagen a4 cTJNA of 
(he index patient and a normal 
contrtil I he mutation, which 
changes the glycine ( ( i ) codon 
Sü7 CiíiCi into the glutamic acid 
(fc) codon G A G is indicated hy 
an arrow. Type IV collagen 
chains consist of collagenous 
and non-collagenous (N( ' ) do-
mains 1 hree type IV collagen 
chains form a triple helix, which 
is interrupted by the substitution 
of a conserved glycine residue 
Haelll RFLP in une of Ihe exons of the COL4A4 gene. Be-
cause the genomic slruclure of COUA4 is nol clarified yet. 
Ihe exact numbering ol exons is unknown, bul most likeh exon 
8 is involved (counting trom the 3' end). The Rr-LP is caused 
b\ a polymorphism, a neutral G to A nucleotide substitution at 
Glycine11УХ (GGG info GGA) (17). The allele frequencies of 
this polymorphism were 0.5/0.5 (70 unrelated individuals 
tesled). 
Normal 
F 1 0 0 -
ZZZZZZZZZZZ3 
Patient Alu I site 
F100 • X 
ΖΖΖΖΖΖΖΖΖΖΖΆ 
104 
bp 
86 
bp 
18 
bp 
Τ 
n-ri ρ ι i i ι a i — г -
^тьп à m" '¿ ι 
I (Mbp — I 
86bp —1 
Figure 3. Segregation of GlvK47(ilu 
mutation in the BFH family I he 
presence of the mutation creates an 
additional A l u l restriction site. 
Cleavage ol the 104 bp PC R frag­
ment in two shorter fragments of 86 
and IS basepairs is indicative for the 
presence of the mutation Onh the 
affected family members (filled sym­
bols) show the shorter D N A frag­
ment (86 bp). the ¡.mallest fragment 
of 18 bp is not visible D N A fragment 
lengths are indicated in hasepairs 
(bp). 
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Linkage analysis was performed in the paternal ( I I 7) side 
of the pedigree (Fig 1) The mother ( I I 8) and her (wo sons 
I I I 10and I I I 11 (Fig I) were not included in the linkage stud 
íes, because BFH segregated diso in the maternal line The 
maternal relatives were not available for linkage analysis A 
maximum lod score (Z™,) of 401 was obtained in the paternal 
(117 Fig 1) line with the COL4AVC014A4 С A repeal al re­
combination fraction (O) of 00 in our familv The 7miy ob­
tained with the intragenic СОЫА4 RI-LP is 1 S\ al 0 = 0 0 
Al l affected individuals share the hnplolvpe [78 2] for both 
markers (Fig I) This haplotvpe was linked lo BFH with a 
Z m i , o n S 8 a l O - 0 0 
Mutation anatwts RT-PC R was performed on total lym­
phocyte RNA followed bv direct sequence analysis of ampli 
fied COI4AÌ and C014A4 cDNA fragments A heterozy-
gous G to A nucleotide substitution was identified at position 
2898 of lheCrJ/-//Wgciie in the patients I I I 10 and III 11 and 
in their father II 7 but not in their mother II 8 The glveme 
codon ( I C I O at position K97 was changed into GAG encoding 
a glutamic aetd residue (r ig 2) The mutation introducid a 
novel site for the restriction en/vme Alul and the other familv 
members and controls were screened for the presence of this 
site If the Alul site is present a KM bp К R lr.igmi.nt will be 
cleaved in two smaller fragments of 86 and IS bp (Гц; 2) Al l 
affected lamilv members were hucro/vgous lor the mutation 
(Fig 1) and (he mutation was not delected in the unaffected 
familv members and SO unrelated controls (dala nol shown) 
Discussion 
For several reasons the G1\XM7Glu mutation in the, tvpe IV 
collagen u4 chain is like tv Ю bc the pathogenic mutation in the 
BFI i lamiK f-irsl the, mutation change's a lilvcme in a con 
served collagenous triple helical domain in the tvpe 1\ col­
lagen «4 chain (17) Г егл third amino acid is a цКспіе be 
cause it is the onlv residue small cnouuh to fit into the cenici ol 
ihe Inpk helical molecule (14) II ці ипе residues ari. subsii 
tu(ed b\ bulkier amino acids such as glutamic acid the triple 
helix structure will be distorted ( h g 2) L nliki. hbnllar col-
lagens tvpe IV eollaiien triple helices eontain 21 26 inlcrrup 
lions which are assumed to provide flexibility io the molecule 
However the positions of these interruptions are піцЫ eon 
served during evolution and the generation ol an additional in 
terruplion mav interfere with correct folding ol the intricate 
tvpe IV collagen trimers consisting ol tvpe IV соііацепи^ «4 
and uS chains Substitutions lor glvcuies in the eollagLnous tn 
pie helical domain are also a common cause ol other collagen 
disorders like osteogenesis impericela and L hlers Danlos svn 
drome (20) Furthermore ihe mutation coscgrcgatcs with 
BFH in our familv and fm.'llv (he mulaiion is absent I rom a 
control group of 'SO individuals which provides additional evi 
dence for Ihe pathogenicity ol the delect 
In 1994 homo7Vgous mutations in the tvpe IV collagen u l 
and a4 genes have been identified in patients with autosomal 
recessive Alport syndrome (8 9) Two diflerenl mutations 
were reported in the ivpe IV collagen «4 gene a glveme to 
serine substitution and a serine to slop mutation (9) Similar to 
the Gly897Glu mutation in Ihe BFH family presented here.' 
(he glycine is substituted in the triple helical domain of ihe 
tvpe IV collagen a4 chain Our dala suggest that BFH patients 
can be manifesting carriers of autosomal recessive Alport syn­
drome This is in line with the histological examination of the 
kidney biopsy and the presence of protei η una in the index pa­
tient, who is a suspected compound BFH heterozygote The 
definite proof awaits the detection of the second maternal 
BFH mutation and the progression of his renal disease 
In conclusion this is the first report on a genetic defect ex­
plaining benign hematuria The identification of type IV col­
lagen defects similar to those found in Alport syndrome, ts im­
portant for genetic counseling and prognostic prediction As 
vet this prediction can not be based on the mutation only but 
needs a complete investigation of familv history follow-up ex­
amination and renal biopsy In a recent report linkage of the 
rare autosomal dominant form of Alport syndrome to the tvpe 
IV collagen α ϊ and u4 locus was demonstrated in a large 
Northern Irish lamilv (Jellerson J A A P Maxwell A F 
Hughes С M Hill С С Dohertv and N С Ncvin Autosomal 
dominant Alport svndromc linked to the tvpe IV collagen α ϊ 
and «4 genes (COL4A1 and С OL4A4) manuscript submitted 
for publication) It is obvious that Ihe tvpe IV collagenal and 
u4 genes are strong candidates lor the autosomal dominant 
form of Alport svndromc as well I his would complete Ihe 
speetrum of pheiiolvpes of l\pe IV соііацепиі and «4 defects 
ranging I rom neutral amino acid substitutions (8) and benign 
hematuria to mild autosomal dominant and severe recessive 
Alport syndrome In this wav Ihe ivpe IV colla"cn mutations 
fit within the rule, ol extreme clinical and genetic variability of 
collagen disorders (21) 
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CHAPTER 9 
GENERAL DISCUSSION AND SUMMARY 
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1. Diagnostic strategy for Alport syndrome 
The first step in establishing the diagnosis Alport syndrome is a clinical investigation of the index-
patient, routine laboratory investigation (creatinine level in serum, hematuria, proteinuria), and 
determination of the family history. This is followed by electronmicroscopy of the renal biopsy 
specimen of the patient. A skin biopsy can replace the kidney biopsy in a number of patients (see 
paragraph lb). If the results fit within the criteria of Flinter et al. (1988), the diagnosis Alport 
syndrome is established. Based on the segregation in families or immunohistochemistry, mutation 
analysis can start with the X-linked COL4A5 gene or the autosomal COL4A3 and COL4A4 genes. 
In individual male cases, DNA analysis is started with the X-linked gene, as X-linked Alport 
syndrome forms the majority of cases. However, if the patient is a severely affected female, an 
autosomal recessive form is likely and the COL4A3 and COL4A4 genes should be tested. 
la: DNA diagnostics 
Mutation analysis in large type IV collagen genes is extremely laborious and at the moment, after 
screening the entire COL4A5 gene by SSCP analysis only half of the expected number of 
mutations is found. Therefore, DNA analysis is not offered as a routine diagnostic test at the 
moment. Several explanations account for a mutation score of only 50%. First, clinical diagnosis 
may be incorrect. Only the French group provides data on the number of mutations in evidently 
and suspected X-linked families. The mutation score in the first group is 60% and in the second 
40% (Knebelmann et al., 1996). Secondly, a common mutation may be missed, because of the 
common exon-based strategies applied. A large rearrangement, similar to the inversion in the 
factor VIII gene, which explains 25% of the cases with hemophilia A (Lakich et al., 1993), will 
remain undetected and should be tested for by Pulsed-field gel electrophoresis and Southern blot 
analysis. Finally, mutations can be missed because of limited sensitivity of the techniques used. 
An optimal mutation detection procedure should be highly sensitive, fast, inexpensive, 
easy to perform and lend itself to automation. No single mutation detection technique currently 
meets these criteria. Several procedures have been employed, but all have their specific limitations 
(Mashal and Sklar, 1996). The method for rapid mutation screening that has gained the widest 
application is single-stranded conformational polymorphism (SSCP) analysis (Orita et al., 1989). 
The exact conditions of electrophoresis (e.g. gel temperature or presence of glycerol) affect the 
number of mutations that can be identified. Under a single gel condition around 70% of mutations 
can be detected as by multiple gel conditions the detection rate may be increased up to 95% 
(Sheffield et al., 1993; Grompe, 1993). SSCP analysis is more sensitive in shorter fragments. The 
combination with dideoxy fingerprinting may increase the number of mutations identified (Liu et 
al., 1996). A relatively new procedure, the Protein Truncation Test (PTT) (Roest et al., 1993) is 
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not yet suitable for detecting COL4A5 mutations because of the low amounts of COMAS mRNA 
in pheripheral blood lymphocytes (PBL). It may be applied to screening the COL4A3 and 
COL4A4 genes, which are more highly expressed in PBL and fibroblasts. 
Other new mutation detection methods have been published, based on the ability of 
bacterial repair enzymes (MutS) and bacteriophage resolvases (T4 endonuclease П and T7 
endonuclease I) to detect mismatches in relatively long stretches of DNA (Mashai et al., 1995; 
Youil et al., 1995; Ellis et al., 1994; Lishanski et al., 1994). The problem with these techniques 
is the high number of background bands, due to aspecific cleavage. These techniques have yet to 
be applied to type Г collagen genes. More promising is the development of DNA CHIP 
technology. DNA oligonucleotide arrays of predetermined sequence are synthesized on semisolid 
supports (Lipshutz et al., 1995). Fluorescently labeled DNA is hybridized to the oligonucleotide 
array under stringent conditions and the hybridization pattern is then analyzed by fluorescent 
scanning. Mutant DNA fragments result in an altered hybridization pattern. As the sequence and 
position of each nucleotide in the array is known, the location, and possibly the precise nature, of 
the mutation can be determined. This method has been succesfully applied to the large BRCA1 
gene (Hacia et al., 1996) and the mitochondrial DNA (Chee et al., 1996). The applicability of this 
technique in general and to type IV collagen genes in particular will depend on the cost for 
developing such a CHIP and the number of mutations outside the coding region. 
lb: Immunohistochemistry 
A promising development for establishing the diagnosis Alport syndrome and determining the 
genetic locus involved, is provided by immunohistochemical analysis of basement membranes. In 
the GBM of a large group of Alport patients no COL4A3, COL4A4 and COL4A5 chair, s can be 
detected, when compared to normal controls (Gubler et al., 1995; Kashtan et al., 1996; f'aito et 
al., 1996; Peissel et al., 1995). In 2 of our patients, one with a mutation in the COL4A5 gene 
(chapter 1: Table 2, no. 99) and one in the COL4A3 gene (chapter 1: Table 3, no. 3), both the 
COL4A5 and COL4A3 chains were absent, indicating that the COL4A3 and COL4A5 chains have 
an obligatory interaction and a defect in one of these chains destroys the entire network (Lemmink 
et al., unpublished data). The COL4A4 chain is also part of this netwerk (Kashtan and Michael, 
1993). The COL4A1 and COL4A2 chains are normally present in the GBM of Alport patients, 
indicating the presence of two separate networks in the GBM, one of which is affected in Alport 
syndrome. In contrast, in the skin (EBM), the COL4A3 and COL4A4 chains are absent and the 
COL4A5 chain probably associates with the COL4A6 chain (Hino et al., 1996). Again the 
COL4A1 and COL4A2 chains form a separate network. 
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The diagnosis X-linked Alport syndrome can be established based on 
immunohistochemistry of type IV collagen in a skin biopsy specimen. The EBM is incubated with 
a5(IV) specific antibodies. About 2/3 of the currently known mutations are predicted to lead to a 
truncation and subsequently to the absence of the COL4A5 protein (chapter 1). If the COL4A5 
chains are present in the EBM and an autosomal recessive form of Alport syndrome is suspected, 
then analysis of the GBM with antibodies against the COL4A3, COL4A4 and COL4A5 chains 
might provide the solution (Table 1). Although the number of characterized mutations is still 
limited, 7 out of 8 mutations in either COL4A3 or COL4A4 are predicted to have no 
COL4A3/COL4A4/COL4A5 network in the GBM and no positive immunostaining has been 
detected (Gubler et al., 1995; Lemmink et al., unpublished data). 
We propose a diagnostic protocol which starts with clinical investigation of the patient and his or 
her family. Next, in small families a skin biopsy specimen of the index patient should be tested 
for the absence of the COL4A5 chain to establish the diagnosis X-linked Alport syndrome. If the 
COL4A5 chain is present in the EBM, analysis of the GBM may provide the clue for the 
diagnosis (electron microscopy) or the involvement of the COL4A3/COL4A4 chains (Table 1). 
Based on these results or on linkage data in large families, mutation analysis can be performed of 
the most likely candidate genes. 
2. Pathogenic mechanisms COL4 mutations 
Preliminary genotype-phenotype correlations can be established for the COL4A5 mutations as 
described in section "Phenotype-genotype correlations" of the introduction (chapter 1). Most 
effects are based upon the nature of the DNA mutation and a prediction of the altered protein. 
Only limited experimental data are available on how COL4 mutations exert their pathogenic effect 
and how they influence the other chains with which they associate. Furthermore, it is clear that 
not only the mutation is involved as identical mutations can yield a different phenotype in different 
patients and even in affected brothers, and may depend on other genetic (Freedman et al., 1997) 
or environmental factors. Several strategies exist to gain more insight in the pathogenic 
mechanisms, both at the RNA level and the protein level. 
2a. In situ hybridization 
The expression of the type IV collagen genes can be studied at the RNA level by in situ 
hybridization using antisense cRNA as a probe (Heidet et al., 1997). The intracellular localization 
of the transcripts and their quantity can be determined to establish whether the absence of all three 
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type Г collagen chains from the GBM is due to the absence of their respective mRNAs. It is 
unclear at the moment if a mutation in one of the chains affects the transcription of the other 
chains with which it associates (see also section on animal models). 
2b. Fibroblast model 
Fibroblasts are frequently used as cell line model for example for bone collagene (COLIA 1 and 
COL1A2) and extracellular matrix proteins (fibrillin). The majority of osteogenesis imperfecta 
(OI) variants are caused by mutations in one of the two type I collagen genes (Kuivaniemi et al., 
1997). The production of type I collagen is sufficiently high for direct analysis of fibroblasts on 
SDS-PAGE and Western blots. Most mutations result in the synthesis of abnormal pro-α 1 or -ál 
type I collagen chains. Structurally altered COLI chains can interfere with normal COLI chain 
assembly and cause preliminary degradation of the altered chain within the endoplasmic reticulum 
(ER) while the excess normal COL1A2 was degraded after leaving the ER. Other mechanisms are 
defective processing of altered procollagen I al/a2 chains or mutant chains which interfere with 
normal chain assembly by a dominant negative mechanism (Prockop et al., 1992; Figure 1). 
Abnormal collagen was demonstrated in the extracellular space and revealed overmodification. 
The incorporation of these abnormal molecules into collagen fibers may disturb matrix assembly 
and contribute to the OI severe phenotype (Kuivaniemi et al., 1991; Lamande et al., 1995). 
From studies with dermal fibroblasts from Marfan patients it was shown that the 
intracellular transport of mutant fibrillin molecules was delayed but that synthesis and deposition 
were not affected (Aoyama et al., 1993). Mutations may lead to decreased mRNA stability, 
inefficient secretion or intracellular degradation of the mutant protein product. Furthermore mutant 
fibrillin molecules of normal or truncated size may interfere with the function of the normal 
protein by a dominant negative mechanism (McGookey-Milewicz et al., 1992; Aoyama et al., 
1994). 
Fibroblasts can not be directly used for investigating the effect of type Г collagen 
mutations, because the expression level is too low and the type Г collagen network differs 
between tissues. The COL4A5 chain associates with the COL4A3 and COL4A4 chains in the 
GBM, but most likely with the COL4A6 chain in the EBM. However, after induction the 
fibroblast model may be suited to study the intracellular processing and secretion of the 
COL4A3/A4/A5 chains similar to FBN-1 in Marfan syndrome (Dietz et al., 1995). To induce 
expression of type IV collagen, skin fibroblasts from Alport patients can be cultured in the 
presence of Transforming growth factor-ß (TGF-ß) or matrigel (ECM extract from EHS tumor 
cells). Matrigel is an ECM extract which contains a variety of growth factors including TGF-ß. 
TGF-ß has been shown to induce COL4A1 and COL4A2 mRNA expression (Grande et al., 1993). 
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Figure 1: 
Biosynthesis of normal and mutant COL4 chains by epithelial cells localized upon glomerular 
basement membranes (GBM). 
Numbers I to VI show the different stages of COL4 synthesis at which a mutation may exert its 
effect. After transcription and processing of the primary transcript, the COL4 mRNA is 
transported to the ribosomes where translation occurs. The mutant COL4 chain is indicated by a 
gray-coloured arrow. 
A: Translation of COL4 mRNA into COL4 protein followed by post-translational hydroxylation 
and glycosylation of (Г ) chains in cisternae of rough endoplasmic reticulum (RER), В and 
C:Assembly of individual COL4 chains into triple-helical structures followed by transport through 
Golgi apparatus and are subsequently secreted into extracellular space, D: Trimers are 
incorporated into extracellular type Г collagen network. I: Synthesis of primary COL4 transcript, 
II: Translation of mutant COL4 mRNA into type IV collagen chain, III: Assembly of three COL4 
chains containing one mutant chain into triple-helical structure. The incorporation of mutant COL4 
chains prevents correct folding and causes preliminary intracellular degradation of abnormal COL4 
structure, Г : Misincorporation of mutant COL4 chains into type Г collagen network produces 
abnormal collagen fibril chains which will make them more susceptible to extracellular 
degradation. V: No translation due to absence of transcription or preliminary degradation of 
mutant COL4 mRNA, VI: Absence of mutant COL4 chain may result in the assembly of only two 
COL4 chains. This defective type Г collagen structure may be more prone to intracellular 
degradation. 
No tissue specific growth factors are currently available to induce a GBM specific expression 
pattern. 
2c. Transfection studies 
An alternative approach for studying fibroblasts of patients is the use of transfection systems. 
Normal and mutant cDNAs can be cloned in expression cassettes and transfected into COS or 
HEK cell lines. Several strategies can be applied to study the effect of the mutations. The 
expression vector may contain a strong promoter and a reporter system, such as Green 
Fluorescent Protein (Graham et al., 1997) or histidine tags (Tinker et al., 1996). The use of Yeast 
Artificial Chromosomes (YAC) mimics the natural situation better. Recent advances in YAC 
technology improved cloning and transfection assays. A YAC clone of 150 kb containing the 
complete mouse Collai locus was introduced into a mouse fibroblast cell line with a defective 
endogenous Collai synthesis. Transfected cell clones expressed Col lal mRNA allowing 
molecular complementation of mutations with clones of large gene segments or provide a model 
system to establish a protocol to correct the genetic defect (Strauss and Jaenisch, 1992). 
Furthermore the path of the protein towards excretion can be followed by inducing the reporter or 
by using collagen chain specific antibodies. For example, amino acid subsitutions, which are 
predicted to be incorporated in the protein, may be retained in the endoplasmic reticulum, as has 
been shown for other proteins (Gow and Lazzarini, 1996). In this way an amino acid substitution 
essentially displays a null phenotype. 
2d. Animal models 
Animal models, either genetically engineered or occurring naturally, are important for a better 
understanding of the molecular pathology of Alport syndrome and are a prerequisite for the 
development of therapeutic protocols. 
2dl. Dog models for X-linked and autosomal dominant Alport syndrome 
The first animal model described for Alport syndrome is a naturally occurring Samoyed dog 
model in which affected dogs carry a glycine to stop mutation in the canine COMAS gene (Jansen 
et al., 1984; Zheng et al., 1994). Affected male dogs reveal abnormal GBM structures 
characteristic for Alport syndrome while female carrier dogs show a mixture of abnormal and 
normal GBM structures. Affected male dogs show both decreased amounts of COMAS mRNA as 
well as decreased COM A3 and COM A4 mRNAs (Thomer et al., 1996). Apparently, the 
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mutation in the COL4A5 gene negatively affects the expression of the COL4A3 and COL4A4 
genes, explaining the absence of all three chains from the GBM. Whether this is also the case in 
human patients remains to be determined. 
A hereditary nephritis in a Bull terrier dog has been proposed as a model for autosomal 
dominant Alport syndrome (Hood et al., 1995). The diagnosis Alport syndrome is based on the 
presence of hematuria, progressive renal failure, anterior lenticonus and multilamellated GBM. 
The disease in Bull terriers is different in the lack of an association with deafness, the 
demonstration of cystic changes in the kidney and the presence of both COL4A3 and COL4A5 
chains in the GBM. The identification of a COL4A3 or COL4A4 mutation is necessary to confirm 
the clinical diagnosis Alport syndrome and to use this dog for further studies (Lees et al., 1997). 
2d2. Transgenic mice model for autosomal recessive Alport syndrome 
As yet no mouse model has been constructed for Col4a5 mutations, but two mouse models for 
autosomal recessive Alport syndrome have been generated by inactivating both Col4a3 genes in 
mouse embryonic stem cells, using standard transgenic technology (Miner et al., 1996; Cosgrove 
et al., 1996). Both mutant mouse strains lack Col4a3 mRNA, but have normal amounts of Col4a4 
and Col4a5 mRNAs. The Col4a3 chain as well as the Col4a4 and Col4a5 chains are absent from 
the GBM (Miner et al., 1996; Cosgrove et al., 1996). The evolution of the renal pathology from 
thin GBM to thickened GBM structures in both Col4a3 knockout mouse models closely resemble 
those found in glomeruli of Alport patients (Kashtan and Kim, 1992; Cangiotti et al., 1996). 
Col4a3 mouse mutants were normal up to 2 months after gestation when glomerular filtration 
decreased with elevated urinary protein and serum creatinine ratios which ultimately progressed to 
complete renal failure at 3 to 4 months after gestation. Surprisingly, hematuria, a characteristic 
feature of Alport syndrome, and sensorineural deafness were not evident. No ultrastructural 
defects were identified in tissues like lung, testis, cochlea or skeletal neuromuscular junctions 
(Miner et al., 1996). 
The absence of the Col4a3, Col4a4 and Col4a5 chains from the GBM, causes drastic alterations in 
the composition and distribution of Col4al, Col4a2, heparan sulfate proteoglycan, entactin, 
laminins /31, 02 and γΐ and Col6 proteins. These alterations may play a key role in Alport disease 
pathogenesis. The major basement-membrane associated proteins accumulate, although Northern 
blot analysis of mRNA levels revealed no differences between control and diseased kidney. 
Therefore, enhanced stability or reduced breakdown of these proteins in the diseased GBM is a 
more likely explanation (Cosgrove et al., 1996). 
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3. Pathogenesis and possible therapeutic approaches 
3a. Modulating pathogenesis 
Extracellular matrix synthesis and degradation are tightly regulated in the normal glomerulus 
(Woessner et al., 1991). Both matrix removal and synthesis occur simultaneously in an orderly 
and progressive fashion. The end-stage of differentiation is homeostasis between new matrix 
formation and matrix turnover. If this occurs in a balanced fashion there is preservation of matrix 
function and no gross change in matrix composition. Apparently, in Alport syndrome this 
equilibrium is disturbed because of the absence of type IV collagen chains and results in increased 
amounts of COL4A1/A2 chains, heparan sulfate and COL6 proteins (Kim and Kashtan, 1992). 
In the GBM of the Alport patients, the COL4A3/A4/A5 network is either absent or 
altered. The absence of this network increases the synthesis of the COL4A1 and COL4A2 chains 
and two other collagens in the GBM, of types V and VI, respectively, resulting in the 
characteristic ultrastructural changes of the Alport GBM. 
Immunohistochemical analysis of renal biopsy specimens revealed the absence of mutated 
as well as normal a(IV) chains in the GBM in about 2/3 of the male X-linked Alport patients 
(Gubler et al., 1993). This is consistent with the percentage of mutations leading to a COL4A5 
chain that cannot be incorporated in the GBM. In renal biopsy samples from autosomal recessive 
AS patients all five COL4 chains were found in a normal or abnormal distribution pattern which 
indicates that defective COL4 chains may be incorporated within basement membranes (Gubler et 
al., 1995; Nakanishi et al., 1994). 
Based on immunohistochemical staining of COL4A3 and COMAS chains in the GBM of 
Familial Benign Hematuria (FBH) patients (Yoshioka et al., 1994; Nieuwhof et al., 1997) we 
predict that the entire COL4A3/A4/A5 network will be present (Figure 2). FBH or thin basement 
membrane nephropathy generally holds a good renal prognosis. GBM alterations resemble the 
characteristic GBM thinning as seen in the initial stages of Alport syndrome. In case of Alport 
syndrome the GBM develops into a multilayered and thickened structure and patients progress to 
renal failure (Figure 2) but in FBH it remains thin. What mechanisms or mediators are involved 
in aberrant ECM synthesis and how can the transition of the thin basement membrane into a huge 
multilayered basement membrane with protein leakage be prevented ? 
An early event in GBM development is the switch of al-2 to o¡3-5 type Г collagen chain 
synthesis demonstrated in rodent and human GBM (Miner and Sanes, 1994; Kalluri et al., 1997). 
This change in transcription of type IV collagen genes is probably arrested in X-linked Alport 
patients (Kalluri et al., 1997). The GBM stability is better in normal renal basement membranes 
containing СОЫАЗ, COL4A4 and COL4A5 chains because these are shown to be less sensitive 
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Figure 2: 
Predicted model of GBM pathogenesis indicated by the distribution of type IV collagen 
chains (a 1-OÍ5) in the GBM of controls, patients with Alport syndrome and familial benign 
hematuria. 
Two type Г collagen networks can be identified; COL4A1/A2 chains and the COL4A3/A4/A5 
chains. The COL4A3/A4/A5 network is absent in the GBM of a large group of Alport patients. 
The absence of this network may alter the accumulation of the COL4A1/A2 chains, type V 
collagen and type VI collagen, and perhaps other proteins, in the GBM. Adapted from Kashtan 
and Michael, 1993. Epi: epithelial cells; endo: endothelial cells. 
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to endopeptidase digestion than the COL4A1 and COL4A2 network found in X-linked Alport 
kidneys (Kalluri et al., 1997). The COL4A3 and COL4A4 chains contain more cysteine residues 
than COL4A1 and COL4A2 chains, and possibly enabling them to form more covalent disulphide 
bonds (Hudson et al., 1993). 
Several endopeptidases are secreted by cells surrounding the GBM, and the circulation 
likely carries such moieties in varying states of activation. Prominent among these endopeptidases 
are collagenase, elastase, cathepsins, and metalloproteinases (MMPs). These latter enzymes 
degrade both the collagenous and noncollagenous components of the ECM. Tissue inhibitors of 
metalloproteinases (TIMPs) are inhibitors of MMPs. The regulation by MMPs and TIMPs are 
considered to contribute to maintain homeostasis in the production and degradation of ECM in the 
glomeruli. It remains to be investigated whether activated matrix proteinases-antiproteinases play a 
role in ECM remodeling in patients with Alport syndrome. A better understanding of the basic 
cell biology of ECM turnover and progressive renal failure is needed to develop avenues for 
therapeutic intervention. 
3b. Gene therapy for Alport syndrome 
Alport syndrome is an attractive candidate for gene therapy because the life-threatening defect is 
limited to the kidney with only minor extrarenal symptoms. Additionally, the kidney has a well 
separated circulatory system which can be used for direct transport of gene transfer agents 
(Tryggvason et al., 1997). However, despite these good prospects some major hurdles have to be 
taken before molecular therapy can be applied in a clinical setting. As is valid for most gene 
therapy protocols the vehicle for delivery of the gene to its target has to be optimized. This means 
efficient and correct targeting of type Г collagen gene constructs in addition to coordinate 
expression. Type Г collagen is synthesized by endo- and epithelial cells surrounding the GBM. 
These cells have to be transfected with high efficiency. Some promising results have been obtained 
by using combined liposome and perfusion methods (Heikkilä et al., 1996). 
Currently most gene transfer constructs are based on recombinant adenovirus vectors 
which until now only provide limited temporal expression. This means that treatment has to be 
repeated several times during life. The continuous use or expression of adenovirus vectors can 
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cause the development of a specific anti-adenoviral vector immune response (Yang et al., 1995). 
Another problem is the coordinate expression and proper incorporation of transferred type Г 
collagen into a functional GBM network. Possibly, by using the COL4A5 own promoter in 
association with the expression of normal type Г collagen molecules into the proper cells may 
ameliorate renal disease features. In this respect it is encouraging that production and secretion of 
normal type IV collagen molecules may be sufficient to ameliorate some of the renal disease 
features. As female X-linked Alport patients carry one normal and one mutant COL4A5 gene 
copy, they show mild disease features in most cases and rarely progress to renal failure. 
Additional experimental work in cell lines and animal models have to be performed to support 
these speculations. 
4. Conclusions 
Animal models can be used for further studies concerning the biochemical processes involved in 
the pathogenesis of the GBM in Alport patients and also provide further information about GBM 
formation and function itself. The information gathered until now is limited to the observation of 
absent or mutant type IV collagen molecules followed by subsequent aberrant synthesis of other 
extracellular matrix proteins. The developmental or compensatory mechanisms behind this 
phenomenon are unknown. 
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Summary 
Alport syndrome (AS) is a progressive hereditary kidney disorder with a heterogenous 
clinical picture. Patients can be classified by the age of end-stage renal disease and the presence of 
accompanying features, such as sensorineural deafness, ocular malformations and leiomyomatosis 
of the oesophagus. The most prevalent mode of inheritance is X-linked, but autosomal recessive 
and dominant families have been described as well. Electron microscopic examination of renal 
biopsy specimen shows a typical irregular thickening and multilamination of the glomerular 
basement membrane (GBM). Biochemical studies pointed to a type Г collagen defect in the GBM 
of Alport patients. In 1989 the type Г collagen a5 (COMAS) chain gene was cloned and 
mapped to the genetic locus for X-linked Alport syndrome at Xq22 and a year later the first 
COL4A5 mutations in Alport patients were reported. Since then more than 250 mutations have 
been detected by groups all over the world, collaborating in an International Consortium on Alport 
syndrome. 
Different strategies, such as DGGE, RNaseA and chemical cleavage, PCR-SSCP and 
direct sequence analysis, were applied on COL4A5 DNA or in some cases RNA to search for 
mutations in Alport patients (Chapter 1-4). Mutation analysis was started by using PCR-SSCP 
analysis of individual exons of the COL4A5 gene. The COL4A5 mutations are variable and 
scattered all over the gene. They include amino acid substitutions, insertions, deletions, 
frameshifts and splice site mutations. Almost every family has its own unique mutation, but no hot 
spots for mutation have been identified. Around 18% of the mutations were large rearrangements 
and 10% of the small mutations were de novo events. The total mutation score was 50%. 
A number of conclusions on genotype-phenotype correlations can be drawn: 
1. Deletions of the 5' part of the COL4A5 and COL4A6 genes, which are located 
head to head at Xq22, are involved in Alport syndrome with leiomyomatosis. 
2. The effect of missense mutations is variable and some of these have no effect at all. 
3. Mutations leading to a shorter of absent protein cause severe Alport syndrome with 
complete renal failure at a young age. 
4. Mutations leading to the absence of the C-terminal NC-domain increase the risk of 
developing anii-GBM nephritis after renal transplantation. 
In 1994, the first COL4A3 and СОЫА4 gene mutations were identified in patients with 
autosomal recessive Alport syndrome (chapter 5) and in a group of sporadic and non-X-linked 
Alport syndrome (Chapter 6). These genes are located at the tip of chromosome 2. The number 
of mutations described is limited, but all, except one, are predicted to lead to truncated proteins. 
Homozygous COL4A3 mutations were found in two families and in COL4A4 in two others. 
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Clinically, autosomal recessive Alport syndrome is indiscernable from the X-linked form, except 
that female patients are more severely affected. Linkage data indicate that the autosomal dominant 
form of Alport syndrome may be caused by COL4A3 and COL4A4 defects as well (Chapter 7). 
The initial stages of Alport syndrome can not be clinically differentiated from benign familial 
hematuria (BFH). Therefore we investigated whether BFH could be a type IV collagen disease as 
well and we identified a COL4A4 mutation in patients from a Dutch BFH family. Our data 
suggest that the clinical manifestations of type Г collagen mutation are variable, ranging from no 
effect at all or carriership of autosomal recessive Alport syndrome, or revealing hematuria in BFH 
to severe renal disease in Alport syndrome (Chapter 8). 
In conclusion, the characterization of the genetic defect in Alport syndrome, both at the 
DNA and the protein level, has raised new opportunities for post- and prenatal diagnosis of this 
disease. Furthermore, insight in the pathogenesis of the disease is emerging and will contribute to 
reliable genotype-phenotype correlations. These data together with results from investigations in 
model systems are essential to determine the feasibility of therapeutic interventions in Alport 
syndrome (Chapter 9). 
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Samenvatting 
Alport syndroom (AS) is een erfelijke nieraandoening met een progressief verloop en een 
heterogeen klinisch beeld. Patiënten worden ingedeeld naar leeftijd waarop volledig nierfalen 
wordt bereikt en de aanwezigheid van bijbehorende klinische verschijnselen, zoals sensorineurale 
doofheid, oogafwijkingen en leiomyomatosis van de slokdarm. 
Elektronenmicroscopisch onderzoek van een nierweefselbiopsie laat typische onregelmatige 
verdikkingen met een meerlagige bladerdeegachtige structuur zien van de glomerulaire 
basaalmembraan (GBM). Biochemische studies duidden op een type Г collageen defect in de 
GBM van Alport patiënten. In de meeste gevallen is sprake van een X-chromosomale erfgang 
maar autosomaal recessieve en dominante Alport families zijn eveneens beschreven. In 1989 werd 
de a5 keten van het type IV collageen (COL4A5) gen gedoneerd en gelokaliseerd op de q22 band 
van het X chromosoom, waarin een jaar later de eerste COL4A5 mutaties in Alport patiënten 
werden geïdentificeerd. Sindsdien zijn er meer dan 250 mutaties gevonden door verschillende 
onderzoeksgroepen over de gehele wereld, die zijn verenigd in een Internationaal Consortium voor 
onderzoek naar het syndroom van Alport. 
Verschillende mutatie detectie-technieken zoals DGGE, RNaseA en chemische digestie, 
PCR-SSCP alsmede directe DNA sequentie-analyse zijn toegepast op DNA of RNA als 
uitgangsmateriaal om COL4A5 mutaties te vinden in Alport patiënten (Hoofdstuk 1-4). De 
mutatiedetectie in het COL4A5 gen is gestart door de afzonderlijke exonen met behulp van PCR-
SSCP analyse te testen op de aanwezigheid van een mutatie. De mutaties in het COL4A5 gen zijn 
verschillend van aard zoals aminozuursubstituties, inserties, deleties, frameshifts en mutaties die 
leiden tot een foutieve splicing van het mRNA. Er is geen hot spot voor mutaties gevonden en 
patiënten in iedere familie hebben een eigen unieke mutatie. Het totale aantal mutaties bestond 
voor 18% uit grote gendefecten en in 10% van de kleinere gendefecten was er sprake van een de 
novo mutatie. De totale mutatiescore bedroeg 50%. 
Op basis van deze gegevens zijn een aantal genotype-fenotype correlaties vast te stellen: 
1. Deleties van het 5' uiteinde van de COL4A5 en COL4A6 genen, die kop aan kop 
liggen op chromosoom Xq22, zijn gevonden in patiënten met het syndroom van 
Alport en leiomyomatosis. 
2. Het effect van aminozuur-substituties op het Alport phenotype is variabel waarbij 
sommige geen enkel pathogeen effect hebben. 
3. Mutaties die leiden tot verkorte of afwezigheid van COL4A5 eiwitten veroorzaken de 
ernstige vorm van het Alport syndroom met een volledig nierfalen op jonge leeftijd. 
4. Mutaties die resulteren in afwezigheid van het carboxy-terminale niet-collagene 
domein verhogen de kans op het ontstaan van een anti-GBM nephritis na 
niertransplantatie. 
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In 1994 werden de eerste COL4A3 en COL4A4 mutaties gevonden in patiënten met autosomaal 
recessief Alport syndroom (Hoofdstuk 5) alsmede in een groep van sporadische Alport patiënten 
en een groep patiënten waarbij de X-chromosomale vorm van het Alport syndroom was 
uitgesloten (Hoofdstuk 6) Beide genen liggen aan het uiteinde van de lange arm van chromosoom 
2 Het aantal beschreven COL4A3 en COL4A4 mutaties is klein maar alle behalve een, resulteren 
in verkorte collageen IV ketens Klinisch verschillen patiënten met de autosomaal recessieve vorm 
van Alport syndroom met ten opzichte van patiënten met de X chromosomale Alport variant, 
behalve dat vrouwelijke patiënten ernstiger zijn aangedaan dan die met de X chromosomale 
variant Koppehngsonderzoek heeft aangetoond dat patiënten met de autosomaal dominante vorm 
van het Alport syndroom mogelijk mutaties hebben m de COL4A3 of COL4A4 genen (Hoofdstuk 
7) 
De eerste stadia van het Alport syndroom zijn klinisch niet te onderscheiden van de verschijnselen 
bij patiënten met familiaire benigne hématurie (FBH) Wij hebben onderzocht of BFH een type Г 
collageen aandoening is met behulp van koppehngsonderzoek en mutatie-analyse in een grote 
Nederlandse familie waarbij in de patiënten een COL4A4 mutatie is gevonden 
Aan de hand van deze resultaten is geconcludeerd dat de phenotypische expressie van type Г 
collageen afwijkingen kan variëren van helemaal geen effect tot aan een ernstige progressieve 
meraandoening zoals in Alport syndroom (Hoofdstuk 8) 
De identificatie van type IV collageenafwijkingen op zowel DNA als eiwitniveau biedt 
nieuwe mogelijkheden voor post- en prenatale diagnostiek Verder inzicht in de mechanismen die 
een rol spelen in de Pathogenese van het Alport syndroom zal toenemen en bijdragen tot meer 
betrouwbare genotype-fenotype correlaties Deze gegevens samen met de resultaten verkregen uit 
studies met geschikte modelsystemen zijn essentieel om vast te kunnen stellen of er een therapie 
mogelijk is voor patiënten met het syndroom van Alport (Hoofdstuk 9) 
142 
Dankwoord 
Op de eerste plaats wil ik Dr. Bert Smeets en Dr. Cock Schroder, als mijn beide 
copromotores en Prof. Dr. Leo Monnens als mijn promotor bedanken, omdat zij mij in de 
gelegenheid hebben gesteld het onderzoek zoals beschreven in dit proefschrift uit te 
voeren. Bert, zonder jou zou het Alport onderzoek alsook dit proefschrift niet de vorm 
hebben gekregen zoals die nu tot stand is gekomen. Jouw inzet, geduld en de manier 
waarop jij omgaat met mensen heb ik als zeer plezierig ervaren. Leo, jouw inzicht en 
wetenschappelijke kennis, die onstuitbare inzet en drang tot weten, de manier waarop jij 
onderzoek van een hele groep stuurt, bindt en leidt, en daarbij ruimte laat voor ieder 
afzonderlijk, is meer dan ongelofelijk. Cock, jij hebt de basis gelegd voor dit onderzoek 
en ben je dankbaar voor de steun en een luisterend oor in een periode van verandering. Ik 
heb veel van jullie geleerd en ik denk dat ik steeds meer zal gaan beseffen welk een 
voorrecht het is om met jullie te mogen werken. 
Het lijkt een cliché maar het is een feit dat een promotieonderzoek niet alleen 
wordt uitgevoerd door de promovendus. Een van de belangrijkste ingrediënten is de 
prettige werksfeer op zowel het lab DNA diagnostiek als kindergeneeskunde. Sinds de 
periode dat ik ben begonnen met mijn promotieonderzoek hebben een aantal mensen een 
werkkring elders gevonden, zoals bijvoorbeeld Marcel Neelen, Jos Dreesen, Ans van den 
Ouweland en Marian Verdijk. Uit die beginperiode zijn alleen nog Ilse, Cor, Betsie, 
Margaret, José en Willy Nillesen overgebleven. Ik dank jullie allen voor de 
samenwerking en de sfeer in, maar vooral ook buiten het laboratorium. Ik bedank Jos 
Meienhorst die mij wegwijs maakte op het lab DNA diagnostiek. Willy, ik wil jou 
speciaal bedanken voor jouw inzet en bijdrage aan het Alport project, samen met Adri 
van Drunen en Léonard Kluijtmans die als studenten hun bijdrage hebben geleverd aan 
het Alport onderzoek. Bernard van Oost, als voormalig hoofd DNA diagnostiek, wil ik 
bedanken voor zijn enthousiasme en interesse in het Alport onderzoek en zijn bijdrage in 
het schrijven en corrigeren van manuscripten. Han Brunner, dank ik als actief lid van de 
Alport groep voor zijn resultaatgerichtheid en dadendrang, want zonder zijn inbreng zou 
het defect in de familie met benigne hématurie niet zo snel zijn gevonden. 
Het onderzoek is uitgevoerd op de laboratoria van Anthropogenetica, 
Kindergeneeskunde en korte tijd op het lab Pathologie. Dit betekent automatisch dat ik 
kennis heb mogen maken en samengewerkt met een behoorlijk aantal mensen. Het is 
onmogelijk en weinig zeggend om al die namen te noemen maar ik dank hen allen voor 
143 
de vriendelijke en open wijze waarop zij direct of indirect hebben bijgedragen aan het 
Alport onderzoek. Echter enkele personen wil ik toch met name noemen, zoals Saskia, 
Liesbeth en Bert Janssen voor hun inzet, omdat zij te pas en te onpas lymphocyten hebben 
getransformeerd of fibroblasten opgegroeid voor nog een RNA isolatie. 
En Betsie, jij die het lab draaiende houdt door ons elke keer weer te voorzien van schoon 
glaswerk en koppen voor de koffie. Margaret, José en Helmie, voor jullie werk op het 
secretariaat en bereidheid om op elk moment vraag en antwoord te geven. De tweede 
generatie DNA diagnostiek heeft veel nieuwe en bekende gezichten opgeleverd. Joop, 
bedankt voor jouw ondersteuning in het computerwerk, verder Neeltje, Paul, René, 
Ermanno, Berna, Hetty, Kirsten, Marloes, Monique, Frans Hol, Melan en Frans, jij 
bedankt voor de avondjes Ajax, en voor jullie interesse en uiterst prettige omgang op het 
lab. Ik ben de nieuwe staf DNA diagnostiek (Edwin, Erik, Marjolijn en Lies) erkentelijk 
voor de mogelijkheid om het onderzoek naar het syndroom van Gitelman in dezelfde 
opzet als die gold voor het Alport project te kunnen continueren. 
Een essentieel onderdeel van het onderzoek, de RT-PCR analyse, kon ik uitvoeren 
op het DNA-lab kindergeneeskunde. Ik bedank Bert (van den Heuvel) voor zijn rol in de 
eerste antilichaamstudies op nierbiopten van Alport patiënten. Ik ben blij dat ik nu de 
gelegenheid heb om met jou, Nine, Rene, Henk en Leo de lijn door te kunnen trekken in 
het Gitelman onderzoek. Leo Berrevoets dank ik voor zijn financiële beheer en interesse 
in het Alport project. Bedankt ook allen op het lab Kindergeneeskunde en Neurologie 
voor jullie bereidheid en inzet om goed samen te werken. Ik waardeer Frank van der 
Loop en Erika Timmer voor de prettige samenwerking en hun bereidheid maandelijks 
naar Nijmegen te komen voor een laatste update van hun Alport onderzoek in Maastricht. 
Verder bedank ik de patiënten en hun familieleden voor hun medewerking alsmede 
alle huisartsen, kinderartsen, nefrologen en andere medische specialisten uit verschillende 
klinieken en klinisch genetische centra in Nederland voor hun bijdrage, want zonder hen 
is dit onderzoek eenvoudigweg niet mogelijk. 
I thank Corinne Antignac, Bertrand Knebelmann, and Marie-Claire Gubler for 
their hospitality and opportunity to work on your lab at Hôpital Necker in Paris. I thank 
Karl Tryggvason, Jing Zhou, Jörgen Wieslander, Raghurem Kalluri, and Toshio 
Mocnizuki for sharing DNA probes, antibodies, and unpublished data as well as Prof. 
Karl Schärer from Heidelberg and Prof. Wolfgang Rascher from Giessen, Germany, for 
providing blood samples and biopsy specimen from Alport patients. 
144 
De dank de wetenschappelijke raad van de Nierstichting Nederland voor de 
ondersteuning door middel van een subsidie waardoor dit onderzoek kon plaatsvinden 
(projector. C90-1022). Tevens bedank ik de adviescommissie van het Van Walree Fonds 
voor de subsidie voor een werkbezoek aan het 'Seventh International Symposium on 
Basement Membranes' op het NIH in Bethesda, Maryland, en het Simonsfonds voor hun 
bijdrage om deel te kunnen nemen aan de 27th Annual Meeting of the American Society of 
Nephrology in Orlando, Florida. 
Tenslotte wil ik mijn ouders bedanken, René, Bianca en Arie voor hun steun en 
aanmoediging. De ouders van Angélique, Johan en Ria, en verder Gerard en Christien, 
vrienden, familie en kennissen voor hun interesse en meebeleving. 
Angélique, jouw rol in dit geheel is zo groot en belangrijk voor mij dat die niet in 
woorden zijn uit te drukken. 
145 

Curriculum vitae 
Hendrikus Herman Lemmink werd op 30 november 1960 geboren te Oldenzaal. Hij 
behaalde het diploma Gymnasium-ß in 1980 aan het Twents Carmellyceum te Oldenzaal. 
In 1980 werd de studie biologie gestart aan de Landbouwuniversiteit te Wageningen en het 
kandidaatsexamen behaald in januari 1986. Het doctoraalexamen werd afgelegd in augustus 1989 
met als hoofdvakken celbiologie, toxicologie en moleculaire biologie. Het laatst genoemde vak 
werd uitgevoerd in de vorm van twee stages bij respectievelijk de sectie Moleculaire Genetica in 
het Antoni van Leeuwenhoekhuis (NKI) te Amsterdam (Prof. Dr. A. Berns) en bij de vakgroep 
Medische Biochemie in het Sylvius Laboratorium te Leiden (Prof. Dr. A. vd. Eb). 
In 1990-1991 werd de vervangende dienstplicht vervuld gedurende 16 maanden als 
onderzoeksmedewerker binnen de sectie gentherapie aan het toenmalige ITRI-TNO (Instituut 
Toegepaste Radiobiologie en Immunologie) instituut te Rijswijk (Prof. Dr. D. Valerio). 
In de periode 1991-1995 werkte hij op basis van een subsidie toegekend door de 
Nierstichting Nederland als promovendus op de afdelingen Anthropogenetica en 
Kindergeneeskunde in het Academisch Ziekenhuis Nijmegen "St. Radboud" te Nijmegen waar het 
in dit proefschrift beschreven onderzoek is uitgevoerd. 
Vanaf mei 1996 is hij op een post-doc plaats werkzaam als moleculair bioloog op de afdeling 
Kindergeneeskunde in het AZN te Nijmegen. 
147 

Publications 
Smeets HJM, Meienhorst JJ, Lemmink HH, Schroder CH, Nelen MR, Zhou J, Hostikka 
SL, Tryggvason K, Ropers H-Η, Jansweijer MCE, Monnens LAH, Brunner HG, van 
Oost BA (1992) Different mutations in the COL4A5 gene in two patients leading to 
different types of Alport syndrome. Kidney International 42: 83-88. 
Lemmink HH, Schröder CH, Brunner HG, Nelen MR, Zhou J, Tryggvason K, Haagsma-
Schouten WAG, Roodvoets AP, Rascher W, van Oost BA, Smeets HJM (1993) 
Identification of four novel mutations in the COL4A5 gene in patients with Alport 
syndrome. Genomes 17: 485-489. 
Lemmink HH, Kluijtmans LAJ, Brunner HG, Schröder CH, Knebelmann В, Jelinkova E, 
van Oost BA, and Smeets HJM (1994) Aberrant splicing of the COL4A5 gene in patients 
with Alport syndrome. Human Molecular Genetics 3: 317-322. 
Mochizuki T, Lemmink HH, Mariyama M, Antignac C, Gubler M-C, Pirson Y, Verellen-
Dumoulin C, Schröder CH, Smeets HJM, Reeders ST (1994) Identification of mutations 
in the аЗ(Г ) and a4(IV) collagen genes in autosomal recessive Alport syndrome. Nature 
Genetics 8: 77-82. 
Lemmink HH, Mochizuki T, van den Heuvel LPWJ, Schröder CH, Barrientes A, 
Monnens LAH, van Oost BA, Brunner HG, Reeders ST, and Smeets HJM (1994) 
Mutations in the type IV аЗ (COL4A3) gene in autosomal recessive Alport syndrome. 
Human Molecular Genetics 3: 1269-1273. 
Schröder CH, Lemmink HH, van den Heuvel LPWJ, Smeets HJM (1995) Nieuwe 
ontwikkelingen in de diagnostiek van het syndroom van Alport. Nederlands Tijdschrìft 
voor Geneeskunde 139(2): 66-69. 
Kalluri R, van den Heuvel LP, Smeets HJM, Schroder CH, Lemmink HH, Boutand A, 
Neilson EG, Hudson BG (1995) COL4A3 gene deletion and posttransplant anti-аЗ 
alloantibodies in Alport syndrome. Kidney International 47: 1199-1204. 
149 
Lemmink HH, Nillesen WN, Mochizuki T, Schröder CH, Brunner HG, van Oost BA, 
Monnens LAH, Smeets HJM (1996) Benign familial hematuria due to mutation of the type 
IV collagen o¡4 gene. Journal of Clinical Investigation 98: 1114-1118. 
Smeets HJM, Knoers NVAM, van den Heuvel LPWJ, Lemmink HH, Schroder CH, and 
Monnens LAH (1996) Hereditary disorders of the glomerular basement membrane. 
Pediatric Nephrology 10: 779-788. 
Lemmink HH, Schroder CH, Monnens, LAH, and Smeets, HJM (1997) The clinical 
spectrum of type IV collagen mutations. Human Mutation 9: 477-499. 
Jefferson JA, Lemmink HH, Hughes AE, Hill CM, Smeets HJM, Doherty CC, Maxwell 
AP (1997) Autosomal dominant Alport syndrome linked to the type IV collagen a3 and 
£*4 genes (COL4A3 and COL4A4). Nephrology Dialysis Transplantation 12: 1595-1599. 
Janssen JJ, Maassen, JA, Van der Woude, FJ, Lemmink HH, van den Ouweland, JMW, 
't Hart LM, Smeets HJM, Bruijn JA, and Lemkes HHPJ (1997) Mutation in mitochondrial 
tRNALal<ulJR)gene associated with progressive kidney disease. Journal of the American 
Society of Nephrology 8: 1118-1124. 
Lemmink HH, van den Heuvel LPWJ, van Dijk HA, Merkx GFM, Smilde TJ, Taschner 
РЕМ, Monnens LAH, Hebert SC, and Knoers NVAM (1996) Linkage of Gitelman 
syndrome to the thiazide-sensitive sodium-chloride cotransporter gene with identification 
of mutations in Dutch families. Pediatric Nephrology 10: 403-407. 
International Collaborative Study Group for Bartter-like syndromes (1997) Mutations in 
the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the 
antenatal variant of Banter syndrome: evidence for genetic heterogeneity. Human 
Molecular Genetics 6: Π-26. 
150 


Stellingen 
1. Familiaire benigne hématurie kan behoren tot het klinische spectrum van type IV 
collageen aandoeningen (dit proefschrift). 
2. De autosomaal recessieve en dominante vorm van het syndroom van Alport 
komen voor en hebben mutaties in het COL4A3 of COL4A4 gen (dit proef schrift). 
3. Het voorkomen van COL4A6 transcripten in benigne leiomyomas van Alport 
patiënten met diffuse leiomyomatosis en de afwezigheid van COL4A6 eiwit na 
immunohistochemische analyse (Lab Invest 76: 233-243, 1997) zou kunnen wijzen 
op een frameshift in het reading frame van het COL4A6 mRNA zoals 
waargenomen voor Vasopressine transcripten in Brattleboro ratten (Proc Natl 
Acad Sci USA 91: 6059-6063, 1994). 
4. Genotype-phenotype correlaties zoals SLC12A3 gen mutaties en het Gitelman 
syndroom bij de mens blijken niet te gelden voor de muis (J Am Soc Nephrol 8: 
43A, 1997). 
5. Mutation detection is a field whose time has come, it is now beginning to assume 
a crucial position in biology and medicine (Genome Digest 2: 1, 1995). 
6. De introductie van DNA micro-array systemen is een van belangrijkste technische 
ontwikkelingen om te komen tot een grotere capaciteit en nauwkeurigheid om 
DNA variaties en expressie-patronen op te sporen (Science 274: 610-614, 
1996). 
7. Agrine is kwantitatief het belangrijkste proteoglycaan van de humane glomerulaire 
basaalmembraan (Groffen et al. submitted). 
8. De PPT-Telecom slogan, "Praat tegen hem of praat tegen haar, het gaat niet om 
de woorden het gaat om de stem, hoe ver het ook is het is altijd dichtbij", wekt de 
indruk alsof telefonisch contact het persoonlijke contact zou kunnen evenaren, is 
absoluut niet waar (eigen ervaring). 
9. Een chaotisch niet opgeruimd bureau dwingt de geest geordend te blijven. 
(Concentrations of microcontaminants and response of organisms in laboratory 
experiments and rhine delta field surveys, A.J. Hendriks, stelling 13). 
10. De gevolgen en belangen voor de economie van de recente BSE en pest-
epidemieën onder koeien en varkens worden groter geacht dan de gevolgen en 
belangen van veehouders en dieren. 
11. De opmerking van sommige Amerikaanse burgers dat Nederland toch behoort tot 
een van de Scandinavische landen toont niet alleen een gebrek aan geografische 
kennis maar geeft ook een beeld over hun kijk op de rest van de wereld. 
12. De criteria van mensenrechten zijn in continenten als Azië, Afrika en Zuid-
Amerika niet verschillend ten opzichte van deze in het Westen. 
H.H. Lemmink 
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